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Abstract 
Cytoskeletal regulation in tumour invasion and metastasis involves Ras-related small 
GTPases and their effectors, such as PAKs. PAK isoforms have been found to be overexpressed 
in many tumours and are generally associated with poorer prognosis. PAK1 overexpression has 
been associated with bladder tumour recurrence and progression but the roles for other PAKs 
are unclear. We found that PAK5 has a distinct expression profile in bladder cancer. We 
proceeded to characterise the role of PAK5 in the cell biology of bladder cancer. 
Bladder cancer cell-lines of invasive and non-invasive origins were screened for the 
expression of PAK5 using isoform-specific antibody. Confocal microscopy and co-
immunoprecipitation were used to characterise the subcellular localisation and interacting 
partners of PAK5. Functional studies were performed using recombinant PAK5 and siRNA. PAK5 
mRNA expression in patient samples was screened by quantitative RT-PCR. 
We found that PAK5 protein is differentially expressed in bladder cancer cell lines, with 
higher expression levels in non-invasive bladder cancer cells. In tissue samples, PAK5 expression 
was also higher in normal bladder tissues, and reduced in tumours. Endogenous PAK5 co-
localises with adherens junction proteins such as E-cadherin and P120-catenin, and their 
interactions were confirmed by co-immunoprecipitation. Silencing of PAK5 in RT4 cell using 
siRNA technology affected the cell morphology resulting in smaller and more rounded cells. 
Silencing of PAK5 also affected the protein level of E-cadherin and the integrity of cell-cell 
adherens junction. 
Our results have indicated that PAK5 expression is associated with non-invasive tumours 
and cell morphology. We found that in bladder cancer cells, PAK5 is a component of the 
adherens junction complex. We hypothesise that PAK5 contributes to maintain the adherens 
junction stability. Further research investigating the mechanism of interaction of PAK5 within 











- 4 - 
 
Table of Contents 
Abstract .......................................................................................................................................... 2 
Table Of Contents .......................................................................................................................... 4 
Table of Figures ............................................................................................................................. 5 
Table of Tables ............................................................................................................................ 13 
Acknowledgements ...................................................................................................................... 14 
Chapter 1- Introduction 
Chapter 2 - Materials and Methods 
Chapter 3 - Characterisation of bladder cancer cell lines and PAK expression 
Chapter 4 - Characterisation of PAK5 expression in bladder cancer 
Chapter 5 - Interactions between PAK5 and E-Cadherin 
















- 5 - 
Table of Figures 
Figure 1-1: Tumour staging for bladder cancer differentiating Non Muscle-Invasive bladder cancer 
(NMIBC) and Muscle-Invasive Bladder Cancer (MIBC) in men .................................................. 19 
Figure 1-2 :  Divergent pathway of urothelial tumorigenesis. Adapted from reviews (Wu 2005, 
Knowles 2006, Bolenz and Lotan 2008) ..................................................................................... 24 
Figure 1-3 : Schematic diagram of cadherin-catenin protein complex at cell-cell adherens junction
 .................................................................................................................................................... 25 
Figure 1-4 : Structural domains of groups 1 and 2 PAKs showing N-terminal regulatory domain 
and C-terminal kinase domain .................................................................................................... 30 
Figure 1-5 : The domain structure of Human PAK5 .................................................................... 37 
Figure 2-1 : The protein-protein blast for this peptide sequence showed that this epitope is PAK5 
specific (http:/blast.ncbi.nlm.nih.gov). ......................................................................................... 65 
Figure 3-1 : Morphological characteristics of well and moderately differentiated bladder 
cancer cell lines in 2D culture:  Immunofluorescent F-actin and nuclear staining of bladder 
cancer cell lines RT4 (A) and RT112 (B) in 40-60% subconfluent monolayer. Scale bar = 10m.
 .................................................................................................................................................... 73 
Figure 3-2 : Morphological characteristics of poorly differentiated bladder cancer cell lines 
in 2D culture: Immunofluorescent phalloidin staining for F-actin in T24 (A), 253J (B) and 
TCCSUP (C) cells at 40-60% subconfluent monolayer.  Arrows indicate areas of contact between 
adjacent cells without distinct accumulation of F-actin. Scale bar = 10m. ................................ 74 
Figure 3-3 : Quantitative analysis of the cell shape of bladder cancer cells in 2D culture on 
glass coverslips. The shape was manually outlined based on the F-actin staining: A) Cell 
area. B) Cell circularity C) Cell aspect ratio. D) Student t-test was performed comparing the 
individual cells to the cell shape parameters of RT4 cells (Analysis performed on 30 cells, from 3 
separate experiments). ............................................................................................................... 76 
Figure 3-4 : Cadherin switch in bladder cancer cell lines. Whole cell lysates of bladder cancer 
cell lines were probed classic markers of cadherin switching in EMT. A) E-cadherin total protein 
level with GAPDH loading control. B) N-cadherin total protein level with GAPDH loading control. 
Images are representative of 3 independent experiments. ......................................................... 78 
Figure 3-5 : Characteristic of E-cadherin positive cell-cell junction of RT4 and RT112 cells 
in 2D culture: Immunofluorescence and line scan of E-cadherin staining at cell:cell junction of 
 
 
- 6 - 
RT4 (A) and RT112 (B) cells. The dashed red boxes approximately register the edges of the 
contact plotted for fluorescence (arbitrary unit). Images shown  are representative of at least 3 
independent experiments. Bar = 10m ....................................................................................... 80 
Figure 3-6 : Protein expression of C-Met receptor in bladder cancer cell lines A) Western 
blot of whole cell lysates of bladder cancer cell lines for C-Met Receptor, probed with Met (C-12) 
SCBT™ antibody. B) Analyses of C-Met Receptor expression on Western blot using densitometry 
quantification on ImageJ from 3 independent experiments ........................................................ 82 
Figure 3-7 :  Disruption of cell adhesion following HGF stimulation in RT112 cells A) E-
cadherin staining in RT112 distribution of E-cadherin along the contact margins in RT112 cells. 
B) Following HGF stimulation, the cells dissociated from each other, and areas of cell: cell contact 
were replaced by multiple thin spikes of membrane protrusions. Magnified images of E-cadherin 
distribution at cell contact margins are boxed in yellow. Images shown are representative of 3 
independent experiments. Bar = 10m ....................................................................................... 84 
Figure 3-8 : Changes in E-cadherin cell adherens junction following HGF stimulation in RT4 
cells A) Distinct cadherin staining appear as continuous plaques at margins of cell: cell contact 
in RT4 cells. B) Following HGF stimulation, subtle changes at the adherens junctions were 
characterised by appearance of E-cadherin puncta along the cell contact margin. Magnified 
images of E-cadherin distribution at adherens junction are boxed in yellow. Images shown are 
representative of 3 independent experiments. Bar = 10m ........................................................ 85 
Figure 3-9 : Protein expression of PAK1 in bladder cancer cell lines A) Western blot of whole 
cell lysates of bladder cancer cell lines probed with PAK1 antibody. B) Analyses of PAK1 
expression on Western blot using densitometry quantification on ImageJ from 3 independent 
experiments. ................................................................................................................................ 87 
Figure 3-10 : Protein expression of PAK4 in bladder cancer cell lines A) Western blot of whole 
cell lysates of bladder cancer cell lines probed with PAK4 (inhouse) antibody. B) Analyses of 
PAK4 expression on Western blot using densitometry quantification on ImageJ from 3 
independent experiments. ........................................................................................................... 89 
Figure 3-11 : Protein expression of PAK6 in bladder cancer cell lines A) Western blot of whole 
cell lysates of bladder cancer cell lines probed with PAK6 isoform specific antibody. B) Analyses 
of PAK6 expression on Western blot using densitometry quantification on ImageJ from 3 
independent experiments. ........................................................................................................... 91 
 
 
- 7 - 
Figure 3-12 : Generation of PAK5 in-house antibody A)Hopp and Woods hydrophobicity 
/hydrophilicity profile of PAK5 protein used for epitope selection (boxed).B) Epitope for antibody 
presentation (boxed) within the N-terminal regulatory domain of PAK5 ..................................... 94 
Figure 3-13 : Generation of recombinant PAK5-fusion proteins and validation for PAK5 in-
house antibody A) Detection of GFP PAK5 and Myc-PAK5 at the estimated molecular weights. 
B) Detection of recombinant GFP-PAK5 protein overexpressed in T24 cells, but not GFP-PAK4 
or GFP-PAK6 on Western blot using PAK5 in-house antibody. B) GFP antibody recognised all 
GFP-tagged recombinant Group-2 PAKs at the estimated MW (with the addition of 27kDa to 
account for GFP tag) in the same set of lysates as B ................................................................ 96 
Figure 3-14 : Protein expression of PAK5 in bladder cancer cell lines A) Western blot of whole 
cell lysates of bladder cancer cell lines for PAK5, probed with PAK5 in-house antibody. B) 
Analyses of endogenous PAK5 expression on Western blot using densitometry quantification on 
ImageJ from 3 independent experiments. ................................................................................... 98 
Figure 3-15 : Expression of PAK5 and E-Cadherin in cancer cell lines with epithelial and 
mesenchymal morphology. Whole cell lysates of breast and pancreatic tumours were probed 
for protein levels of E-Cadherin and PAK5 with GAPDH as loading control.  Lysates of bladder 
tumour cell lines T24 and RT112 were included as positive and negative indicators. Western blots 
of relative protein expressions were representative of 3 independent experiments. ................ 100 
Figure 4-1 (A-C): The mRNA expression level for PAK1, PAK5 and PAK6 in normal and 
malignant urothelial tissue samples. The levels shown are the average (mean) values of PAK 
expression normalised to GAPDH. Standard error of the mean was calculated for all the samples 
included in the array. The results were not statistically significant (Student’s t-test). ............... 111 
Figure 4-2 A): Analysis for expression of PAK5 mRNA transcript in a microarray of 60 
urothelial tissue specimen A) mRNA expression of PAK5 in normal bladder tissue compared to 
bladder tumours. B) Micro array data for PAK5 mRNA were subdivided into groups for normal 
bladder tissue, low risk non-muscle invasive bladder cancer, (LR NMIBC), high risk non-muscle 
invasive bladder cancer, (LR NMIBC), and muscle invasive bladder cancer, (MIBC). B) Statistical 
analysis (ANOVA) for the difference in PAK5 mRNA transcription levels between the groups.
 .................................................................................................................................................. 114 
Figure 4-3 A) Expression of PAK1 mRNA transcript in a microarray of 60 urothelial tissue 
specimen subdivided into groups of normal bladder tissue, low risk non-muscle invasive bladder 
cancer, (LR NMIBC), high risk non-muscle invasive bladder cancer, (LR NMIBC), and muscle 
 
 
- 8 - 
invasive bladder cancer, (MIBC). B) Statistical analysis (ANOVA) for PAK1 and PAK6 mRNA 
levels between the groups within the cohort. ............................................................................ 115 
Figure 4-4:  The mRNA expression profile for PAK5. Total mRNA for bladder cancer cell lines 
were extracted and reverse transcribed into cDNA for stability in storage. The values presented 
are the average (mean) PAK5 mRNA expression normalised to GAPDH from 3 independent 
experiments. .............................................................................................................................. 117 
Figure 4-5 : Validation of in-house PAK5 antibody. A) GFP-PAK5 was overexpressed in T24 
cells and immunolabelled with PAK5 in-house antibody conjugated to Alexafluor 568. Images 
were merged to emphasise sensitivity of the antibody. B) T24 cells overexpressing GFP-empty 
vector was used as negative control. ........................................................................................ 119 
Figure 4-6 : Subcellular localisation of endogenous PAK5 in RT4 cells. Indirect 
immunofluorescent confocal microscopy images of RT4 cells at basal growth condition, co-probed 
with PAK5 and E-cadherin antibodies. Nuclei were stained with DAPI. Bar = 10m. .............. 121 
Figure 4-7 : Subcellular localisation of endogenous PAK5 in RT112 cells. Indirect 
immunofluorescent images of RT112 cells at basal growth condition, co-probed with PAK5 and 
E-cadherin antibodies. Nuclei were stained with DAPI. Bar = 10m. ....................................... 122 
Figure 4-8 : Subcellular localisation of PAK5 in RT4 cells following HGF stimulation A) RT4 
cells in serum-starved conditions stained for nucleus, PAK5 and E-Cadherin. B) RT4 cells in 
following 30 minutes of HGFstimulation stained for nucleus, PAK5 and E-Cadherin.. Boxed area 
in the merged image indicates the area magnified in figure (C), where the boxed area included 
the vesicular and membranous distribution of PAK5 and E-Cadherin in HGF-stimulated condition.
 .................................................................................................................................................. 124 
Figure 4-9 : HGF stimulation of RT4 cells. A) Co-localisation of PAK5 with E-cadherin in 
cytoplasmic vesicular structures in RT4 cells at 30-minutes of HGF-stimulation. Line-scans across 
the cytoplasmic vesicular structures of corresponding confocal images were performed, and the 
fluorescent intensities were quantified. The overlapping intensity peaks indicated co-localisation. 
B) Effects of HGF-stimulation on E-Cadherin/PAK5 colocalisation in cytoplasmic punctate. For 
HGF-stimulation, cells were fixed after 30 minutes following addition of HGF to serum-starved 
media. Values presented are the average (mean) representation of 50 cells from 3 independent 
experiments. Statistical significance compared to unstimulated/starve condition was calculated 
using Student’s t-test; **, P, 0.05. ............................................................................................. 125 
 
 
- 9 - 
Figure 4-10  : Relative ERK phosphorylation of RT4 cells upon HGF stimulation. Whole cell 
lysates of RT4 cells at different time-points of   HGF-stimulation were assayed for ERK/MAPK 
activation. The levels of phosphorylated ERK was normalised relative to the total ERK levels. 
Relative expressions quantified represent the mean of 3 independent experiments. .............. 126 
Figure 4-11 : Optimisation of transient downregulation of PAK5 protein expression by 
siRNA knockdown. Western blots for total protein levels of PAK5 and quantification of relative 
expression normalised to GAPDH at; A) 24 hours, B) 48 hours, and C)72 hours of siRNA 
transfection. Data represent the mean of 3 independent experiments. Statistical significance 
compared with Scrambled SiRNA (ScRNA) was calculated using Student’s t-test; **, P, 0.05 128 
Figure 4-12 : Representative images of RT4 cells at 48 hours of transfection with (A) control 
siRNA, (B) PAK5 siRNA63 and (C) siRNA70. Cells were stained for nucleus (DAPI) and E-
cadherin.  Arrows indicated cells with <50 cell-cell adherent contact. Bar = 10m .................. 131 
Figure 4-13 : Quantification for cell-cell dissociation in RT4 cells following transient 
transfection with PAK5 siRNA.  A) Schematic representation of RT4 cells with established 
epithelial cell-cell adherens junctions (>50% cell-cell contact) and immature or dissociating 
junctions (<50% cell-cell contact). B) Quantification for the number of RT4 cells without 
established (mature) cell-cell junctions over the total number of cells. Quantification was 
performed on at least 50 cells per condition. The values presented are the average (mean) 
quantifications from 3 independent experiments; error bars indicate standard deviation of the 
means. Statistical significance for the difference compared to control siRNA was calculated using 
Student’s t-test, **, P < 0.05. ..................................................................................................... 132 
Figure 4-14 : Cell shape analysis of RT4 following PAK5 siRNA knockdown. A) Area. B) 
Circularity. C) Aspect ratio. The values presented are the mean values and standard error of the 
mean calculated from 3 independent experiments (50 cells analysed per condition/experiment). 
Statistical significance for the difference in morphological parameters of each PAK5 siRNA 
compared to control siRNA was calculated using Student’s t-test; ** = P < 0.05 ..................... 134 
Figure 4-15 : The effects of PAK5 siRNA knockdown at 48 hours on the total protein levels of 
A) E-Cadherin, and B) P120-Catenin in RT4 cells. Western blots for total protein levels were 
quantified for relative expression normalised to GAPDH. Relative expressions quantified 
represent the mean of 3 independent experiments. Statistical significance compared with 
Scrambled SiRNA (ScRNA) was calculated using Student’s t-test; **, P, 0.05 ........................ 136 
 
 
- 10 - 
Figure 5-1:  Model for E-Cadherin-Catenin protein complex at epithelial cell-cell adherens 
junctions .................................................................................................................................... 143 
Figure 5-2 : Co-immunoprecipitation of endogenous PAK5 with E-Cadherin in RT4 cells. (A) 
RT4 whole cell lysates were incubated with PAK5 or E-Cadherin antibody, followed by 
Sepharose™ beads. Precipitated proteins were dissociated and analysed by western blots with 
antibody against PAK5 and E-Cadherin. Images are representative of 3 independent 
experiments. .............................................................................................................................. 146 
Figure 5-3 : Co-immunoprecipitation assays for endogenous PAK5 with p120-Catenin in 
RT4 cells.  RT4 whole cell lysates were incubated with PAK5 or p120-Catenin antibodies, 
followed by Sepharose beads. Precipitated proteins  were dissociated and analysed by western 
blots with antibody against PAK5 and p120-catenin. Images are representative of 3 independent 
experiments. .............................................................................................................................. 147 
Figure 5-4 : Co-immunoprecipitation assays for endogenous PAK5 with - and -Catenin in 
RT4 cells. (A) RT4 whole cell lysates were incubated with PAK5 or E-Cadherin antibodies, 
followed by Sepharose™ beads. Precipitated proteins were dissociated and analysed by western 
blots with antibody against - and -catenins. Images are representative of 3 independent 
experiments. .............................................................................................................................. 148 
Figure 5-5 : Co-immunoprecipitation of endogenous PAK5 with E-Cadherin RT112 cells.  
RT112 whole cell lysates were incubated with PAK5 or E-Cadherin antibodies, followed by Protein 
A Sepharose beads. Precipitated proteins were analysed by western blots with antibody against 
PAK5 and E-Cadherin. Images are representative of 3 independent experiments. ................. 151 
Figure 5-6 : Co-immunoprecipitation assays for endogenous PAK5 with - and -Catenin 
in RT112 cells. RT112 whole cell lysates were incubated with PAK5 or p120-Catenin antibodies, 
followed by Sepharose™ beads. Precipitated proteins were analysed by Western blots with 
antibody against - and -catenins. Images are representative of 3 independent experiments.
 .................................................................................................................................................. 152 
Figure 5-7 : Co-immunoprecipitation assays for endogenous PAK5 with - and -Catenin 
in RT112 cells. (A) RT112 whole cell lysates were incubated with PAK5 or E-Cadherin antibodies, 
followed by Sepharose™ beads. Precipitated proteins were analysed by western blots with 
antibody against - and -catenins. Images are representative of 3 independent experiments.
 .................................................................................................................................................. 153 
 
 
- 11 - 
Figure 5-8 : Generation of PAK5 N-terminal and C-terminal mutants. A) Schematic 
representation of full length PAK5 and N- and C-termini PAK5 protein fractions. B) PCR products 
of full length PAK5, and N- and C-termini mutants cloned into Gateway™ expression vectors.
 .................................................................................................................................................. 156 
Figure 5-9 : Fluorescent images of RT4 cells transiently transfected with RFP-tagged full 
length PAK5, and N- and C-termini mutant. Nuclei were stained with DAPI , A) RFP-FL-PAK5 
was distributed in punctate distribution in RT4 cells.B) N-terminal PAK5 protein was also 
distributed in distinct punctate. C) C-terminal PAK5 was distributed in RT4 cells in diffuse 
cytoplasmic distribution and nuclear accumulation. Cell images are representative of 30 
transfected cells from 3 independent experiments. Bar=10m. ............................................... 157 
Figure 5-10 : Interactions between E-Cadherin-GFP and RFP-tagged Full-length PAK5, and 
N- and C-termini PAK5 fractions overexpressed in HEK293 cells. A) Whole cell lysates of 
HEK293 cells transfected with E-Cadherin-GFP with or without RFP-(FL/N/C)-PAK5 were 
incubated with RFP or PAK5 antibodies as indicated. Precipitated proteins were analysed by 
Western blots and probed for co-immunoprecipitation of E-Cadherin-GFP. Co-
immunoprecipitation of E-Cadherin-GFP and RFP-tagged PAK5 N- or C-termini constructs could 
not be verified using RFP antibody as direct interaction between RFP antibody with E-Cadherin-
GFP protein was  observed in the immunoprecipitation of negative control lysates (RFP-PAK5 
null cells). PAK5 antibody was used to confirm both positive and negative controls. B) Input 
lysates for cells over-expressing E-Cadherin-GFP and RFP-(FL/N/C)-PAK5 as indicated by the 
lane numbers. ........................................................................................................................... 159 
Figure 5-11 : Interactions between E-Cadherin-GFP and HA-tagged Full-length PAK5, and 
N- and C-termini PAK5 fractions overexpressed in HEK293 cells. A) Whole cell lysates of 
HEK293 cells transfected with E-Cadherin-GFP with or without HA- (FL/N/C)-PAK5 were 
incubated with HA antibody as indicated. Precipitated proteins were analysed by Western blots 
and probed for co-immunoprecipitation of E-Cadherin-GFP. B) Input lysates for cells over-
expressing E-Cadherin-GFP and HA-(FL/N/C)-PAK5 which correspond with the CO-IP assay as 
indicated by the lane numbers. ................................................................................................. 160 
Figure 6-1 Schematic representation of PAK5 interaction with E-cadherin, p120-catenin and -
catenin at cell-cell adherens junction. ....................................................................................... 166 
 
 
- 12 - 
Figure 6-2: Proposed mechanism for Cadherin/Catenin engagement at the cell membrane in 
association with PAK5 (upper section) and uncoupling of the adherens junction complex upon 























- 13 - 
Table of Tables 
Table 1-1 : Grading of urothelial tumours ................................................................................... 20 
Table 1-2: Extensively studied immunohistochemical biomarkers in bladder cancer, adapted from 
the following reviews (Bryan, Zeegers et al. 2010, Matsushita, Cha et al. 2011, Kamat, Hegarty 
et al. 2013) .................................................................................................................................. 22 
Table 1-3: Rho GTPases interaction and regulation of PAK5 .................................................... 38 
Table 1-4 Validated PAK5 substrates or interacting partners ..................................................... 39 
Table 2-1 : List of general materials and reagents ..................................................................... 50 
Table 2-2 : List of bladder cancer cell lines used in the study .................................................... 51 
Table 2-3 : List of plasmids used in the study ............................................................................. 53 
Table 2-4 : Small interfering RNAs used for PAK5 (PAK7 gene) knockdown experiments ....... 53 
Table 2-5 : Primers used for cloning full length, N-terminal domain and C-terminal domain of PAK5
 .................................................................................................................................................... 54 
Table 2-6 : RT-qPCR primers used for quantification of PAK1, PAK5 and PAK6 mRNA in human 
bladder cancer cell lines and tissue samples.............................................................................. 55 
Table 2-7 : List of antibodies used in the project, with the concentration for use in Western blots, 
indirect immunofluorescence and immunoprecipitation as indicated ......................................... 57 
Table 2-8 :  List of secondary antibodies used in the project, with the concentration for use in 
Western blots or indirect immunofluorescence as indicated ....................................................... 57 
Table 2-9 : PCR reaction components of PAK5 cDNA amplification .......................................... 61 
Table 2-10 : Conditions for PCR amplification of PAK5 .............................................................. 61 
Table 2-11 : Calcium Phosphate transfection mixture for HEK-293 cells ................................... 63 
Table 2-12 : Transfection mix composition  for X-tremeGENE HP ............................................. 64 
Table 2-13 : Reagent amounts and volumes for reverse transfection of RT112 and RT4 cells using 






- 14 - 
Acknowledgements 
I would like to thank my supervisor extraordinaire, Dr Claire Wells, for her insightful supervision 
and guidance the course of my PhD.  
I would also like to thank my inspirational second supervisor Professor Prokar Dasgupta for his 
support and encouragement as my clinical and academic mentor. 
 I would a like to thank the following individuals and organisations for their contributions to my 
personal development and research into PAK5 in bladder cancer. 
Mr Shamim Khan whose tireless work and dedication on managing the complex disease of 
bladder cancer had inspired me to start this research 
Professor John Masters for the bladder cancer cell lines. 
Malaysian Ministry of Higher Education/ University Institute of Technology Malaysia for funding 
Wells’ Lab Group past and present – Anna Dart, Nicole Taylor, Nouf Babteen, Sally Fram, 
Fariesha Hashim, Katerina Pilipi, Mario De Piano, Andrew Whale, Helen King 
The New Hunt’s House Supergroup: Professor Anne Ridley, Jez Carlton, Yolanda Olmos Buchelt,  
Steve Terry, Barbara Borda D’agua, Ritu Garg, Richard Foxon  
Cardiff University Hospital – Professor Wen Jiang, Dr Tracey Martin, Andy and Shiv 
Guy’s Hospital Urology Centre 
Family: Mom and dad for their unconditional love equally shared by all your children.  





- 15 - 
Abbreviations 
AID   Auto-inhibitory domain 
AJ   Adherens junctions 
α-catenin  Alpha-catenin 
AR   Androgen receptor 
ATP   Adenosine triphosphate  
β-catenin  Beta-catenin 
Cdc42   Cell division control protein 42 homolog 
CRIB   Cdc42/Rac Interactive binding domain 
DAPI   4’, 6-diamidino-2-phenylindole   
E. coli   Escherichia coli 
E-cadherin  Epithelial-cadherin 
ECM   Extracellular matrix 
EGF   Epidermal growth factor 
(E)GFP   (Enhanced) green fluorescent protein 
EGFR   Epidermal growth factor receptor 
EL cells   Mouse L fibroblasts stably expressing E-cadherin 
EMT   Epithelial to mesenchymal transition 
ERK1   Extracellular receptor kinase 1   
ERK2   Extracellular receptor kinase 2  
F-actin   Filamentous actin 
FBS   Foetal bovine serum 
G-actin   Globular actin 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GDP   Guanosine diphosphate 
GEF(s)   Guanine nucleotide exchange factor(s)  
GTP   Guanosine triphosphate 
HGF/SF  Hepatocyte growth factor/Scatter factor 
MAPK   Mitogen activated protein kinase 
PAK   P21-ras Activated Serine/Threonine Kinase 
PBD   p21 binding domain 
 
 
- 16 - 
RAC1   Ras-related C3 botulinum-toxin substrate 1 
Mbt   Mushroom bodies tiny 
MDCK   Madin-Darby Canine Kidney (cell line) 
mRFP1/RFP  Monomeric red fluorescent protein   
siRNA   Short interfering RNA 
WB   Western blotting/immunoblotting 
WCL   Whole cell lysate(s) 
WT   Wild-type 

























- 18 - 
 
Chapter 1 - Introduction 
1.1 Bladder cancer  
 Bladder cancer overview 
Urothelial bladder cancer (UCB) is a major cause of morbidity and mortality worldwide, causing 
an estimated 150,000 deaths per year (Jemal, Bray et al. 2011). It is the 7th most common cancer 
worldwide in men and 17th most common cancer worldwide in women. The incidence of bladder 
cancer rises with age, peaking between ages of 50 to 70 years. In the European Union, the age 
standardised incidence rate is 27 per 100 000 men, and 6 per 100 000 in women, and in 2008, 
UCB was the 8th most common cause of cancer-specific mortality in Europe (Ferlay, Shin et al. 
2010). Risk factors for bladder cancer include chemical and environmental exposures to aromatic 
amines, aniline dyes, nitrites and nitrates, acrolein, coal and arsenic, but the most important 
environmental factor in current clinical practice is cigarette smoking (Kaufman, Shipley et al. 2009, 
Rink, Zabor et al. 2013)  
Histopathological tumour staging of UCB is by the Tumour-Node-Metastasis (TNM) staging 
system (approved by the Union International Contre le Cancer (UICC), updated in 2009) in which 
the primary tumour is assessed on the extent of penetration into the bladder wall, as illustrated in 
figure 1.1. Approximately 75% of patients with bladder cancer present with non-muscle-invasive 
bladder cancer (NMIBC) that is either confined to the mucosa (stage Ta, CIS) or to the submucosa 
(stage T1), while further 25% of patients present with muscle-invasive bladder cancer (MIBC) 
(Abdollah, Gandaglia et al. 2013). Non-muscle-invasive bladder tumours can be effectively 
treated in a bladder-conservative approach by transurethral resection and adjuvant intravesical 
therapy. Patients with non-muscle-invasive bladder cancer have good prognosis, with survival 
rates of up to 94% (Kaufman, Shipley et al. 2009). However, as many as 50-70% of these 
superficial tumours can recur, and 20-30% progress to muscle-invasive disease within 5 years of 
treatment (Rubben, Lutzeyer et al. 1988, Rink, Babjuk et al. 2013). The significant risk of 
recurrence and progression means that most patients undergo prolonged bladder surveillance 
(cystoscopy), and in some cases cytological or molecular urinary tests, making NMIBC one of the 
most expensive human malignancies to manage (Sievert, Amend et al. 2009).  
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Figure 1-1: Tumour staging for bladder cancer differentiating Non Muscle-Invasive bladder cancer (NMIBC) 
and Muscle-Invasive Bladder Cancer (MIBC) in men 
 
In contrast, muscle invasive bladder cancer differs significantly in its management, and the 
associated prognosis compared to NMIBC. The established standard of care for organ-confined 
bladder cancer invading the muscularis propria/ detrusor muscle is radical cystoprostatectomy for 
men, and anterior exenteration (removal of the bladder, urethra, uterus and anterior vaginal wall) 
for women (Kaufman, Shipley et al. 2009, Gakis, Efstathiou et al. 2013). In addition to radical 
surgery, chemotherapy either in adjuvant or neo-adjuvant setting has the potential to eradicate 
micrometastasis, and was shown to improve recurrence free and overall survival in patients, 
especially those with pathologic extravesical and lymph node positive MIBC (Sonpavde and 
Sternberg 2010). However, despite radical treatment, the prognosis for MIBC is poor, with 5-year 
overall survival of 36-49%, and 10-year overall survival of 27-32% (Dalbagni, Genega et al. 2001, 
Stein, Lieskovsky et al. 2001, Grossman, Natale et al. 2003). Invasion of urothelial carcinoma into 
the surrounding smooth muscle of the bladder wall, and dissemination of metastasis are 
associated with the worst prognosis leading to significant morbidity and mortality. Patients with 
locally advanced or metastatic bladder cancer are only expected to have a 5-year survival of 10-
15% despite active chemotherapy regimens (von der Maase, Sengelov et al. 2005, Roberts, von 
der Maase et al. 2006). 
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In addition to TNM staging, tumour grading is also a very useful prognostic tool in the 
management of bladder cancer, especially NMIBC, and has been incorporated in the EORTC 
nomogram to predict the risk of tumour recurrence and progression (Sylvester, van der Meijden 
et al. 2006). The new classification for grading urothelial carcinomas proposed by the World 
Health Organisation (WHO) and International Society of Urological Pathology was published in 
2004. However, in clinical practice, both the 1973 and 2004 classifications (table 1.1) are 
simultaneously included in pathological reporting, as attempts to demonstrate better prognostic 
value of one over the other have yielded controversial results (May, Brookman-Amissah et al. 
2010, Pan, Chang et al. 2010). (Otto, Denzinger et al. 2011). It has therefore been recommended 
that until the WHO 2004 system is validated by more prospective trials and incorporated into 
prognostic models, both the 1973 and 2004 classifications should be used (Babjuk, Burger et al. 
2013). 
 
World Health Organisation (WHO) Grading of Urothelial tumours 
1973 WHO grading 
Urothelial papilloma 
Grade 1 Well differentiated 
Grade 2 Moderately differentiated 
Grade 3 Poorly differentiated 
   
2004 WHO grading 
Flat lesions 
Hyperplasia (flat lesion without atypia or papillary 
Reactive atypia (flat lesion with atypia)  
Atypia of unknown significance 
Urothelial dysplasia 
Urothelial carcinoma in situ 
Papillary lesions 
Urothelial papilloma (benign lesion) 
Papillary urothelial neoplasm of low malignant potential 
Low-grade papillary urothelial carcinoma 
High-grade papillary urothelial carcinoma 
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One of the disadvantages of the TNM staging and WHO grading systems is the variability of 
reporting amongst the pathologist, despite the well-defined criteria, and the general conformity in 
staging and grading is only between 50-60% (Witjes, Moonen et al. 2006, May, Brookman-
Amissah et al. 2010). The areas where significant variability have been noted were for the 
diagnosis of CIS, in the classification of T1 versus Ta tumours, and the tumour grading in both 
the 1973 and 2004 classifications. This variability can significantly impact the management of 
patients with NMIBC, where they may be over- or under-treated, both of which encompass high 
risk of morbidity and mortality. Resources must therefore be allocated to further understand the 
biology of bladder cancer, in search of molecular markers which can be used as an adjunct to 
improve the risk stratification of NMIBC, and appropriate selection of treatment or therapeutic 
target.  
Another point of note is that as the outcomes for many types of cancers have improved over the 
decade but no significant improvement has been noted for bladder cancer (Malmstrom 2011). 
High recurrence and progression rates still characterise non-muscle-invasive bladder tumours, 
associated with high mortality as patients with muscle invasive tumours succumb to the disease. 
Despite complete excision, patients with MIBC have significantly poorer prognosis than patients 
with NMIBC. This may be explained by the hypothesis that MIBC is a systemic disease, with or 
without clinical evidence for invasion or metastasis, and extending the boundaries of surgery in 
these patients may not drastically improve survival (Malmstrom 2011). Further research to 
understand the cellular and molecular behaviour of urothelial cells leading to MIBC holds the 
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 Cellular and molecular aberrations associated with urothelial cancer  
 
In order to understand the remarkable diversity of neoplastic diseases, Hanahan and Weinberg 
(Hanahan and Weinberg 2000, Hanahan and Weinberg 2011) published 2 review articles in 2000 
and 2011 on proposed hallmarks of cancer, which together constitute an organising principle for 
a logical framework in cancer studies. The reviews proposed that as normal cells evolve 
progressively to neoplastic state, they acquire a succession of hallmark capabilities; these 
hallmarks of cancer constitute the ability of tumours to sustain proliferative signalling, evade 
growth suppressors, resist cell death, enable replicative immortality, induce angiogenesis, and 
activate invasion and metastasis. In addition to these hallmarks, new developments in cancer 
research over a decade have added two enabling characteristics (genome instability and 
mutation, and tumour-promoting inflammation), and two emerging hallmark capabilities (avoiding 
immune destruction, and deregulating cellular energetics) to the list (Hanahan and Weinberg 
2011). These hallmarks complement each other to enable tumour growth, invasion and 
metastasis. By directly or indirectly applying the logical framework proposed by Hanahan and 
Weinberg, several studies have attempted to characterise the molecular pathways and 
biomarkers associated with bladder cancer. The biomarkers that have been extensively studied 




p53, pRb, Ki-67, p21 (CIP1/WAF1), p27, Cyclins 
Apoptosis Fas (CD95), Caspace-3, Bcl-2, Survivin 
Angiogenesis Thrombospondin-1, VEGF, bFGF 
Signalling proteins EGFR, HER2,  FGFR3 
Hormone receptors Androgen receptor, Oestrogen receptor 
 
Table 1-2: Extensively studied immunohistochemical biomarkers in bladder cancer, adapted from the 





- 23 - 
The hallmarks of cancer, as proposed by these reviews have been challenged as a valid strategy 
in the understanding of bladder cancer (Malmstrom 2011). In the development of bladder cancer, 
clinical and pathological studies indicate that there are two distinct subtypes of bladder cancer; 
NMIUC/low grade and MIUC/high grade tumours. Urothelial carcinoma of the bladder is unique 
amongst epithelial cancers in its divergent pathways of tumorigenesis (figure 1.2), based on the 
genetic aberrations, biological behaviour and prognosis (Koss 1998, Wu 2005, Knowles 2006). 
The only common aberration shared by both low grade and high grade urothelial carcinomas is 
the deletion of both arms of chromosome 9, which occurs at the earliest stage of tumorigenesis, 
and these chromosomal aberrations do not distinguish between the two tumour developmental 
pathways (Stoehr, Zietz et al. 2005).  
Consequently, some tumours progress from urothelial hyperplasia to low-grade non-invasive 
superficial papillary tumours. Low grade papillary tumours rarely become muscle invasive, and 
they frequently harbour gene mutations that constitutively activate the receptor tyrosine kinase-
Ras pathway (Dinney, McConkey et al. 2004), as well as mutations of fibroblast growth factor 
receptor 3 (FGFR3) oncogene (Cappellen, De Oliveira et al. 1999).  
By contrast, more aggressive variants arise either from flat high grade carcinoma in situ and 
progress to invasive tumours, or they arise de novo as invasive tumours. Most high-grade invasive 
tumours progress to life threatening metastasis and have defective p53 and/or Retinoblastoma 
protein (pRB) tumour-suppressor pathways. (Cordon-Cardo, Dalbagni et al. 1994, Spruck, 
Ohneseit et al. 1994, Orntoft and Wolf 1998, Billerey, Chopin et al. 2001, Lu, Wikman et al. 2002, 
Wu 2005) .  
Tumour invasion and progression in bladder cancer appear to be parts of multifactorial process, 
promoted by intracellular and micro-environmental changes that include the upregulation of N-
Cadherin and the corresponding downregulation of E-cadherin (Garcia del Muro, Torregrosa et 
al. 2000, Nakopoulou, Zervas et al. 2000, Popov, Gil-Diez de Medina et al. 2000, Bryan, Atherfold 
et al. 2008), the overexpression of matrix metalloproteinases 2 and 9 (Kanayama 2001, Slaton, 
Karashima et al. 2001), and imbalance between angiogenic and anti-angiogenic factors 
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Figure 1-2 :  Divergent pathway of urothelial tumorigenesis. Adapted from reviews (Wu 2005, Knowles 2006, 
Bolenz and Lotan 2008) 
 
Despite the insights that have been obtained into the mechanisms involved in the cell biology of 
bladder cancer, the disease specific mortality has changed very little over the last 20 years in 
Western Europe and the USA (Whelan 2008). As most of the cancer mortality is associated with 
MIBC, further research in the regulation of urothelial cancer invasion and metastasis is warranted. 
Progression to, or presentation with muscle invasive disease represents the critical step in the 
disease course of bladder cancer. Thus, detailed biological and molecular insights into the 
pathogenesis of high grade, muscle invasive bladder cancer are urgently needed so that the 
disease can be more adequately treated at presentation, progression from non-muscle invasive 
stages can be abrogated, and the risk of recurrence after radical treatment can be minimised. A 
controversial, yet extensively studied process that may have a crucial role in the divergent 
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 An overview of epithelial to mesenchymal transition as a precursor to 
bladder cancer invasion and metastasis 
 
Epithelial to mesenchymal transition (EMT) is a biologic process during embryologic development 
in many animal species by which polarised epithelial cells lose their characteristic cell polarity, 
disassemble cell-cell junctions and become more migratory as they assume mesenchymal 
cellular phenotype (Yang and Weinberg 2008, Kalluri and Weinberg 2009). EMT has been 
observed in physiological, as well as pathological processes in cancer biology associated with 
tumour invasion, migration and metastasis (Thiery 2002, Tam and Weinberg 2013). In the context 
of cancer biology, Cadherins represent an important aspect of EMT, where the normal expression 
of epithelial Cadherin (E-cadherin), is suppressed, and switched to neural Cadherin (N-Cadherin) 
or placental Cadherin (P-Cadherin), a process known as Cadherin switching (Cavallaro, 
Schaffhauser et al. 2002).  
 
Figure 1-3 : Schematic diagram of cadherin-catenin protein complex at cell-cell adherens junction 
 
The presence of adherens junctions (AJs) is a defining feature of all epithelial tissue (Fristrom 
1988, Baum and Georgiou 2011). The prototypical protein that forms the transmembrane core of 
adherens junctions is E-cadherin. Formation of cell-cell adherens junctions requires interactions 
of the cytoplasmic tail of the E-Cadherin molecule in complex with p120-, - and -Catenins with 
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the actin cytoskeleton (figure 1.4).  Whilst the extracellular domain of E-Cadherin is responsible 
for homotypic, calcium-dependent interactions with E-Cadherins on the surface of adjacent cells, 
the cytoplasmic domain of E-Cadherin interacts with p120-Catenin and catenin through its 
juxtamembrane and catenin-binding domains respectively. catenins provides linkage between 
adherens junctions and the actin cytoskeleton through interactions involving catenin 
(Vasioukhin and Fuchs 2001, Nelson 2008).  
Decreased E-cadherin immune-reactivity was first described in bladder cancer in 1993 (Bringuier, 
Umbas et al. 1993). A number of studies then followed, which demonstrated cadherin switching 
in the setting of bladder cancer, associated with late stage, high grade disease (Rieger-Christ, 
Cain et al. 2001, Clairotte, Lascombe et al. 2006, Lascombe, Clairotte et al. 2006, Bryan, Atherfold 
et al. 2008, Mandeville, Silva Neto et al. 2008). Rieger-Christ et al observed that N-Cadherin 
expression was not detected in normal urothelium, but was localised to the membrane in focal 
areas of tumour mass in the majority (61%) of invasive bladder cancer. In addition to N-cadherin, 
membranous P-Cadherin was expressed throughout the tumours in high grade disease, where 
E-cadherin expression was decreased or absent.  
A detailed study on cadherin-switching using pT1 and T2-T3 bladder tumour samples (Lascombe, 
Clairotte et al. 2006) demonstrated that N-Cadherin expressing bladder cancer progressed more 
rapidly, and the majority of T2-T3 tumours demonstrated no expression of E-cadherin. 
Furthermore, Bryan et al (Bryan, Atherfold et al. 2008) investigated P-Cadherin in 153 human 
bladder cancer specimen, and observed that in high grade, muscle invasive tumours, E-Cadherin 
expression was decreased, P-Cadherin expression was increased, and this cadherin switching 
was associated with worse bladder cancer specific survival. Functional in vitro models by Bryan 
et al demonstrated profound changes when E-Cadherin and P-Cadherin expression were 
manipulated, where P-Cadherin alone was unable to mediate normal cell-cell adhesion, and 
altering the balance of E-Cadherin and P-Cadherin, with decreases E-Cadherin expression 
enhanced anchorage independent cell growth, one of the prerequisites for invasive, metastatic 
phenotype. 
P120-catenin is a cytoplasmic molecule closely associated with E-cadherin at cell-cell adherens 
junction, and p120-Catenin and E-Cadherin are expressed in membranous pattern in normal 
bladder epithelium. Loss of normal surface P120-catenin has be reported in bladder tumours, with 
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significant correlation to tumour grade, stage and poor survival (Syrigos, Karayiannakis et al. 
1998, Silva Neto, Smith et al. 2008). These studies have also noted that in comparing the pattern 
of expression of p120-Catenin and E-cadherin from the same tumour samples, there was a high 
frequency of simultaneous occurrence of E-Cadherin loss with abnormal expression or 
relocalisation of p120, and the prognosis was worse for cancer specific survival when p120 and 
E-Cadherin loss of expression were grouped together.  
The regulatory mechanisms of cadherin switching in bladder cancer remains unclear, but they 
most likely involve transcriptional and post transcriptional events, and influenced by cytokines or 
growth factors associated with EMT (Wheelock, Shintani et al. 2008). It can therefore be 
postulated that EMT does not just represent a change in cell-cell adhesion, but a rather 
fundamental reorganisation of cell biology, involving changes to the cytoskeleton, membrane 
protrusions and extracellular microenvironment (Yilmaz and Christofori 2009). P21-activated 
Serine/Threonine Kinases (PAKs), a family of Rho-GTPases effectors which regulate the actin 
cytoskeleton could potentially provide further insights into the regulation of EMT in bladder cancer 
to enable well-directed diagnosis and targeted management of high risk bladder cancer in the age 
of personalised cancer care. An overview of Rho-GTPases, PAKs, actin cytoskeleton and their 
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1.2 P21-Activated Serine/Threonine Kinases (PAKS)  
 
The invasion of cancer cells into the surrounding tissue is a prerequisite and initial step in 
metastasis. Invasive cell migration requires the formation of various cellular structures, which 
require actin assembly and cytoskeletal organisation (Sit and Manser 2011). Actin forms the 
cellular scaffold structure that provides cells with their shape, tension support, intracellular 
vesicular transport, cell attachment, adhesion properties and the ability to move. There are 4 
distinct ways of extending the membrane at the leading edge; lamellopodia, filopodia, invadopodia 
and membrane blebs (Ridley 2011).Each protrusion requires the coordination of wide spectrum 
of signalling molecules and regulators of cytoskeletal dynamics.  
 Rho family GTPases regulation of actin cytoskeleton and cell: cell 
adhesion  
The Rho-subfamily of GTPases regulates the local assembly or disassembly of filamentous (F)-
actin in the cytoskeleton (Hall 1998).  The best-characterised Rho-GTPases are RhoA, Rac and 
Cdc42. Most Rho-GTPases act as molecular switches, cycling between GTP-bound active form 
and GDP-bound inactive forms. The activity is increased by guanine nucleotide exchange factors 
(GEFs) and down regulated by GTPase-activating proteins (GAPs). Guanine nucleotide 
dissociation inhibitors (GDIs) regulate the activity of Rho-GTPases by binding to the C-terminal 
prenyl group, preventing Rho-GTPase membrane association, and thus inhibits access to their 
effectors (Vega and Ridley 2008) 
Rho family of GTPases; Rho, Rac and Cdc42 are well-known regulators of actin dynamics with 
important roles in intercellular adhesion involving cadherin-catenin complex in epithelial cells 
(McCormack, Welsh et al. 2013). Seminal papers on the formation of cell-cell adherens junction 
in epithelial models had emphasised that the changes to the cell membrane protrusions as a 
regulated process, demonstrating the roles for Rho-GTPases as the master regulators of actin 
cytoskeleton necessary for stable cell-cell adhesion (Vasioukhin, Bauer et al. 2000, Vasioukhin 
and Fuchs 2001, Vaezi, Bauer et al. 2002) (Braga, Machesky et al. 1997, Adams, Chen et al. 
1998, Vasioukhin, Bauer et al. 2000). The spatio-temporal control of small GTPase activation 
drives specific intracellular processes to enable hierarchical assembly, morphology and 
maturation of cell-cell contacts. Dysregulation of Rho GTPases has been demonstrated to induce 
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cell-cell dissociation or cell migration, implicated in the process of cancer invasion and metastasis 
(Kuroda, Fukata et al. 1998, Reymond, Im et al. 2012).  
The current knowledge on the regulation of cell-cell junctions is derived from well-characterised 
RhoA, Rac1 and Cdc42. (Niessen, Leckband et al. 2011). Rac1 is required for the recruitment of 
F-actin to clustered cadherin receptors (Braga, Machesky et al. 1997). RhoA is necessary for the 
formation and function of adhesive complexes, and its interactions with p120-Catenin in adherens 
junctions have been well characterised (Anastasiadis, Moon et al. 2000, Reynolds and Roczniak-
Ferguson 2004). However, conflicting results have demonstrated both activation and inactivation 
of RhoA by cadherin-mediated cell-cell adhesions (Calautti, Grossi et al. 2002, Noren, Arthur et 
al. 2003, Yamada and Nelson 2007). The functions of Cdc42 in epithelial morphogenesis and 
cell-cell adhesion has been well characterised, with distinct roles in the formation of filopodia 
which serves as the sites of actin polymerisation in the initiation of adherens junction 
formation(Vasioukhin, Bauer et al. 2000), stabilisation and localisation of cadherin-catenin 
complexes to adherens junctions, in part, by regulation of endocytic trafficking of adhesion and 
polarity proteins (Harris and Tepass 2008). Most importantly, although Rho, Rac and Cdc42 are 
required in adherens junction assembly, the hyperactivation of the same GTPases may also 
destabilise the epithelial junctional morphology, a mechanism implicated in cancer progression 
and metastasis (Braga, Betson et al. 2000, Bray, Gillette et al. 2013, Ridley 2013).  
Activated Rho-GTPases bind to a variety of effectors that regulate these cytoskeletal dynamics, 
and P21-activated kinases (PAKs) are one family of such effectors (Manser, Leung et al. 1994). 
Although PAK1 has been implicated in the recurrence of urothelial cancer of the bladder (Ito, 
Nishiyama et al. 2007) and progression of upper tract urothelial cancer (Kamai, Shirataki et al. 
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 PAK domain structure and regulation 
PAKs have been well characterised as signal transducers, central to many vital processes in 
physiology and disease, including cell morphology, motility, survival, gene transcription and 
hormone signalling. PAK (PAK1) was first identified in a screen for RAC and Cdc42 effectors 
(Manser, Leung et al. 1994). In the decade following the cloning and characterisation of PAK1, 
additional members of the human PAK-family began to emerge with the identification of PAK-
isoforms 2-6. PAK family of kinases are architecturally similar and their structure can be divided 
into three main domains: an N-terminal PBD (p21-GTPase binding domain), a central region and 
a highly conserved C-terminal serine/threonine kinase domain (Kumar, Gururaj et al. 2006, Wells 
and Jones 2010). PAK-isoforms are subdivided into two groups based on structural and functional 
features (Jaffer and Chernoff 2002, Molli, Li et al. 2009); group-1 consists of PAK1, PAK2 and 
PAK3, while group-2 consists of PAK4, PAK5 and PAK6 (figure 1.2).  
 
 
Figure 1-4 : Structural domains of groups 1 and 2 PAKs showing N-terminal regulatory domain and C-
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The regulatory domain of group-1 PAKs contain a conserved p21-GTPase binding domain (GBD) 
and auto-inhibitory domain (AID). Group 1 PAKs form homo-dimers in cells, adopting a trans-
inhibited conformation where the N-terminal AID of one molecule binds and inhibits the catalytic 
domain of the other (Lei, Lu et al. 2000). Binding of activated Rho GTPases to the PBD disrupts 
dimerization and activates group 1 PAKs. This releases the AID-mediated inhibition and allows 
autophosphorylation of the activation loop, which as a result, prevents refolding and consequent 
inhibition, and when the phosphorylated kinase domain binds to a substrate, it adopts a 
monomeric conformation, which is the active catalytic state (Buchwald, Hostinova et al. 2001, 
Pirruccello, Sondermann et al. 2006). 
The PBD/CRIB domain is conserved in group-2 PAKs, but the roles of Rho-GTPase interaction 
at this site remains under intensive scrutiny. It had been initially postulated that group-2 PAKs 
lack AID, as PAK4 and PAK6 showed no increased kinase activity on GTPase binding as typified 
by group 1 PAKs (Yang, Li et al. 2001, Pandey, Dan et al. 2002). Contrary to initial postulations, 
evidence for distinct autoinhibitory domain in group-2 PAKs have become more consolidated. 
Although the marked kinase activity  observed in group-1 PAKs upon binding to Rho GTPases 
has not been demonstrated in group-2 PAKs, co-expression of Rho GTPases, such as Cdc42, 
with group-2 PAKs resulted in dramatic consequences, often observed to be associated with 
changes in group-2 PAKs subcellular localisation (Abo, Qu et al. 1998{Wu, 2006 #5453, Wu and 
Frost 2006).  
Group 2 PAKs have been demonstrated to possess higher basal kinase activity than group 1 
PAKs (Wells, Abo et al 2002). It had also been demonstrated that the kinase activity of group 2 
PAKs are significantly higher in the truncated versions which only contain the kinase domains 
(lacking the regulatory domain), compared to the full length proteins (Abo, Qu et al. 1998, Yang, 
Li et al. 2001). In relation to Rho GTPase regulation/interaction, although PAK4 and PAK6 are 
still able to bind to CDC42, the binding does not enhance their kinase activity (Abo, Qu et al. 1998, 
Dan, Nath et al. 2002, Pandey, Dan et al. 2002, Wells, Abo et al. 2002). In addition, PAK5 has 
also been found to bind to Cdc42, and a study has identified an auto-inhibitory fragment of PAK5 
that is absent from PAK4 and PAK6 (Ching, Leong et al. 2003). Taken together, these results 
suggest that group 2 PAKs are regulated intra-molecularly, but through different mechanisms to 
group 1 PAKs. 
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 PAKs in cell motility and invasion 
 
PAKs occupy a central position in oncogenic signalling, and drive several hallmarks of cancer, 
which include activating cell invasion and metastasis (reviews: (Molli, Li et al. 2009, Radu, 
Semenova et al. 2014). The initial stages of cancer invasion involve extensive remodelling of the 
cytoskeleton, disruption of cell adhesions and release of proteases that break down the 
extracellular matrix. PAKs have an important role in the regulation of these events, usually by 
mediating responses to Rho family GTPases such as Rac or Cdc42, by phosphorylation of 
downstream PAK substrates that control cytoskeletal dynamics.  
Group 1 PAKs have been implicated in cell migration through their ability to phosphorylate multiple 
cytoskeletal regulators (Arias-Romero and Chernoff 2008). In epithelial cells, PAKs may 
contribute to both lamellopodial extension and disruption of cell-cell junctions. For example, PAK1 
is activated by HGF in MDCK cells and expression of the N-terminal regulatory domain of PAK2 
as a dominant negative blocks HGF-induced peripheral actin remodelling and lamellopodium 
extension (Royal, Lamarche-Vane et al. 2000). LIM domain Kinase 1 (LIMK1) is one of the most 
established PAK1 substrates which directly regulate the actin cytoskeleton. PAK1 phosphorylates 
LIMK1 at Threonine residue 508, which stimulates its activity (Edwards, Sanders et al. 1999). 
Rac1/PAK1/LIMK1 signalling pathway controls cofilin activity within the lamellapodium by 
phosphorylation at Ser3 on its N-terminal, and the enhancement of cofilin activity accelerates F-
actin turnover and retrograde flow, resulting in widening of the lamellapodium (Delorme, 
Machacek et al. 2007). This pathway of Rac1 induced actin reorganisation may be specific to 
particular PAK isoforms. In breast carcinoma, PAK1 but not PAK2 mediates the formation of 
heregulin-stimulated lamellapodial protrusions, the maturation of focal adhesions, cofilin 
phosphorylation and the loss of RhoA activity (Coniglio, Zavarella et al. 2008). A similar dichotomy 
regarding PAK isoforms and cytoskeletal activity has also been demonstrated in mast cells, in 
which PAK1 and PAK2 have opposing roles in actin organisation and degranulation(Allen, Jaffer 
et al. 2009, Kosoff, Chow et al. 2013). 
In prostate cancer cells, HGF has also been demonstrated to stimulate phosphorylation of PAK1 
and PAK2, and knockdown of PAK1 inhibits HGF-stimulated migration in DU145 cells, whereas 
knockdown of PAK2 increases lamellapodium extension but not migration speed (Bright, Garner 
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et al. 2009). The study by Bright et al also reported that PAK2 knockdown increased 
phosphorylation of PAK1, which indicates that PAK2 provides a negative feedback on PAK1. 
Group 2 PAKs have also been characterised in the regulation of actin cytoskeleton to mediate 
changes in cell motility, adhesion and morphology, of which PAK4 is the well-characterised 
isoform. As the founding member of group 2 PAKs, PAK4 was demonstrated to induce filopodia 
formation downstream of Cdc42 (Abo, Qu et al. 1998). Overexpression of PAK4 has also been 
shown to result in the dissolution of stress fibres and cell rounding, which is accompanied by loss 
of focal adhesions (Wells, Abo et al. 2002, Barac, Basile et al. 2004). Similar to PAK1, PAK4 also 
has the capacity to regulate actin depolymerisation through the phosphorylation of LIMK1 on 
Threonine residue 508, which in turn phosphorylates cofilin (Dan, Kelly et al. 2001, Ahmed, Shea 
et al. 2008). PAK4 forms a multiprotein complex with LIMK1, Slingshot phosphatase (SSH-1L) 
and the scaffolding protein 14-3-3zeta, and within this signalling pathway, PAK4 activates LIMK1 
and inactivates SSH-1L, resulting in actin filament turnover through an increase in cofilin activity 
(Soosairajah, Maiti et al. 2005).  
PAK4 has also been shown to regulate cell focal adhesions, where activated PAK4 expression 
causes loss of focal adhesion, and cells with reduced PAK4 expression have increased focal 
adhesions (Wells, Abo et al. 2002, Wells, Whale et al. 2010). This is consistent with the finding 
that cells from PAK4 knockout mice also showed elevated levels of focal adhesions, suggesting 
dysregulation of adhesion molecules in the absence of PAK4 (Qu, Li et al. 2003). PAK4 may 
regulate focal adhesions either through PAK4-mediated phosphorylation of Paxillin on Serine 272 
(Wells, Whale et al. 2010), or by the phosphorylation of the cytoplasmic tail of integrin v5 (Li, 
Lock et al. 2010). Activated PAK4 induces accelerated integrin v5 turnover within the adhesion, 
which in turn inhibited  integrin v5 clustering, reduced integrin to F-actin connectivity and 
perturbed focal adhesion complex maturation, which ultimately lead to reduced cell adhesion 
strength and increased cell motility (Li, Lock et al. 2010).  
A number of studies had supported the role for PAK4 in cancer invasion and metastasis. 
Expression of constitutively active PAK4 in pancreatic ductal cells resulted in an increase 
migratory capacity and invasion, whilst PAK4 siRNA knockdown reduced invasion in an in vitro 
assay (Kimmelman, Hezel et al. 2008). PAK4 was also shown to have a role in migration and 
adhesion of prostate cancer cells (Wells, Abo et al. 2002, Ahmed, Shea et al. 2008, Wells, Whale 
 
 
- 34 - 
et al. 2010). Studies by Wells et al demonstrated the regulation of PAK4 downstream of HGF, 
which in turn mediated loss of cell-cell adhesion and cell migration through activation of LIMK1. 
The level of auto-phosphorylated PAK4 is elevated in prostate cancer cells in response to HGF, 
and when PAK4 levels are reduced using siRNA, the cells become deficient in their invasive and 
migratory abilities in response to HGF.  Taken together, these data point to an important link 
between PAK4 and EMT in a number types of cell from different epithelial tissues, closely related 
to the role of PAK4 in the regulation of actin cytoskeleton and cell adhesion. 
The reorganisation of the extracellular matrix is also required for tumour cell invasion to provide 
space for cell movement (Gupta and Massague 2006), and the destruction of the extracellular 
matrix is partly controlled by the release of matrix metalloproteinases (MMP). It is likely that PAKs 
mediate certain aspects of extracellular matrix reorganisation downstream of Cdc42, as matrix 
remodelling could not be restored to Cdc42-/- mouse embryonic fibroblasts (MEFs) by 
reintroducing mutants of Cdc42 that lacked PAK binding capability(Sipes, Feng et al. 2011). 
Increased expression of MMPs has been suggested to result from PAK-mediated activation of 
Jun N-terminal kinase (Zhou, Yan et al. 2009), and PAK1, PAK2, PAK4 and PAK5 have been 
shown to regulate MMP expression in various cancer cell types, where group 1 PAKs was shown 
to regulate MMP9 (Goc, Abdalla et al. 2012, Rider, Oladimeji et al. 2013), whereas group 2 PAKs 
interact with MMP2 (Kesanakurti, Chetty et al. 2012, Wang, Cheng et al. 2013).  
Cancer invasion involve extensive remodelling of the cytoskeleton for cell motility and migration, 
and release of proteases that break down the extracellular matrix. In epithelial cancers such as 
urothelial carcinoma of the bladder, the disruption of cell-cell adhesions may play a significant 
role in differentiating low risk against high risk bladder tumours with great impact on prognosis 
(reviewed in section 1.1.3). Therefore, a detailed review on the role of PAKs in the regulation of 
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 PAKs and cell-cell adhesions 
 
PAK family of proteins, downstream effectors of Rho GTPases in the signalling pathways in the 
regulation of actin cytoskeleton, have been demonstrated to be directly involved with formation, 
or dissociation of epithelial cell-cell junctions. The most extensively studies group-1 PAKs, PAK1, 
has been shown to modulate the cadherin-catenin complex at the cell-cell adherens junction. 
PAK1 kinase mutants have also been shown to  induce loss of cell-cell junctions in MDCK cells, 
and active Rac1 signals via PAK1 to induce disassembly of E-cadherin based adhesions in 
keratinocytes (Zegers, Forget et al. 2003, Lozano, Frasa et al. 2008). PAK1 has been shown to 
promote transcription-repression activity of Snail for E-Cadherin (Yang, Rayala et al. 2005). In the 
study by yang et al, PAK1 phosphorylation of Snail on Ser246 was demonstrated to be one of the 
mechanisms for downregulation of E-cadherin, and EMT associated with invasion and metastasis 
in breast cancer.  
The evidence for the role of group-2 PAKs in cell adhesion is emerging, albeit poorly understood. 
One of the studies has demonstrated that Cdc42 regulates the apical junction formation in human 
bronchial epithelial cells through PAK4 (Wallace, Durgan et al. 2010). The conclusion of this study 
may appear contradictory, as PAK4 was found to be necessary for the formation of cell-cell apical 
junctions in bronchoepithelial cells, but the expression of constitutively active PAK4 caused cell-
cell dissociation. It could therefore be hypothesised that tight control in the kinase activity or 
spatial regulation of PAK4 by Cdc42 is necessary in the maintenance and formation of cell 
adhesions.   
PAK6, which was initially identified to be an androgen receptor protein, has recently be reported 
to be involved in cell-cell dissociation in response to HGF independent of androgen receptor (AR) 
signalling (Fram, King et al. 2014). In the study, Fram et al demonstrated that PAK6 was required 
for AR-deficient DU145 prostate cancer cells and HT29 colon cancer cells to dissociate and 
scatter following HGF stimulation, and PAK6 overexpression resulted in destabilisation of cell-cell 
adhesion, independent of growth factor (HGF) stimulation. Mechanistically, a complex of PAK6/E-
cadherin/IQGAP1 was identified as the cells dissociate in response to HGF, and the level of PAK6 
auto-phosphorylation was elevated in the presence of IQGAP1. The in vitro kinase assay 
performed in the study did not show phosphorylation of IQGAP1 by PAK6, but identified -Catenin 
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to be a novel substrate for PAK6, and may be involved in cell-cell dissociation by phosphorylation 
of serine-675 downstream of PAK6.  
The interactions between PAK6 with E-Cadherin and -Catenin described by Fram et al poses 
the question whether PAK6 may also interact with other members of adherens junction Cadherin-
Catenin complex such as p120-catenin. This question had already been addressed in a study on 
Group 2 PAKs interactions with p210-Catenin, where in contrast to PAK4 (constitutively active) 
and PAK5 (wild-type and constitutively active), neither wild-type nor constitutively active PAK6 
showed distinct interaction with p120-Catenin (Wong, Reynolds et al. 2010). The findings of this 
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1.3 PAK5, a novel member of the PAK-family 
PAK5 is a novel, and the least understood member of the PAK-family of proteins. The gene 
encoding for PAK5 is located on chromosome 20 at 20p12. It is structurally most related the 
members of group-2 PAK subfamily (Dan, Nath et al. 2002, Pandey, Dan et al. 2002). Unlike 
group-1 PAKs (PAK1, PAK2 and PAK3) which are quite similar to each other throughout their 
sequences, PAK4, PAK5 and PAK6 only share up to 60% of their sequence homology (Jaffer and 
Chernoff 2002).  
High expression of PAK5 mRNA was detected in the brain on Northern blot and in situ 
hybridisation, with moderate expression in a number of epithelial tissues (Pandey, Dan et al. 
2002). It had also been noted that in mouse brain development, PAK5 was preferentially 
expressed in mature neural system than developing ones (Dan, Nath et al. 2002, Pandey, Dan et 
al. 2002). In addition to neural tissues, PAK5 has also been found to be moderately expressed a 
selection of normal and malignant human epithelial tissues (Dan, Nath et al. 2002, Pandey, Dan 
et al. 2002, Gong, An et al. 2009). Although the expression of PAK5 in bladder tissues has not 
been well characterised, PAK5 expression has been described to be expressed at moderate 






Figure 1-5 : The domain structure of Human PAK5 
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 PAK5 regulation  
Similar to other members of the PAK family, PAK5 has a conserved PBD: AID, and has been 
shown to interact with a number of Rho GTPases (table 1.3). PAK5 preferentially binds to Cdc42 
in the presence of GTP, and the AID motif is essential for this interaction (Pandey, Dan et al. 
2002). The AID domain within PAK5 is critical for proper targeting within the cell. In addition to 
Cdc42, PAK5 was also observed to interact with RhoD and RhoH.  The interaction with RhoD 
targets PAK5 to subcellular locations different from those stimulated by Cdc42 (Cotteret, Jaffer et 
al. 2003, Wu and Frost 2006). Unlike group 1 PAKs, PAK5 does not bind with wild-type Rac1, 
and only very weakly to constitutively active Rac1 V12 (Dan, Nath et al. 2002).  
Rho 
GTPase 
Reference Affinity Notes 
Cdc42 (Wu and Frost 2006)  
(Dan, Nath et al. 2002) 
(Pandey, Dan et al. 
2002) 
+++ Formation of filopodia,  
Targets PAK5 to the cell membrane 
Rac (Dan, Nath et al. 2002) 
{Pandey, 2002 #5459 
(+) Very weak interaction noted 
RhoD (Wu and Frost 2006) ++ Targets PAK5 to the mitochondria 
RhoH (Wu and Frost 2006) + Binding to constitutively active RhoH was 
observed but not functionally investigated 
 
Table 1-3: Rho GTPases interaction and regulation of PAK5 
 
A number of N-terminal regions have been identified that regulate the localisation of PAK5: a 
mitochondrial targeting sequence, a nuclear export sequence, and a nuclear localisation 
sequence. Deletion of mitochondrial and nuclear transport sequences causes PAK5 to be 
retained in the nucleus and suppresses PAK5 cellular activity (Cotteret and Chernoff 2006). 
Localisation of PAK5 to mitochondria has been well characterised and associated with the 
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 PAK5 substrates  
 
Protein Site Pathway Reference 
Raf-1 Serine 338  ERK/MAPK  (Wu, Carr et al. 2008) 
BAD Serine 112 Apoptosis 








et al. 2005) 
p120-Catenin Serine 288 Cell adhesion 
(Wong, Reynolds et 
al. 2010) 
Pacsin1 Serine 1291 Vesicle trafficking 
(Strochlic, Concilio et 
al. 2012) 
Synaptojanin1 Serine 343 Vesicle trafficking 
(Strochlic, Concilio et 
al. 2012) 
 
Table 1-4 Validated PAK5 substrates or interacting partners 
 
Both group 1 and group 2 PAKs have been implicated in apoptosis. PAK1, PAK4 and PAK5 
possessed anti-apoptotic properties whereas PAK2 have been shown to be pro-apoptosis. Similar 
to PAK1 and PAK4, PAK5 inhibits apoptosis by phosphorylates BAD on Serine 112, and this 
function requires PAK5 localisation to the mitochondria (Cotteret and Chernoff 2006).  
Another substrate of PAK5 which requires localisation to mitochondria is Raf-1. Raf-1 is an 
important effector of Ras-mediated signalling, and is a critical regulator of the ERK/MAPK 
pathway. PAK5 phosphorylates Raf-1 on the obligate Serine 338 most efficiently compared to 
other group 2 PAKs (PAK4 and PAK6), and the interaction of PAK5 with Raf-1 targets a 
subpopulation of Raf-1 to the mitochondria (Wu, Carr et al. 2008). In the same study, a very 
interesting observation was made, where despite the efficient phosphorylation of Raf-1 by PAK5, 
mitochondrial targeting of Raf-1 by PAK5 interaction was independent of Serine 338 
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phosphorylation. These findings have given rise towards the speculation of a kinase-independent, 
or scaffolding role for PAK5 in the regulation of its interacting partners.  
The kinase-independent interaction of PAK5 has since been further characterised in its inhibition 
of MARK/Par-1 in neuronal cells in vitro and in vivo (Matenia, Griesshaber et al. 2005). 
MARK/Par-1 is a kinase involved in the development of embryonic polarity. PAK5 has been shown 
to suppress the kinase activity of MARK2 towards its target; tau protein, and the inhibition requires 
the binding between the kinase domains of both PAK5 and MARK2. This inhibition does not 
require phosphorylation, and this interaction appears to depend on the conformational states of 
the proteins. The phosphorylation- independent interaction of PAK5 with MARK2 in neuronal cells 
is functionally significant in the regulation of microtubules and actin cytoskeleton; resulting in 
stable microtubules, and dynamic actin (loss of stress fibres, dissolution of focal adhesion and 
formation of filopodia). In contrast to the previously described constitutive subcellular localisation 
of PAK5 to mitochondria (Cotteret, Jaffer et al. 2003, Wu, Carr et al. 2008), the interaction 
between PAK5 and MARK2 was localised to the cell membrane, neurites and distinct vesicular 
structures apart from the mitochondria. This observation hints that the subcellular localisation and 
spatial regulation significantly affect the function of PAK5. 
The role of PAK5 in the regulation of actin cytoskeleton was further consolidated by its interaction 
with p120-Catenin (Wong, Reynolds et al. 2010). P120-Catenin is the founding member of the -
Catenin family (Reynolds, Roesel et al. 1989), and is a well-characterised regulator of cytoskeletal 
reorganisation and cell-cell adhesion, which also has a feedback loop to the Rho GTPases. P120 
interacts with the juxtamembrane domain of classical Cadherins, where it is essential for cadherin 
stabilisation (Reynolds, Herbert et al. 1992, Mo and Reynolds 1996). P120 is phosphorylated on 
multiple tyrosine, serine and threonine residues, but the distinct function of serine/threonine 
phosphorylation of p120 has yet to be elucidated (Xia, Mariner et al. 2003).  
In the study on p120 interaction with group 2 PAKs (Wong, Reynolds et al. 2010), p120 was 
observed to preferentially interact with wild-type (WT) PAK5, constitutively-active PAK5 and 
constitutively-active PAK4, but not wt-PAK4, wt-PAK6 or constitutively active PAK6. Co-
expression of PAK5 also increases the total protein level of p120 in the cells, in conjunction with 
elevated level of phosphorylation exclusively on serine 288 (S288), and it is hypothesised that 
serine phosphorylated p120 does not turn over as rapidly, and more stable in the cells in the 
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presence of PAK5 protein. The study also highlighted the distinct difference between PAK5 and 
oncogenic PAK4 in their interaction with a common substrate; p120-catenin, where PAK4 was 
demonstrated to phosphorylate additional serine/threonine sites, and have different subcellular 
co-localisation upon interaction with p120-catenin. Specific to the common interaction which 
involves phosphorylation of serine 288 of p120, PAK5 and phospho-S288 p120 colocalised in 
discrete vesicular structures in the cytoplasmic compartment, and neither PAK5 nor phospho- 
S288 p120 were detected in the nucleus. The co-localisation of constitutively active PAK4 and 
phospho S288 p120 was observed in diffuse cytoplasmic distribution, with marked nuclear 
localisation of p120.  
P120-catenin is a tightly regulated protein, and in cancer studies, has been implicated to have a 
dual role in possessing both oncogenic and tumour suppressor properties (Schackmann, 
Tenhagen et al. 2013). It could therefore be postulated that PAK5 has a distinct function in the 
regulation of p120-Catenin, different to PAK4, which may facilitate or inhibit cancer progression. 
As the study was focussed neuronal cell models, the functional significance of the interaction 
between PAK5 and p120-Catenin in the epithelium, and the effect on cadherin-catenin adherens 
junction complex has not been elucidated. As PAK5 has no distinct transcriptional role, it may be 
necessary to utilise well differentiated human epithelial cell models, for which differentiated 
urothelial tumour cell lines may be suitable candidates. 
In contrast to the well-studied tyrosine phosphorylation of p120 by growth-factor stimulation, the 
role for serine/threonine phosphorylation of p120 in Cadherin function is not very well understood. 
In the study characterising the interaction between PAK5 and p120-Catenin (Wong, Reynolds et 
al. 2010), PAK5 was shown to phosphorylate p120-catenin on Serine 288, but the effect of this 
interaction on the adherens junctions has not been assessed. However, a number of studies on 
cell lines with well-differentiated epithelial morphology have identified constitutive phosphorylation 
of serine/threonine residues in cells with functional E-Cadherin (Xia, Mariner et al. 2003, Xia, 
Carnahan et al. 2006), and over-expression of E-Cadherin in MiaPaCa-2 Cadherin-deficient cells 
resulted in serine/threonine phosphorylation of p120, which co-localised with E-cadherin to cell-
cell junctions (Fukumoto, Shintani et al. 2008). Although the specific kinase involved was not 
identified in these studies, the authors had postulated that serine/threonine phosphorylation of 
p120 may provide initial signals during junction assembly, by either rapid organisation of E-
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cadherin at cell-cell contact, by rescuing E-Cadherin from degradation and prolonging its 
localisation at the cell surface, or by providing a plasma retention signal.  
The interactions previously described between both wild-type and constitutively active PAK5 with 
p120-Catenin, and the associated serine/threonine phosphorylation (Wong, Reynolds et al. 
2010), suggest a potential role for PAK5 in the establishment of stable epithelial cell-cell 
adhesions. This postulation however, may be paradoxical to reports associating PAK5 expression 
with progression and metastasis of a number of epithelial cancers, including colorectal (Gong, An 
et al. 2009) and breast (Wang, Cheng et al. 2013) carcinomas. However, the mechanistic role of 
PAK5 in the progression of cancer described in these studies were mostly attributed to the anti-
apoptotic or proliferative functions of PAK5, with limited information on cell invasion or migration. 
Two further PAK5 substrates, Pacsin-1 and Synaptojanin-1 have recently been identified, which 
implicates PAK5 in synaptic vesicle trafficking (Strochlic, Concilio et al. 2012). Pacsin1 and 
Synaptojanin1 directly interact with one another to regulate synaptic vesicle endocytosis and 
recycling. Both proteins are phosphorylated by PAK5, and PAK5 phosphorylation promotes 
Pacsin1 and Synaptojanin1 binding both in vitro and in vivo. However, it is very unlikely that this 
interaction has a role in bladder cancer studies, as both Pacsin1 and Synaptojanin1 are highly 
brain specific in their expression, with absent or minimal expression in normal and malignant 
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 PAK5 in development 
 
The specific functions of the group 2 PAK family members have been studied using gene 
knockout mice. PAK4 knockout mice die in utero, and the embryos have several structural 
abnormalities (Qu, Li et al. 2003). In contrast, PAK5, PAK6 and PAK5/PAK6-double knockout  
mice were viable and fertile, and it was postulated that PAK5 expression begins later in 
development and not essential for early embryonic development.(Li and Minden 2003, 
Nekrasova, Jobes et al. 2008, Furnari, Jobes et al. 2013). Initial study on PAK5 showed that in 
PAK5-null mice, the nervous system and other tissues in which PAK5 was normally expressed 
were structurally normal, which suggested functional redundancy between PAK5 and other Rho-
GTPase targets (Li and Minden 2003). The hypothesis was further supported by findings that 
PAK5/PAK6 double knockout mice had several locomotor and behavioural deficits, compared to 
single PAK5 or single PAK6 knockout mice (Nekrasova, Jobes et al. 2008).  
However, in the most recent study, PAK6 knockout mice were found to weigh significantly more 
than PAK5 or PAK5/PAK6 double knockout, and the PAK5 or PAK5/PAK6 double knockout mice 
performed worse on the rotorod test of motor co-ordination and balance, indicating  distinct 
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 PAK5 and Cancer  
 
To date, PAK5 has not been shown to be involved in bladder cancer. However, evidence for 
PAK5’s role in oncogenic pathways are emerging. PAK5 has been reported to be over-expressed 
in a variety of colorectal cancer cell lines, and immunohistochemistry of colorectal tumour 
resection specimens also showed higher expression level of PAK5 in poorly differentiated, 
invasive and metastatic colorectal tumours (Gong, An et al. 2009). PAK5 has also been 
demonstrated to inhibit camptothecin-induced apoptosis in colorectal carcinoma cells (Wang, 
Gong et al. 2010). In the study by Wang et al, camptothecin-induced activation of caspace-8 and 
PARP was shown to be inhibited in PAK5 overexpressing cells, whereas shRNA knockdown of 
PAK5 increased apoptosis in colorectal cells in response to camptothecin stimulation.  
PAK5 has also been implicated in the carcinogenesis of gastric cancer (Gu, Li et al. 2013), where 
immunohistochemical evaluation of 57 tumour tissues and the corresponding adjacent normal 
gastric tissue detected significant PAK5 upregulation in gastric tumours, compared to normal 
adjacent tissues. However, it is interesting to note that upregulation of PAK5 in gastric cancer in 
the study did not correlate with histological differentiation, tumour size, TNM stage, 
lymphovascular invasion or distant metastasis. Further evaluation for the role of PAK5 by 
Lentivirus-mediated PAK5 siRNA knockdown was performed by Gu et al, and indicated that PAK5 
has a significant role in gastric cancer cell growth, proliferation and cell-cycle regulation. In 
hepatocellular carcinoma, elevated mRNA and protein expression of PAK5 have also been 
detected in tumours, compared to the adjacent normal liver tissues (Fang, Jiang et al. 2014). In 
the study, Fang et al also demonstrated that PAK5 siRNA knockdown inhibited hepatocellular 
carcinoma cell proliferation in vitro, and tumour formation in nude mice following subcutaneous 
injection.  
A study using breast cancer cell lines (MDA-MB-231 and BT549) had also implicated PAK5 in the 
migration and invasion of breast carcinoma through PAK5-Egr1-MMP2 signalling (Wang, Cheng 
et al. 2013).This study found that silencing of PAK5 inhibited breast cancer cell line proliferation, 
promoted apoptosis, and decreased cell migration in wound-healing and Matrigel transwell 
invasion assay. Knockdown of PAK5 in MDA-MB-231 and BT549 was associated with increased 
protein level of Egr1, and decreased level of cleaved MMP2. MMP2 is one of the proteases 
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involved in breast cancer invasion, associated with poor prognosis (Talvensaari-Mattila, Paakko 
et al. 2001, Talvensaari-Mattila, Paakko et al. 2003), and Egr1 is a member of the immediate 
gene family of transcription factors which can bind to MMP2 promoter and inhibit its activity 
(Zcharia, Atzmon et al. 2012). In epithelial ovarian cancer (EOC), the expression of PAK5 was 
associated with the occurrence and development of EOC, and PAK5 overexpression may also 
promote paclitaxel-chemoresistance (Li, Yao et al. 2013). Using immunohistochemistry, Li et al 
found that PAK5 was overexpressed in epithelial ovarian cancer, and the increase of PAK5 
expression was also associated with EOC progression through the adenoma to carcinoma 
sequence, with the highest expression level in invasive and metastatic EOC. In vitro studies by 
this group demonstrated that in SK-OV-3 cells, downregulation of PAK5 by shRNA significantly 
affected proliferation and apoptosis upon treatment with paclitaxel as chemotherapeutic agent. 
Systematic sequencing of cancer genomes had also identified PAK7 gene (which encodes for 
PAK5 protein) as one of the top 20 (positioned 17th out of 20) protein kinase genes ranked by 
probability to be carrying driver mutations in several cancers which include breast, lung, gastric, 
renal and ovarian carcinomas (Greenman, Stephens et al. 2007). Despite the large scale study 
carried out by Greenman et al, the data on whether somatic mutation in bladder cancer was 
unclear, as bladder cancer tissues were not screened in this study.  
Complimentary to the study by Greenman et al, targeted genetic dependency screen has 
facilitated identification of actionable mutation in FGFR4, MAP3K9, and PAK7 in lung cancer 
(Fawdar, Trotter et al. 2013). The gain of function (GOF) mutations in these three different kinases 
were activating towards the ERK pathway, and the study demonstrated that targeted depletion of 
the kinases with siRNA resulted in reduced viability of lung cancer cells. Specific to PAK5, lung 
cancer H2087 cell line was used by Fawdar et al as a model. H2087 cell line harbours 79 non 
synonymous somatic mutations in 79 different genes, among 4700 genes sequenced (Greenman, 
Stephens et al. 2007). Using on-target siRNA SMART pools, the transcripts that carried the 79 
nonsynonymous mutations were depleted and the effects on proliferation were monitored. Based 
on the screening criteria, PAK5 was found to have the most significant Strictly Standardised Mean 
Difference (SSMD) value for H2087 cell line proliferation, and the study further verified this with 
Caspace assay. The single PAK5 siRNA oligos was demonstrated to significantly suppressed 
proliferation, induced apoptosis and attenuated signalling in the in the MAPK/ERK pathway. 
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  PAKs and urothelial carcinoma 
 
PAK1 is the most extensively studied member of the PAK family and has been studied in the 
context of urothelial carcinoma. Increased Rac1 activity and PAK1 over-expression in urothelial 
carcinoma of the upper urinary tract were associated with lymphovascular invasion and lymph 
node metastasis based on analyses of surgical specimen(Kamai, Shirataki et al. 2010). Oligo-
microarray of surgical specimen from transurethral resection of bladder tumour (TURBT) also 
identified PAK1 to be associated with increased risk of intravesical recurrence, independent of 
histopathological grade and stage(Ito, Nishiyama et al. 2007). Wound healing assay was 
performed in bladder cancer 253J cells transfected with constitutionally active T234E-PAK1, and 
EJ cells transfected with kinase dead K299R-PAK1(Ito, Nishiyama et al. 2007). The cells with 
constitutionally active PAK1 completed the wound healing process, whereas the kinase dead form 
did not migrate.  
 The oncogenic PAK1 in bladder cancer has recently been reported to be modulated by tumour 
suppressor microRNA; miR-145 (Kou, Gao et al. 2014). The level of miR-145 negatively 
correlates with PAK1 protein expression in bladder cancer, and miR-145 directly targets PAK1 to 
inhibit bladder cancer cell invasion partly by suppressing the protein expression of PAK1 and  one 
of its downstream effectors; metallic metalloproteinase 9 (MMP9).  
Paradoxically, a recent study has demonstrated that PAK1 may be a marker of treatment 
response of bladder tumours to BCG therapy (Redelman-Sidi, Iyer et al. 2013). BCG intravesical 
therapy is an established adjuvant treatment for high risk NMIBC, which reduces the rate of 
recurrence of NMIBC (Sylvester, van der et al. 2002, Babjuk, Burger et al. 2013). Despite being 
one of the most successful cancer immunotherapy, its mechanism of action and response 
determinants remains obscure. The study published by Redelman-Sidi et al demonstrated that 
the uptake of BCG into bladder cancer cells occur by macropinocytosis, and this process relies 
upon Rac1, Cdc42, and one of its effectors, PAK1 and to a lesser extent PAK2. The study 
however did not specifically tested the role of group-2 PAKs in the uptake of BCG into bladder 
cancer cells. PAK1-dependent macropinocytosis of BCG into bladder cancer cells was 
independent of Dynamin and Clathrin, and the internalised BCG colocalised with fluid-phase 
fluorescent dextran (MW 10000). 
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Despite these findings, PAK1 has not yet been integrated into the clinical management of bladder 
cancer as a molecular biomarker of disease progression, treatment response, nor therapeutic 
target. Apart from PAK1, the role of other members of the PAK family in bladder cancer has not 
yet been characterised. As members of group 1 PAKs have been more extensively studied, I have 








Despite their structural similarities, PAK4, PAK5 and PAK6 appear to have distinct roles in 
oncogenesis. In studying bladder cancer, it would be pertinent to further assess the role of these 
novel member of the PAK family in the loss of epithelial morphology in bladder tumour cells, 
indicating epithelial to mesenchymal transition associated with invasion and metastasis of bladder 
carcinoma.   
I therefore aimed to identify and characterise additional member(s) of the PAK family with distinct 
role in regulation the activation or suppression of invasion and metastasis in bladder cancer. PAKs 
may play a role in one or more steps in the complex cascade of metastasis, which include altered 
adhesion (invasion), intravasation, survival in the circulation, extravasation and seeding at distant 
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Chapter 2 Materials and Methods 
 
2.1 Materials 
 General materials 
Reagent Supplier 
Accuprime PFX supermix Invitrogen, UK 
Acrylamide (30%)  Severn Biotech Ltd, UK 
Agarose Invitrogen, UK 
Ammonium persulfate (APS) Sigma Aldrich, UK 
Ampicillin Sigma Aldrich, UK 
Aprotinin Sigma Aldrich, UK 
Beta () mercaptoethanol Sigma Aldrich, UK 
Bovine serum albumin (BSA) VWR International, UK 
Bromophenol blue Bio-Rad, UK 
Calcium phosphate transfection kit Invitrogen, UK 
Carbenicillin Sigma Aldrich, UK 
Dimethyl sulfoxide (DMSO) Sigma Aldrich, UK 
Dithiothreitol (DTT) Sigma Aldrich, UK 
DNA (100bp) DNA ladder New England Biolabs, UK 
DNA (1kb) DNA ladder New England Biolabs, UK 
Dulbecco’s Modified Eagle’s Medium (DMEM)  GIBCO®, Invitrogen, UK 
Dulbecco’s phosphate-buffered saline (DPBS) GIBCO®, Invitrogen, UK 
Epidermal growth factor (EGF), (Recombinant 
Human) 
R&D systems, USA 
Enhanced chemiluminescense (ECL) Western 
blotting detection system 
Amersham Biosciences, UK 
Ethidium Bromide Thermo Fisher Scientific, UK 
Ethylene diamine tetraacetic acid (EDTA) Sigma Aldrich, UK 
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FluorSave™ reagent Calbiochem, UK 
Foetal Bovine Serum (FBS) GIBCO®, Invitrogen, UK 
Gateway™ BP Clonase™ 11 Enzyme mix Invitrogen, UK 
Gateway™ LR Clonase™ 11 Enzyme mix Invitrogen, UK 
Gentamicin Sigma Aldrich, UK 
Glutaraldehyde Sigma Aldrich, UK 
Glycerol Sigma Aldrich, UK 
Glycine Sigma Aldrich, UK 
Hepes, acid free, ULTROL grade Calbiochem, UK 
Hepatocyte Growth Factor (HGF), human 
recombinant 
R&D systems, USA 
Kanamycin Invitrogen, UK 
Leupeptin Sigma Aldrich, UK 
Lipofectamine® RNAiMAX Invitrogen, UK 
Luria-agar (L-agar) Sigma Aldrich, UK 
Luria-broth (LB) Sigma Aldrich, UK 
MAX Efficiency® DH5™ Competent cells Invitrogen, UK 
NEB-10-Beta Competent E. coli cells NEB, UK 
Nitrocellulose membrane Perkin Elmer, USA 
Octylphenoxylpolyethoxyethanol/Nonidet™ P40 
(NP40) substitute 
Sigma Aldrich, UK 
One Shot® TOP10 chemically competent E.coli Invitrogen, UK 
OptiMEM GIBCO®, Invitrogen, UK 
PAK7 siRNA oligonucleotides See oligonucleotide list 
Paraformaldehyde (PFA) Sigma Aldrich, UK 
Penicillin-streptomicin (100x) Sigma Aldrich, UK 
Phenylmethysulfonylfluoride (PMSF) Sigma Aldrich, UK 
Phosphate buffered saline (PBS) tablets Oxoid Ltd, UK 
Pierce® ECL Western Blotting substrate Thermo Scientific, USA 
Protein A Sepharose™ fast flow beads  Invitrogen, UK 
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Protein G Sepharose™ fast flow beads  Sigma Aldrich, UK 
Precision Plus Protein™ all blue standards  Bio-Rad, USA 
Purelink™ Hi Pure Plasmid Miniprep kit Invitrogen, UK 
Purelink™ Hi Pure Plasmid Maxiprep kit Invitrogen, UK 
Q5® Hot Start High-fidelity DNA polymerase NEB, UK 
Qiaprep® spin Miniprep kits Qiagen Ltd, UK 
QIAquick gel extraction kit Qiagen Ltd, UK 
RNeasy Mini Kit for RNA purification Qiagen Ltd, UK 
RPMI Media 1640  GIBCO®, Invitrogen, UK 
Sodium chloride (NaCl) Sigma Aldrich, UK 
Sodium dodecyl sulphate (SDS) Sigma Aldrich, UK 
Sodium fluoride (NaF) Alfa Aesar, UK 
Sodium orthovanadate (Na3VO4) Sigma Aldrich, UK 
Sodium pyrophosphate  BDH Chemicals, UK 
Sucrose Sigma Aldrich, UK 
SulfoLink Immobilization Kits and Coupling Resin Thermo Scientific, USA 
Tris (Tris(hydroxymethyl)aminomethane) - base Sigma Aldrich, UK 
Triton X-100 VWR International, UK 
Trypsin/EDTA GIBCO®, Invitrogen, UK 
Tween 20 VWR International, UK 
X-ray films Scientific Laboratory Supplies, UK 
X-tremeGENE HP DNA transfection reagent  Roche, UK 
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 Mammalian cell lines 
Bladder cancer cell lines: RT4, RT112, T24, TCCSUP and 253J were gifts from Professor John 
Masters, University College London. The origin of these cell lines are listed in table (x) (Masters, 
Hepburn et al. 1986). Cell line authentication by STR analysis was performed on these cell lines 
by our collaborator and no cross contamination by another human cell lines were detected 
(appendix 1). 
Cell line  Tumour origin Clinical stage Histological 
grade 
Sex of patient 
T24 Primary bladder Not recorded High grade Female 
RT112 Primary bladder Stage 2 Low grade Male 
RT4  Primary bladder Not recorded Low grade Male 
TCCSUP Primary bladder Stage 4 High grade Female 
253J Retroperitoneal lymph 
node metastasis 
Stage 4 High grade Female 
 
Table 2-2 : List of bladder cancer cell lines used in the study 
  
Human embryonic kidney 293 (HEK293) cells line was obtained from Dr Claire Wells, King’s 
College London. Cells were cultured in DMEM supplemented with glucose (4500mg/L), L-
glutamine, NaHCO3, pyridoxine HCl, 10% foetal bovine serum and 1% penicillin/streptomycin 
(100U/ml penicillin and 100g/ml streptomycin). HEK293 cells were incubated in the same 
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 Plasmids and Vectors 
Plasmid/Vector Supplier/Source 
PAK5 cDNA (ORF) Thermo Scientific Open Biosystems 
Human ORFeome Collaboration Clone 
PAK5 (Wild type) Gateway™ Entry 
Clone 
Generated using Gateway™ Technology Cloning 
system 
PAK5 (N-terminal) Gateway™ Entry 
Clone 
Generated using Gateway™ Technology Cloning 
system 
PAK5 (C-terminal) Gateway™ Entry 
Clone 
Generated using Gateway™ Technology Cloning 
system 
pDONR™ 207 Invitrogen, UK 
pEGFP-C1 Expression vector  Clontech, UK 
modified for use as a Gateway™ Technology 
Destination vector by Kerry Shea, KCL 
pDEST™ monomeric Red Fluorescent 
Protein (mRFP) Expression vector  
Invitrogen, UK 
modified for use as a Gateway™ Technology 
Destination vector by Kerry Shea, KCL 




modified for use as a Gateway™ Technology 
Destination vector by Kerry Shea, KCL 
GFP-Cdc42 (wild type)  A generous gift from Dr Maddy Parsons, KCL 
E-cadherin GFP A generous gift from Dr Penny Morton, KCL 
GFP-PAK5 Generated using Gateway™ Technology Cloning 
system 
mRFP-PAK5 Generated using Gateway™ Technology Cloning 
system 
Myc-PAK5 Generated using Gateway™ Technology Cloning 
system 
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Myc-CPAK5 Generated using Gateway™ Technology Cloning 
system 
GFP-PAK4 A generous gift from Dr Anna Dart, KCL 
GFP-PAK6 A generous gift from Dr Sally Fram, KCL 
P120 (wild type) VSV A generous gift from Professor Anne Ridley, KCL 
P120 S288A VSV A generous gift from Professor Anne Ridley, KCL 
 
Table 2-3 : List of plasmids used in the study 
 
 Small interfering RNA (siRNA) 
SiRNA Supplier siRNA Data 








































Table 2-4 : Small interfering RNAs used for PAK5 (PAK7 gene) knockdown experiments 
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 Primers 
All Primers were ordered from Thermo Fisher Scientific, Germany 
2.1.5.1 Primers for cloning 
Target Sequence  






F GGGG ACA AGT TTG TAC AAA GCA GGC 
TTG ATG TTT GGG AAG AAA AAG AAA  
2160 Gateway™ 
R GGG A CCA CTT TGT ACA AGA AAG CTG 
GGT C TCA GTG ATG CCT GTA TTG TCT 
N-terminal 
PAK5 
F GGGG ACA AGT TTG TAC AAA GCA GGC 
TTG ATG TTT GGG AAG AAA AAG AAA 
1275 Gateway™ 
R GGGG A CCA CTT TGT ACA AGA AAG CTG 
GGT C GGA GGG CTG GTC GGA GCC CCA 
C-terminal 
PAK5 
F GGGG ACAC AGT TTGTAC AAA GCA GGC 
TTG AGG GTG TCC CAT GAA CAG TTT CGG 
885 Gateway™ 
R GGG A CCA CTT TGT ACA AGA AAG CTG 
GGT C TCA GTG ATG CCT GTA TTG TCT 
N-terminal 
PAK5 
F AACAAA GAATTC ATG TTT GGG AAG AAA 
AAG AAA AAG ATT G 
1298 EcoR1 
R AACAAA GCGGCCGC CTA CGA AAC TGT 




F AACAAA GAATTC AGG GTG TCC CAT GAA 
CAG TTT CGG 
884 EcoR1 
R AACAAA GCGGCCGC  TCA GTG ATG CCT 
GTA TTG TCT CAT GAG G 
Not1 
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 Primers for Quantitative RT-PCR 
Primers were designed using Primer-Blast (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). The 
reverse primers were incorporated with Z-motif (highlighted in red), a sequence complimentary to 
the Ampliflor Uniprimer probe (Intergen Inc., New York, NY). 
Target Sequence Product size, bp 
GAPDH F GTGAAGGTCGGAGTCAACG 112 
R ACTGAACCTGACCGTACA 
TGAGGTCAATGAAGGGGTC 
PAK1 F CCAGTGATTGCTCCACGCCCA 102 
R ACTGAACCTGACCGTACA 
GGGAGATGTAGCCACGTCCCGA 
PAK5 F CCTCAGCCTCTCATCCAGCACC 99 
R ACTGAACCTGACCGTACA 
AGGGCCGCCCGAAACTGTTC 




Table 2-6 : RT-qPCR primers used for quantification of PAK1, PAK5 and PAK6 mRNA in human bladder 
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 Antibodies 
2.1.7.1 Primary antibody 
Antibody Host Company 
Dilution 
WB IF IP 
-catenin  Rabbit Sigma  1:1000   
Akt  Rabbit Cell Signalling 1:500   
C-myc (9E10) #E3112 Mouse SCBT 1:2000 1:200 1:400 
-tubulin Mouse Sigma  1:2000 1;400  
-catenin  
 Rabbit Sigma  1:1000 
  
-tubulin Mouse Sigma  1:2000 1:400  
C-Met (C-12) Rabbit SCBT 1:1000   
E-Cadherin  Mouse Zymed 1:1000 1:400 1:250 
E-Cadherin  Mouse ABCAM 1:1000 1:400  
EGFR #2232 Rabbit Cell Signalling 1:1000   
EGFR #4267 Rabbit Cell Signalling 1:1000   
ERK1/2 (MAPK) Rabbit Cell Signalling 1:1000   
GAPDH  Mouse Millipore 1:20000   
GAPDH  Mouse SCBT 1:20000   
GFP  Mouse Roche 1:1000  1:250 
HA (Y-11) Rabbit SCBT 1:1000  1:300 
cMyc Ab Mouse SCBT 1:1000   
P120-catenin (pS288)  Mouse BD Transduction  1:1000 1:200  
P120-catenin  Mouse BD Transduction  1:2000 1:400  
PAK1  Rabbit Cell Signalling 1:1000  1:250 
PAK4 (#3242) Rabbit Cell Signalling 1:1000   
PAK4  Rabbit Wells lab 1:2000   
PAK5  Rabbit Abcam 1:500   
PAK5  Rabbit Millipore/Calbiochem 1:500   
PAK5  Rabbit Wells lab 1:2000  1:250 
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PAK5 (H-20) Goat SCBT 1:500   
PAK5 (S-16) Goat SCBT 1:500   
Phospho ERK1/2 (pMAPK) Rabbit Cell Signalling 1:1000   
Phospho-Akt (Ser473)  Cell Signalling 1:1000   
phospho-Pak1/2/3 Rabbit Cell Signalling 1:500   
phospho-Pak4/5/6 Rabbit Cell Signalling 1:500   
Red Fluorescent Protein (RFP) Rabbit Biovision 1:1000  1:250 
Vinculin Mouse Sigma  1:1000   
      
 
Table 2-7 : List of antibodies used in the project, with the concentration for use in Western blots, indirect 
immunofluorescence and immunoprecipitation as indicated 
 
 
2.1.7.2 Secondary antibody/miscellaneous 
Antibody Company  
Alexa Fluor® 488 goat anti rabbit IgG Invitrogen, UK 1:400 (IF) 
Alexa Fluor® 568 goat anti rabbit IgG Invitrogen, UK 1:400 (IF) 
Alexa Fluor® 488 goat anti mouse IgG Invitrogen, UK 1:400 (IF) 
Alexa Fluor® 568 goat anti mouse IgG Invitrogen, UK 1:400 (IF) 
Goat anti-mouse IgG-HRP Dako 1:2000 (WB) 
Goat anti-rabbit IgG-HRP Dako 1:2000 (WB) 
Rabbit  anti-goat IgG-HRP Dako 1:2000 (WB) 
Rabbit  anti-mouse IgG-HRP Dako 1:2000 (WB) 
Phalloidin, Alexa Fluor® 488 Invitrogen, UK 1:400 (IF) 
Phalloidin, Rhodamine (Molecular probes®) Invitrogen, UK 1:400 (IF) 
DAPI  1:10000 (IF) 
 
Table 2-8 :  List of secondary antibodies used in the project, with the concentration for use in Western blots 
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 Buffers 
Blocking solution for Western Blot: 5% w/v milk powder or 5% w/v Bovine Serum Albumin (BSA) 
in Tris buffered saline (TBS)-Tween 
Blocking solution for Immunofluoresce: 3% BSA in Phosphate buffered saline (PBS) 
DNA loading buffer: 40% w/v sucrose, 0.25% w/v bromophenol blue 
NP-40 lysis buffer: 0.5% v/v NP-40, 30mM sodium pyrophosphate, 50 mM Tris-HCL pH 7.6, 150 
mM NaCL, 0.1 mM EDTA and protease inhibitor cocktail 
Protease inhibitor cocktail: 50 mM NaF, 1 mM Na3VO4, 1 mM PMSF, 10 g/ml leupeptin, 1 g/ml 
aprotinin and 1 mM DTT 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) running buffer (10x): 
250 mM Tris-base, 1.92 M glycine, 1% w/v SDS. Dilute to 1x with distilled water (dH2O). 
SDS-PAGE transfer buffer (10x): 250 mM Tris-base, 1.92 M glycine, Make up transfer buffer fresh 
on the day by diluting to 1x by adding methanol to a final concentration of 20% v/v. 
SDS-PAGE sample buffer (2x): 100mM Tris-HCl pH 6.8, 4% w/v SDS, 20% w/v  glycerol, 0.2% 
w/v bromophenol blue, 1:50 -mercaptoethanol 
Tris Acetate EDTA (TAE) buffer: 40mM Tris acetate, 1 mM EDTA 
TBS-Tween: 25mM Tris HCl pH7.6, 50 mM NaCL, 0.1% v/v/ Tween20 
PBS-Tween: PBS, 0.1% Tween20 
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2.2 Methods 
 Mammalian cell culture 
2.2.1.1 Bladder cancer cell lines 
Bladder cancer cell lines RT4, RT112, T24, TCCSUP and 253J were cultured in RPMI-1640 
medium supplemented with L-glutamine and NaHCO3, 10% foetal bovine serum and 1% 
penicillin/streptomycin (100U/ml penicillin and 100g/ml streptomycin). Cells were incubated at 
37 0C in a humidified atmosphere of 5% CO2 in air. All cells were confirmed to be mycoplasma-
free by regular DAPI staining.   
HEK293 cell line was cultured in DMEM with 10% FBS and 1% penicillin-streptomycin. All cell 
lines were cultured in tissue culture incubator with humidified air, supplemented with CO2 to 5% 
above atmospheric level. Cells were passaged and maintained at subconfluent levels in T75 
flasks. During cell-passage, the growth medium was removed and the cells were washed with 5 
ml of PBS for 3 times prior to incubation with 2 ml Trypsin/EDTA at 37 0C for 5-10 minutes until 
the cells become detached from the surface.  
2.2.1.2 Seeding cells on glass coverslips for morphological characterisation of cells in 
basal growth condition 
Cells cultured in basal growth condition were seeded on glass coverslips for 24 hours to reach 
50-60% confluency. Cells were then stained with Phalloidin to detect F-actin, and DAPI for the 
nucleus. The immunofluorescent images were analysed to assess the morphology, and the cell 
shape was quantified and analysed using ImageJ software.   
 
2.2.1.3 Cryogenic storage of cell lines 
Cells in T75 culture flask were trypsinised for 5-10 minutes until all become detached, and 4 mls 
of full growth medium was added. Cell suspension was then centrifuged at 1200rpm for 5 
minutes, and the supernatant was discarded. Cells were resuspended in freezedown media 
(50% FBS, 10% DMSO and 40% RPMI-1640 or DMEM) and 1 ml of re-suspended cells were 
transferred into each cryovial. Cryovials were initially inserted into cryo-freezing container for 
slow-freezing overnight in the -80 0C before long-term storage in the liquid nitrogen tank. 
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2.2.1.4 Recovery of cells from cryogenic storage 
Cells were recovered from long term storage in liquid nitrogen and thawed rapidly at 37 0c in a 
water bath.  Thawed cell suspension was then transferred to a 15 ml tube, and 5ml of warmed, 
full growth medium was added slowly drop-wise. The cell suspension was then centrifuged at 
1200rpm for 5 minutes, and the supernatant was discarded. The cell pellet was then resuspended 
in 5 mls of full growth medium, and transferred into a 25ml tissue culture flask (T25) for culture. 
The full growth media would be refreshed after 24 hours, and the cells were passaged at 80% 
subconfluent monolayer.   
 Microscopy 
2.2.2.1 Immunofluorescent labelling 
Cells on coverslips were fixed with 4% PFA in PBS at room temperature for 30 minutes and 
washed 3 times with PBS. The cells were then permeabilised with 0.2% Triton X-100: PBS for 5 
minutes, and washed 3 times with PBS. The cells were then incubated in blocking buffer of 3% 
BSA in PBS for 30 minutes, and washed 3 times with PBS. Next, the cells were incubated with 
the required primary antibody for 2 hours, and washed 3 times with PBS. Following this step, the 
cells were incubated with Alexa Fluor® 488 or 568, (Mouse/Rabbit specificity) according to the 
species from which the primary antibodies were raised. If actin co-staining is required, Phalloidin 
of complementary fluorescent emission (Trit-C/Rhodamine/488/633) was added for incubation 
together with the secondary antibody solution. For nuclear staining, DAPI (1:10000 in PBS) was 
added following secondary antibody incubation and the coverslips were incubated for further 5 
minutes. The cells on coverslips were then washed 2 times with PBS and once in ddH2O before 
being mounted on glass slides using 10L FluorSave™ reagent and left to dry overnight in dark 
environment. The coverslips on glass slides are kept in dark environment at 4 0c. 
 The cells on coverslips were imaged on an Olympus IX71 inverted microscope system or Nikon 
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 Molecular biology 
2.2.3.1 Generation of PAK5 overexpression plasmid using Gateway™ Cloning 
Technology 
Polymerase Chain Reaction (PCR) amplification of PAK5 cDNA 
Polymerase chain reaction amplification of PAK5 cDNA was performed using attB tagged forward 
and reverse primer sequences using the GatewayTM Technology system (Invitrogen, UK). PAK5 
wild-type plasmid was used as the DNA template in the production of PAK5 DNA flanked by attB 
sequences (the addition of attB sequences was required to allow for subsequent cloning into 
GatewayTM vectors). The PCR reaction was performed using Accuprime PFX Supermix DNA 
polymerase. For a 50l reaction, the components listed in table 2-4 were added to the reaction 
tube. The specific conditions used for the PCR reaction for DNA amplification are displayed in 
table 2.5.  
Component Volume 
Accuprime PFX Supermix 45 l  
Forward primer (10pmol/l) 2 l 
Reverse primer (10pmol/l) 2 l 
Template DNA (1000ng/l) 1l 
Table 2-9 : PCR reaction components of PAK5 cDNA amplification 
 
 
 Cycle(s) Process Temperature Duration 
1 Pre-incubation 95ºC 5 minutes 
35 Denaturation 95ºC 15 seconds 
Annealing 58ºC  30  seconds 
Extension 68ºC  2 minutes 30 seconds 
1 Final Extension 68ºC 10 minutes 
 
Table 2-10 : Conditions for PCR amplification of PAK5 
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Gel purification of DNA fragments 
Agarose gel electrophoresis was performed to isolate PCR product of PAK5 fragment estimated 
to be at 2.1kb. PCR products were separated on a 1% w/v TAE agarose gel supplemented with 
0.5 µg/ml ethidium bromide and the band of DNA was visualised under low intensity UV light.  The 
fragment of interest (at 2.1kb) was excised from the gel with a fine scalpel and the DNA extracted 
from the agarose gel using QIAquick gel extraction kit. The purified DNA was eluted in the elution 
buffer and then stored at -20°C for subsequent use. 
 
Construction of Entry Clone 
In order to generate a PAK5 entry clone, a GatewayTM BP recombination reaction was conducted 
between the pDONRTM 207 vector and the attB sequence flanked PAK5 PCR product in 
accordance with the manufacturer’s instructions. The BP reaction was incubated for 1 hour at 
room temperature. Subsequently, proteinase K was added and the reaction mixture was 
incubated at 37 ºC for 10 minutes to terminate the reaction. The BP reaction mixture was then 
transformed into TOP10 E. coli cells and the bacteria were plated onto L-agar supplemented with 
the appropriate antibiotic and incubated overnight at 37oC. Colonies were then selected and the 
plasmid DNA was purified. The presence of PAK5 in individual colonies was verified by restriction 
digest. PAK5-positive clones were subsequently sequenced by Eurofins MWG Operon using 
primers that anneal to the gateway sequence upstream of the PAK5 gene An internal primer was 
also generated to sequence the entirety of PAK5 . 
 
Construction of PAK5 expression clone 
In order to generate GFP-, RFP-, myc-, and HA-PAK5 expression plasmids, GatewayTM LR 
recombination reactions were performed between the pENTR (PAK5) entry clone and the 
selected destination vectors including modified pEGFP-C1 (Clontech, UK), pDEST™ mRFP, and 
pDEST™ myc (pRK5-myc) in accordance with the manufacturer’s instructions. The LR reaction 
was incubated for 1 hour at room temperature. Subsequently, proteinase K was added and the 
reaction mixture was incubated at 37 ºC for 10 minutes to terminate the reaction.  The reaction 
was then transformed into TOP10 E. coli cells as described in previously. The plasmid DNA 
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purified from the individual colonies was then sequenced by Eurofins MWG Operon using 
sequencing primers. 
 Transient transfection of cell lines 
Transient transfection of HEK293 cells using Calcium Phosphate Transfection Kit 
HEK-293 cells were seeded at a density of 1 x 105 cells/ml in 2mls of full growth medium, into 
2cm wells on a 6-well plate. The cells were incubated overnight, and the medium was changed 
to a fresh full-growth medium 3-4 hours prior to transfection. The composition of the transfection 
mixture are documented in table 2.6.  
2cm dish (2ml)/ 6-well plate 
Tube A 6 l 2.5M CaCl2 
2 g DNA 
Make reaction volume up to 60 l with sterile 
water 
Tube B 60 l 2x HEPES buffered saline (HBS) 
 
Table 2-11 : Calcium Phosphate transfection mixture for HEK-293 cells 
 
Mixture from tube A was slowly added with aeration to tube B, and incubated for 30 minutes at 
room temperature. The transfection mixture was then added to the HEK-293 cells in the 2cm wells 
drop-wise, and dispersed for even spreading. The cells were incubated overnight with the 
transfection mixture at 37 0c in the tissue culture incubator, with a change of medium to fresh full-
growth medium at 24 hours. The cells were incubated for further 24 hours before the cells were 
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Transient transfection of bladder cancer cell lines using X-tremeGENE HP 
Bladder cancer cell lines were seeded at the appropriate density in full growth RPMI medium, and 
incubated at 37 0C overnight to attain 60-70% sub-confluent monolayer prior to transfection. The 
DNA-lipid complex for transfection in 6-well plate was prepared as follows: 
Reagent Volume 
Optimem 92 l 
cDNA (at 1 g/l) 2 l 
X-tremeGENE HP 6 l 
 
Table 2-12 : Transfection mix composition for X-tremeGENE HP 
 
The total reaction volume in Optimem™ was 100 l, with reagent to DNA ratio of 3:1. The mixture 
was incubated at room temperature for 20 minutes to allow complex formation. The RPMI growth 
media in the 6-well plates were replaced with serum free Optimem™ prior to adding the 
transfection mixture to the cells. The cells were then incubated at 37 0C for 6 hours, before 
replacing the Optimem™ medium with full-growth RPMI. The cells were incubated and checked 
for transfection efficiency at 24 and 48 hours. 
 
Synthetic siRNA reverse transfection using Lipofectamine RNAiMax 
RT112 cells and RT4 cells were reverse transfected using Lipofectamine™ RNAiMax. The 
protocol was adapted from the manufacturer’s (Invitrogen™) instructions for Transfection of 
SiRNA into MCF7 (colony-forming breast cancer cell-line). Cells were transfected in 6-well and 
24-well plate formats, with the reaction components as documented table 2.13. 
Culture 
vessel 
Volume of plating 
medium 






24-well 500 l 100 l 2 1 l 
6-well 2500 l 500 l 10 5 l 
 
Table 2-13 : Reagent amounts and volumes for reverse transfection of RT112 and RT4 cells using 
Lipofectamine™ RNAiMax scaled to 6-well and 24-well plates. 
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 Generation of PAK5 specific polyclonal antibody 
Designing synthetic peptide for antigen recognition 
Protscale software available on Expasy website http://web.expasy.org/protscale/ was used to 
identify the suitable peptide sequence on PAK5 for antigen recognition.  Two different scales 
(Hopp & Woods, and Kyte & Doolittle) were used to assess the hydrophobicity and the 
hydrophilicity profiles of PAK5 sequence of amino acids. A synthetic peptide sequence (yreks 
lygdd ldpyy) corresponding to aa146-160 of PAK5 protein was identified as a suitable antigen, as 
represented in figure 2.2. The peptide identified was manufactured and inoculated into rabbit 
hosts for polyclonal antibody production by Eurogentec Ltd. 
 
Figure 2-1 : The protein-protein blast for this peptide sequence showed that this epitope is PAK5 specific 
(http:/blast.ncbi.nlm.nih.gov).  
 
2.2.5.1 Affinity purification of PAK5 rabbit polyclonal antibody 
Serum containing PAK5-specific polyclonal antibody was then prepared for affinity purification 
using Sulfolink® Immobilisation kit for peptides according to manufacturer’s protocol. Briefly, 
peptide column was prepared by coupling peptide sequence (yreks lygdd ldpyy) corresponding 
to aa146-160 of PAK5 to the resin within the column. Non-specific binding sites on the resin were 
blocked using 50 mM cysteine. The column with resin coupled to PAK5 peptide was then 
incubated with the serum of rabbit immunised with PAK5 for 45 minutes at room temperature to 
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 Protein analysis 
Cell lysis 
Cells were washed twice in PBS and lysed on ice in 0.5% NP-40 lysis buffer supplemented with 
a protease inhibitor cocktail for 10 minutes. The whole cell lysates were then scraped and 
centrifuged for 10 minutes at 13000 x g for 10 minutes to remove cell debris. The supernatant 
was removed and placed in a fresh tube for storage. 10 µl of 2x SDS Gel sample buffer (GSB) 
was added to the lysates and the samples boiled at 90ºC for 3 minutes. 
 
Immunoprecipitation 
Typically 5 µl of the appropriate IP antibody was added to the lysis supernatant and incubated 
overnight at 4ºC on a rotating wheel. The following day, protein A or G beads were washed three 
times in lysis buffer. The beads were re-suspended in an appropriate volume of lysis buffer prior 
to adding 30 µl of bead slurry to each IP sample. The samples were then incubated for 1 hour on 
a rotating wheel at 4˚C.  Each IP, and untransfected (UT) control, was pulse spun following 
incubation and washed three times with lysis buffer. 2x GSB was added to each sample and 
boiled at 90°C for 3 minutes. 
 
Gel electrophoresis and immunoblotting 
Proteins were loaded onto appropriate % gels and electrophoresed. Proteins were then blotted 
onto nitrocellulose membranes. The blots were then blocked in 5% milk or 5% BSA/TBS-Tween 
as appropriate for one hour at room temperature and incubated with primary antibodies overnight 
at 4°C. Blots were then washed for three 10 minute washes with 0.1% TBS-Tween. Blots were 
then incubated with HRP-conjugated secondary antibodies for one hour at room temperature. 
Blots were then subjected to a further three 10 minute washes with 0.1% TBS-Tween. If re-
probing was required, the blots were incubated in stripping buffer for 15 minutes which was then 
removed and replaced with fresh stripping buffer for a further 15 minutes. The blots were then 
washed with 0.1% PBS-Tween for 5 minutes. Subsequently the blots were blocked for 1 hour in 
5% milk or 5% BSA/TBS-Tween as appropriate and incubated overnight with primary antibodies 
at 4°C.  
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 Data analysis 
Image processing and cell shape analysis 
Image J software was used to elucidate the morphology of each cell by manually drawing around 
individual cells and then processing the data to give elongation ratios and cell spread areas. In 
order to determine the elongation ratio of a cell, Image J shape analysis software divides the 
shortest cell diameter by the longest. Therefore, the ratio for an elongated cell morphology 
generated by Image J is a small numerical value. Hence, in order to aid graphical representation 
of the results acquired, all elongation ratio values have been subtracted from one and all spread 
areas have been multiplied by 1000.  
 
Densitometry Analysis 
The autoradiographs were saved as TIF files in Adobe Photoshop CS5 and ANDOR IQ 
Technology software was used to quantify desired protein levels. In this analysis system it was 
assumed that 0 is black and the maximal value is 255 at 8 bits per pixel. These values were then 
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P21-activated kinases (PAKs) are serine-threonine kinases that are positioned at the intersection 
of various signalling pathways required for oncogenesis (Molli, Li et al. 2009, Radu, Semenova 
et al. 2014). There is accumulating evidence that overexpression or aberrant activation of PAKs 
drives many of the cellular processes associated with biological capabilities that constitute the 
hallmarks of cancer, including activating invasion and metastasis (Hanahan and Weinberg 2000, 
Hanahan and Weinberg 2011).  
There are six mammalian PAKs, categorised into two subgroups on the basis of their sequence 
and structural homology. Group 1 PAKs comprises PAK1, PAK2 and PAK3, and the roles for 
PAK1 in cancer have been extensively characterised, including its role in the oncogenesis of 
urothelial tumours. In bladder cancer, overexpression of PAK1 was associated with increased risk 
of recurrence after transurethral tumour resection (Ito, Nishiyama et al. 2007), while in upper 
urinary tract urothelial tumours, overexpression of PAK1 was associated with lymphovascular 
invasion in tumour histopathology, and increased risk of metastasis on long term follow up (Kamai, 
Shirataki et al. 2010). The roles of other member of the PAK family in urothelial oncogenesis is 
unknown.  
 Group 2 PAKs consists of the more novel members; PAK4, PAK5 and PAK6. The best 
characterised member of this subgroup is PAK4. Amongst PAK4-6, PAK4 is most closely linked 
with cancer, and has been shown to promote anchorage independent growth, regulate cell cycle, 
inhibit apoptosis, and activate invasion and metastasis (Minden 2012, Dart and Wells 2013). 
Overexpression of PAK4 has been demonstrated in a variety of human cell lines and cancers, 
including gastric cancer (Ahn, Jang et al. 2011), ovarian cancer (Siu, Chan et al. 2010) and 
pancreatic cancer (Chen, Auletta et al. 2008). PAK5 has been shown to protect cells from 
apoptosis (Cotteret, Jaffer et al. 2003), and its overexpression has been associated with colorectal 
cancer (Gong, An et al. 2009) and gastric cancer (Gu, Li et al. 2013). PAK6, which was initially 
cloned from prostate cancer cells as an androgen receptor (AR) interacting protein(Yang, Li et al. 
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2001), has been shown to be involved in the regulation of prostate cancer (Wen, Li et al. 2009, 
Fram, King et al. 2013, Liu, Li et al. 2013). Despite the increasing interest in the roles PAKs in 
cancer, no studies have yet linked any of the group-2 PAKs to oncogenesis of urothelial 
carcinoma.  
One of the aims of this study was to investigate the role of group 2 PAKs in the invasion and 
metastasis of bladder cancer. To initiate the project, 5 bladder cancer cell lines were identified to 
form a panel to screen the protein expression level of PAK4, PAK5 and PAK6. As PAK1 has 
previously been studied in bladder cancer, its expression level was also screened for its potential 
utility as an arbitrary positive control (Ito, Nishiyama et al. 2007, Kamai, Shirataki et al. 2010). 
Many bladder cancer cell lines have been characterised and matched to represent clinical tumour 
stages and grades. The characterisation was based on their tumour of origin, cell morphology in 
culture, gene and protein expression,  tumorigenicity and xenograft morphology (Masters, 
Hepburn et al. 1986, Ahlering, Dubeau et al. 1987, Theodorescu, Cornil et al. 1990, Rieger, Little 
et al. 1995, Hurst, Fiegler et al. 2004, Dancik, Ru et al. 2011). In this study, I started the project 
by using 5 different human bladder cancer cell lines; RT4, RT112, T24, TCCSUP and 253J.  
The cell lines included in the panel were selected to represent urothelial cell lines at different 
stages of tumour progression, corresponding to well-differentiated, moderately-differentiated and 
poorly-differentiated primary urothelial tumour. A urothelial cell line (253J) from retroperitoneal 
lymph node with metastatic urothelial tumour was also included in the panel. The origins of these 
cancer cell lines are listed in table 3.1 (Rigby and Franks 1970, Bubenik, Baresova et al. 1973, 
Elliott, Cleveland et al. 1974, Nayak, O'Toole et al. 1977, Masters, Hepburn et al. 1986). 
RT4 is a paradigm for well-differentiated bladder carcinoma. This cell line was established from 
primary bladder tumour (Rigby and Franks 1970), where the histological appearance of the 
original tissue cultured was of a well differentiated, low grade urothelial carcinoma of the bladder.  
RT112 is a moderately-differentiated urothelial carcinoma cell line which originated from a 
histology grade-2 (G2) papillary bladder tumour. In steady state, RT112 cells retain the epithelial-
like morphology, in which the cells grow in distinct colonies to form an epithelial sheet in 2D culture 
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Cell line  Tumour origin Clinical stage Histological 
grade 
Sex of patient 
T24 Primary bladder Not recorded High grade Female 
RT112 Primary bladder Stage 2 Low grade Male 
RT4  Primary bladder Not recorded Low grade Male 
TCCSUP Primary bladder Stage 4 High grade Female 
253J Retroperitoneal lymph 
node metastasis 
Stage 4 High grade Male 
 
Table 3.1: Origin of bladder cancer cell lines used in the project 
 
Tumours produced by RT4 and RT112 cell lines in nude mice xenograph models were shown to 
be morphologically conserved when the histopathological sections were compared to the original 
histopathological images taken  in 1967 and 1973 respectively, despite years of culture and 
propagation (Masters, Hepburn et al. 1986). RT4 and RT112 had been used in many bladder 
cancer studies as the cell lines to represent low grade bladder tumours (Masters, Hepburn et al. 
1986, Schwartz, Redwood et al. 1990, Theodorescu, Cornil et al. 1990, Weidner, Behrens et al. 
1990, Bryan, Atherfold et al. 2008, Rose, Grandoch et al. 2010). Gene expression profiles of RT4 
and RT112 cells have also been analysed, which showed molecular or gene expression alignment 
of these cells to low grade and low stage tumours when independently assessed in multi-centre 
cohorts (Dancik, Ru et al. 2011). 
T24 and TCCSUP cell lines both originated from poorly differentiated, high grade primary 
urothelial tumours (Bubenik, Baresova et al. 1973, Elliott, Cleveland et al. 1974, Nayak, O'Toole 
et al. 1977). T24 was used in the study which identified the first human oncogene, H-ras 
(Taparowsky, Suard et al. 1982), which had led to significant advancement in cancer studies. The 
cell line 253J originated from metastatic retroperitoneal lymph node of a male patient with high 
grade (historically grade-4) bladder tumour with lymph node, bone and cerebral metastasis 
(Elliott, Cleveland et al. 1974, Nayak, O'Toole et al. 1977). It was interesting to note that the cell 
culture from this patient (253J donor) could only be established from the tissue taken from the 
retroperitoneal lymph node, but not the primary tumour, which indicated that tumour cells in 
metastasis may be characteristically different to the primary tumour cells in the same patient.  
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TCCSUP T24, TCCSUP and 253J have been used extensively in the study of bladder cancer, 
particularly as models to represent high grade bladder tumours  (Steele, Rowlatt et al. 1983, 
Kwon, Yoshida et al. 1995, Bui, O'Brien et al. 1998, Pervaiz, Cao et al. 2001, Wu, Shu et al. 2003, 
Gallagher, O'Shea et al. 2008, Mariotti, Castiglioni et al. 2009, Moissoglu, McRoberts et al. 2009, 
da Silva, Evangelista et al. 2011, Mierke, Frey et al. 2011, Yamamoto, Sutoh et al. 2011). In this 
study, T24, 253J and TCCSUP were selected as the likely representatives of high grade, high 
stage, and invasive bladder cancer based on characterisation data already available in 
publications.  
Cross contamination of cell lines is a well-documented problem in urology research (O'Toole, 
Povey et al. 1983, Masters 2002, Jager, Horiguchi et al. 2013). As these different cell lines were 
co-cultured at the same time in my project, the risk was significantly increased. A year after my 
project started, a collaborator had obtained the 5 bladder cancer cell lines from my stock and 
performed Short Tandem Repeat (STR) analysis. The analysis authenticated the cell lines 
obtained from my stock, and ruled out cross-contamination (appendix 1). 
A number of discrepancies in the morphological characteristics of some of the cell lines in my 
panel have been reported when cultured in different laboratories (Mialhe, Levacher et al. 2000, 
Baumgart, Cohen et al. 2007). Thus, in this chapter, I first established the morphological 
characteristics of all the cell lines. I subsequently screened for expression of 2 classical markers 
of epithelial differentiation or EMT (N- and E-cadherin), and characterised the cadherin-based 
cell-cell adhesions in 2 of the cell lines. Finally, the bladder cancer cell-lines were screened for 
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3.2 Results 
 Cellular morphology of bladder cancer cell lines in culture 
The actin cytoskeleton provides a structural framework around which cell shape and polarity are 
defined (Ballestrem, Wehrle-Haller et al. 1998, Hall 1998, Vasioukhin, Bauer et al. 2000). The 
morphology of bladder cancer cell lines were characterised by immunofluorescent staining of the 
F-actin which forms the cell cytoskeleton. Classification of epithelial morphology was broadly 
defined as tightly adherent cuboidal cells growing in discrete colonies, while mesenchymal 
morphology was defined as poorly adherent carcinoma cells displaying stellate morphology, as 
previously described (Baumgart, Cohen et al. 2007) 
RT112 and RT4 cells both grew in distinct colonies which can form an epithelial sheet in 2-D, 
where the archetypal epithelial cell-cell junctions were conserved.  Accumulation of F-actin at the 
margins of cell-cell contact was prominent in these cell lines (figure 3.1), which is also a phenotype 
commonly associated with epithelial cells (Vasioukhin, Bauer et al. 2000).  Actin-based 
membrane protrusions such as filopodia or lamellapodia were rarely observed in RT4 cells when 
cultured in basal growth condition (figure 3.1A) 
T24, TCCSUP and 253J cells, which were all derived from high grade/stage tumours, grow as 
detached cells in 2-D culture (figure 3.2) at 50-60% confluency.  Distinct formation of cell: cell 
adhesion characterised by accumulation of F-actin at cell contact margins was not seen in these 
cells lines, even when the margins of adjacent cell were in contact with another (figure 3.2, 
indicated by arrows)  Formation of thin, elongated membrane protrusions were seen in all 3 cell 
lines in this subgroup. These protrusions may represent filopodia, which are exploratory 
extensions from the plasma membrane that contain bundles of actin filaments, with important 
roles in both processes of cell migration (Mattila and Lappalainen 2008, Ridley 2011), as well as 













Figure 3-1 : Morphological characteristics of well and moderately differentiated bladder cancer cell 
lines in 2D culture:  Immunofluorescent F-actin and nuclear staining of bladder cancer cell lines RT4 (A) 
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Figure 3-2 : Morphological characteristics of poorly differentiated bladder cancer cell lines in 2D 
culture: Immunofluorescent phalloidin staining for F-actin in T24 (A), 253J (B) and TCCSUP (C) cells at 40-
60% subconfluent monolayer.  Arrows indicate areas of contact between adjacent cells without distinct 
accumulation of F-actin. Scale bar = 10m. 
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Cell shape in 2-D as indicated by the actin staining of the cell membrane, was analysed using 
imageJ software using set measurements, which included of area (relative value, 3.3A) and shape 
descriptors (circularity and aspect ratio, 3.3B-C). The analysis showed that RT112 and RT4 cells 
were smaller compared to T24, TCCSUP and 253J. The formation of cell-cell adhesions in the 
epithelial cells could significantly influence the cell shape observed at basal condition (Carthew 
2005).  Larger cell area on 2D in cell lines of invasive origin indicated greater cell spreading and 
motility potentials in these cell lines (Fardin, Rossier et al. 2010).  TCCSUP cells had distinctly 
elongated morphology in basal growth condition, consistent with its mesenchymal phenotype. 
The differences in cell morphology seen in this section (figures 3.1 and 3.2), suggested that high 
grade/stage bladder tumour cells (T24, TCCSUP and 253J) had lost  their epithelial morphology 
and undergone epithelial to mesenchymal transition, whereas RT4 and RT112 cells still retained 






















P-value, for parameters compared to the morphology of RT4 cells 
Cells Area Circularity Aspect Ratio 
T24 <0.001 <0.001 0.122403 
RT112 <0.001 0.346577 0.606717 
TCCSUP <0.001 <0.001 0.550478 
253J <0.001 <0.001 <0.001 
 
Figure 3-3 : Quantitative analysis of the cell shape of bladder cancer cells in 2D culture on glass 
coverslips. The shape was manually outlined based on the F-actin staining: A) Cell area. B) Cell 
circularity C) Cell aspect ratio. D) Student t-test was performed comparing the individual cells to the cell 
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 Cadherins and cell: cell adherens junctions in bladder cancer cell lines 
 
Epithelial mesenchymal transition (EMT) is a process in which epithelial cells lose their 
characteristic polarity, disassemble cell-cell junctions and become more migratory (Radisky 2005, 
Baum, Settleman et al. 2008). Cadherin isoform switching (cadherin switching) involving loss of 
E-cadherin and gain of N-cadherin expression is characteristic in EMT, and tumour cells 
recapitulate this activity, resulting in aggressive tumour behaviour with the ability to invade and 
metastasize (Cavallaro 2004, Cavallaro and Christofori 2004, Wheelock, Shintani et al. 2008, 
Berx and van Roy 2009).  
There is accumulating evidence that EMT and cadherin switching play important roles in bladder 
cancer invasion and metastasis. (Bringuier, Umbas et al. 1993, Bryan, Atherfold et al. 2008, Bryan 
and Tselepis 2010, Jager, Becker et al. 2010). It is speculated that Cadherin switching occurs 
late in the pathogenesis of bladder cancer, and contribute significantly to the divergent pathways 
of urothelial tumorigenesis. 
Previous results (figures 3.1 - 3.3), suggest that T24, TCCSUP and 253J have undergone EMT, 
whereas RT4 and RT112 still retain their epithelial phenotype and markers. To support this 
hypothesis, the whole cell lysates of all 5 bladder cancer cell lines were screened for protein 
expression of E-cadherin and N-cadherin (figure 3.4).  Consistent with the epithelial cell 
morphology seen previously, RT4 and RT112 cells retained the protein expression of E-cadherin, 
with no detectable expression of N –cadherin under basal growth conditions. Conversely, T24, 
TCCSUP and 253J cells have lost the protein expression of E-cadherin, and consistent with the 















Figure 3-4 : Cadherin switch in bladder cancer cell lines. Whole cell lysates of bladder cancer cell lines 
were probed classic markers of cadherin switching in EMT. A) E-cadherin total protein level with GAPDH 
loading control. B) N-cadherin total protein level with GAPDH loading control. Images are representative of 
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The expression and localisation of E-cadherin in RT112 and RT4 were also assessed by indirect 
immunofluorescence at basal growth conditions. In RT4 cells, the e-cadherin staining at cell-cell 
junction was uniform and evenly distributed to form distinct E-cadherin plaques along the areas 
of cell-cell contact margin (figure 3.5A). The e-cadherin staining in RT112 however displayed a 
more disrupted or ‘zippered’ appearance, where multiple E-cadherin-containing punctae cluster 
at varying intensities along the contact margins (figure 3.5B). 
 For cells forming epithelial sheets, three stages of cell-cell adhesion and colony formation have 
been proposed (Adams, Chen et al. 1998, Vasioukhin, Bauer et al. 2000, Vasioukhin and Fuchs 
2001). Stage 1 corresponded with immature adhesions which loosely hold cells together. At stage 
2, E-cadherin plaques develop at the edges of the contact, and at stage 3, the E-cadherin plaques 
cinch together to form multi-cellular vertices, further condensing the cell colonies, which indicated 
mature and stable cell-cell adherens junctions. I have used this analysis technique to estimate 
the maturity and stability of the epithelial junctions in RT4 and RT112 cells under basal growth 
conditions. 
The fluorescence of E-cadherin signal was plotted to represent immunofluorescence intensity at 
the region of cell-cell contact in both these cell lines (figure 3.5). The formation of continuous of  
E-cadherin plaques at the margins of cell-cell contact in  RT4 cells were consistent with more 
established and mature cell-cell junctions (stages 2-3), whereas the interrupted staining pattern 














Figure 3-5 : Characteristic of E-cadherin positive cell-cell junction of RT4 and RT112 cells in 2D 
culture: Immunofluorescence and line scan of E-cadherin staining at cell: cell junction of RT4 (A) and RT112 
(B) cells. The dashed red boxes approximately register the edges of the contact plotted for fluorescence 
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 Changes in epithelial adherens junctions in RT112 and RT4 cells in 
response to HGF stimulation 
 
Studies have shown that activation of tyrosine kinase receptor c-Met by its ligand, hepatocyte 
growth factor (HGF) in epithelial cells in vitro can induce changes in cell morphology, loss of cell 
polarity and dissociation of cell-cell junctions, associated with EMT (Stoker, Gherardi et al. 1987, 
Balkovetz, Pollack et al. 1997). There is also substantial body of evidence correlating HGF/C-Met 
signalling pathway to metastatic spread of tumours, including bladder cancer (Cheng, Trink et al. 
2002) (Joseph, Weiss et al. 1995, Tamatani, Hattori et al. 1999, Wang, Nishitani et al. 2007). A 
member of group-2 PAK family, PAK4 was shown to act downstream of HGF, and PAK4 was 
required for HGF-induced scattering of prostate cancer cells (Wells, Abo et al. 2002, Ahmed, 
Shea et al. 2008). I therefore investigated whether these EMT-associated morphological changes 
in response to HGF could be reproduced in bladder cancer cells.  
Although the expression of tyrosine kinase receptor c-Met has been studied in bladder cancer, 
the data available for all the cell lines as one panel were only available for the mRNA transcription, 
but not the protein expression (Cheng, Trink et al. 2002, Wang, Nishitani et al. 2007). I therefore 
proceeded to assess the expression level of c-Met in my panel of bladder cancer cell lines by 
Western blots (figure 3.6A).  Within this panel, high protein levels of c-Met receptor were detected 
in T24 and 253J cells. RT4 cells expressed low level of c-Met. Moderate total protein levels of c-















Figure 3-6 : Protein expression of C-Met receptor in bladder cancer cell lines A) Western blot of whole 
cell lysates of bladder cancer cell lines for C-Met Receptor, probed with Met (C-12) SCBT™ antibody. B) 
Analyses of C-Met Receptor expression on Western blot using densitometry quantification on ImageJ from 
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Having established that c-Met protein expression can be detected in bladder cancer cell lines, 
albeit at varying levels, I proceeded to investigate the response of ‘epithelial-like’ bladder cancer 
cell lines (RT112 and RT4) to HGF stimulation, and whether this assay can induce EMT-
associated morphological changes. The cells were seeded on glass coverslips in full growth 
conditions at low density to allow formation of distinct cell colonies. The cells were then subjected 
to starve conditions for 24 prior to HGF stimulation. The cells were then stimulated by addition of 
HGF to the starve media, and fixed at different time-points following addition of HGF.  
When the RT112 cells were stimulated with HGF using standard assay protocol, disruption of cell 
junctions was observed at 90 minutes, where the cell-cell junctions were disrupted. The cells 
displayed multiple slender membrane protrusions, within the newly created space as the cells 
dissociated from their epithelial sheet or colonies (figure 3.7). 
 The morphological changes observed in RT4 cells were not as pronounced as those manifested 
in RT112 cells. Following HGF stimulation, the cell contact within the RT4 epithelial sheet was 
maintained. However, the linear, homogenous E-cadherin plaques at the margin of cell-cell 
contact appeared more disrupted or ‘zippered’. I also observed that HGF stimulation of RT4 cells 
resulted in formation of E-Cadherin punctate which aggregated along the E-cadherin plaque at 

















Figure 3-7 :  Disruption of cell adhesion following HGF stimulation in RT112 cells A) E-cadherin staining 
in RT112 distribution of E-cadherin along the contact margins in RT112 cells. B) Following HGF stimulation, 
the cells dissociated from each other, and areas of cell: cell contact were replaced by multiple thin spikes of 
membrane protrusions. Magnified images of E-cadherin distribution at cell contact margins are boxed in 
yellow. Images shown are representative of 3 independent experiments. Bar = 10m 
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Figure 3-8 : Changes in E-cadherin cell adherens junction following HGF stimulation in RT4 cells A) 
Distinct cadherin staining appear as continuous plaques at margins of cell: cell contact in RT4 cells. B) 
Following HGF stimulation, subtle changes at the adherens junctions were characterised by appearance of 
E-cadherin punctae along the cell contact margin. Magnified images of E-cadherin distribution at adherens 
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 PAK1 expression in human bladder cancer cell lines 
 
PAK1 is the most comprehensively characterised member of the PAK-family. In a bladder cancer 
clinical study (Ito, Nishiyama et al. 2007), high expression of PAK1 at both gene transcription and 
protein expression levels were associated with high tumour grade, and increased risk of 
recurrence. Another clinical study, which analysed surgical specimens of patients with urothelial 
tumour of the upper urinary tract, had also demonstrated that over expression of PAK1, and 
activation of its upstream regulator, RAC1, were associated with increased risk of lymphovascular 
invasion and lymph node metastasis (Kamai, Shirataki et al. 2010).  
One of the studies (Ito, Nishiyama et al. 2007) had also included functional analysis of PAK1 in 
bladder cancer cell lines 253J and EJ (previously reported to be identical to T24, (O'Toole, Povey 
et al. 1983)). The endogenous expression level PAK1 was reported to be relatively low in 253J 
compared to EJ cell line. Overexpression of constitutively active PAK1 (T423E) in 253J enhanced 
cell migration in wound healing and Matrigel migration assays. Conversely, suppression of 
endogenous PAK1 function in EJ cells by overexpression of kinase-dead PAK1 K299R delayed 
cell migration.  
As PAK1 had been characterised in urothelial carcinomas, I have included the screen for the 
protein expression of PAK1 my panel of 5 bladder cancer cell lines.  Western blots using PAK1 
isoform-specific (Cell Signalling Technology ™) was performed , and I observed high total protein 
levels  of PAK1 in RT4 and TCCSUP, moderate levels in 253J and T24, and very low protein 
expression of PAK1 in RT112 (figure 3.9). Even though PAK1 was differentially expressed, the 
protein levels of PAK1 per se did not show any direct correlation with the epithelial differentiation 














Figure 3-9 : Protein expression of PAK1 in bladder cancer cell lines A) Western blot of whole cell lysates 
of bladder cancer cell lines probed with PAK1 antibody. B) Analyses of PAK1 expression on Western blot 
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 PAK4 expression in bladder cancer cell lines 
 
Group-2 members of the PAK family are structurally different from group-1 PAKs (figure of PAK 
structure in introduction chapter 1).  The evidence for the role of group-2 PAKs in oncogenic 
transformation and in cellular processes associated with cell survival, proliferation, cytoskeletal 
organisation have been described in a number of studies (Gnesutta, Qu et al. 2001, Gnesutta and 
Minden 2003, Eswaran, Soundararajan et al. 2009). PAK4 is the first identified member of group-
2 PAKs (Abo, Qu et al. 1998). Among members of group 2 PAKs, PAK4 has been most closely 
linked to cancer, and has been shown to be upregulated or overexpressed in a number of human 
malignancies (Dart and Wells 2013, Whale, Dart et al. 2013, Wong, Chen et al. 2013). There is 
currently no research in publication with strong evidence associating PAK4 in the oncogenesis of 
bladder cancer. 
I screened my panel of bladder cancer cell lines for PAK4 expression using in-house PAK4 
specific polyclonal antibody which had been previously validated (Wells, Whale et al. 2010). The 
antibody detects PAK4 at MW 65 kDa. PAK4 was expressed in all bladder cancer cell lines on 
my panel. The expression profile of PAK4 across the cell lines were ubiquitous, and did not 


















Figure 3-10 : Protein expression of PAK4 in bladder cancer cell lines A) Western blot of whole cell 
lysates of bladder cancer cell lines probed with PAK4 (in-house) antibody. B) Analyses of PAK4 expression 














T24 RT112 RT4 TCCSUP 253J
Relative expression of PAK4 (mean)








- 90 - 
 PAK6 expression in bladder cancer cell lines 
 
PAK6 is also a member of the group 2 PAKs with suggested roles in cancer. PAK6 was first 
identified as an androgen receptor (AR) interacting protein (Yang, Li et al. 2001, Lee, Ramos et 
al. 2002). PAK6 overexpression had been shown in prostate and breast cancer cell lines, and 
increase in PAK6 protein expression has been associated with failure of androgen deprivation 
therapy in prostate cancer patients (Kaur, Yuan et al. 2008). Recently, PAK6 overexpression was 
shown to cause disruption of cell-cell junctions in androgen receptor (AR) negative DU145 
prostate cancer cells downstream of HGF (Fram, King et al. 2013).  However, in vivo study had 
also demonstrated that PAK6 may inhibit prostate tumour growth in mice by regulating AR 
homeostasis (Liu, Li et al. 2013). 
The role for PAK6 in bladder cancer has not been described. However, the evidence for androgen 
receptor regulation in urothelial oncogenesis is emerging (Miyamoto, Yao et al. 2012, Hsu, Hsu 
et al. 2013), supported by the epidemiological data for gender-specific differences in the incidence 
and progression of bladder cancer.(Siegel, Naishadham et al. 2012). The role of PAK6 in AR 
regulation had raised the question whether PAK6 may also play a role in bladder cancer epithelial 
mesenchymal transition. 
I proceeded to screen for PAK6 expression in my panel of bladder cancer cell lines. Whole cell 
lysates of bladder cancer cell line cultured in basal growth condition were assayed to detect the 
expression level of PAK6 using isoform specific antibody obtained from Gene Tex (GTX30295). 
This antibody detected PAK6 at 75kDa, and did not display any additional bands of protein which 
may suggest cross reaction with other members of the PAK family. Ubiquitous PAK6 protein 
expression was observed in all bladder cancer cell lines (figure 3.11A). ImageJ densitometry 
quantification of Western blots from 3 separate sets of cell lysates indicated that PAK6 expression 
was homogenous in this panel of bladder cancer cell lines (figure 3.11B), and did not show 











Figure 3-11 : Protein expression of PAK6 in bladder cancer cell lines A) Western blot of whole cell 
lysates of bladder cancer cell lines probed with PAK6 isoform specific antibody. B) Analyses of PAK6 
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 Generation of PAK5 isoform specific rabbit polyclonal antibody  
 
PAK5 is a novel member of the PAK family, and differentially in normal human tissue, with the 
highest expression levels in the brain (Dan, Nath et al. 2002, Pandey, Dan et al. 2002). A number 
of studies had linked PAK5 with tumour development, invasion and metastasis. PAK5 
overexpression had been described in colorectal cancer (histopathology staining), and associated 
with invasion and metastasis (Gong, An et al. 2009). Gain of function (GOF) mutation of PAK5 in 
lung cancer cell line H2097 enhanced the activation of ERK pathway to maintain cell proliferation 
and viability (Fawdar, Trotter et al. 2013). PAK5 has also been studied in the context of pancreatic 
cancer, gastric cancer, hepatocellular carcinoma, ovarian cancer and glioma, and associated with 
tumour proliferation and/or invasion (Giroux, Iovanna et al. 2009, Gu, Li et al. 2013, Han, Wang 
et al. 2013, Li, Yao et al. 2013, Wang, Cheng et al. 2013).   
A number of commercial antibodies were initially tested to detect the protein expression of PAK5 
in bladder cancer cell lines. The detection of PAK5 using commercially available antibodies was 
inconsistent and unreliable (data not shown). Even though PAK5 is a relatively novel protein and 
has not been extensively studied, there were already data on Human Protein Atlas 
(http://www.proteinatlas.org/ENSG00000101349/tissue) accessed in May 2011 which indicated 
that protein levels of PAK5 were detectable in immunostaining of some normal and malignant 
urothelial tissues. In order to probe for PAK5 expression in bladder cancer cell lines, I generated 
a PAK5 isoform-specific rabbit polyclonal antibody (referred to as in-house PAK5 antibody). 
Protscale software available on Expasy website http://web.expasy.org/protscale/ was used to 
identify the suitable peptide sequence on PAK5 for antigen recognition.  Two different scales 
(Hopp & Woods, and Kyte & Doolittle) were used to assess the hydrophobicity and the 
hydrophilicity profiles of PAK5, which helped to identify the most suitable epitope for antigen 
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A synthetic peptide sequence (YREKS LYGDD LDPYY) corresponding to aa146-160 of PAK5 
protein, located in the N-terminal regulatory domain was selected. The Basic Local Alignment 
Search Tool (BLAST, http://blast.ncbi.nlm.nih.gov/)    was used to check for other proteins which 
contain similar peptide sequence, and may also interact with the antibody designed.  The search 
using Protein BLAST showed that this peptide sequence was specific for PAK5. The location of 
the epitope I had selected for PAK5 antibody production was similar, but not identical to the 
epitope for PAK5 antibody previously designed by another group, which corresponded to amino 

























Figure 3-12 : Generation of PAK5 in-house antibody A)Hopp and Woods hydrophobicity /hydrophilicity 
profile of PAK5 protein used for epitope selection (boxed).B) Epitope for antibody presentation (boxed) within 
the N-terminal regulatory domain of PAK5  
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 Validation of in-house PAK5 antibody and generation of PAK5-fusion 
proteins  
 
In order to validate the isoform-specific PAK5 antibody, I generated recombinant PAK5 by sub 
cloning the DNA into GFP and Myc expression vectors (see appendix 4 and method section 2.2.3) 
using Gateway™ Cloning Technology. The recombinant GFP-PAK5 and Myc-PAK5 plasmid 
DNAs were sequenced. The results from DNA sequencing analysis confirmed that no mutations 
had occurred throughout the process, and the DNA matched exactly to the available sequence of 
PAK5 (also known as PAK7) on Human ORFeome Database (http://horfdb.dfci.harvard.edu).  
I overexpressed the PAK5-fusion proteins in T24 cells to obtain the whole cell lysates. The whole 
cell lysates was first probed with one of the commercial antibodies (SCBT SC-16 PAK5 antibody) 
which had been validated for detection of overexpressed PAK5, documented on the 
manufacturer’s product datasheet. Both Myc-PAK5 and GFP-PAK5 recombinant proteins were 
detected by this antibody (figure 3.13A). I proceeded to assess whether the in-house rabbit 
polyclonal PAK5 antibody can sensitively detect these recombinant proteins. Western blots 
confirmed that the antibody was able to detect the bands at approximately 81 kDa for Myc-PAK5 
(figure 3.13B), and at 110 kDa for GFP-PAK5 (figure 3.13C) 
I assessed the specificity of the antibody by testing the antibody with whole cell lysates of T24 
cells over-expressing recombinant GFP-fusion PAK4 and PAK6 proteins, as PAK4 and PAK6 are 
structurally closely related to PAK5. The in-house PAK5 detected GFP-PAK5 but not GFP-PAK4 
or GFP-PAK6 (figure 3.13B). I noted that there was no endogenous PAK5 signal detected in T24 
(figure 3.13A-C). The same sets of whole cell lysates were also probed with GFP-specific antibody 
for to show the expression of all GFP-fusion (PAK4, PAK5 and PAK6) proteins (figure 3.13C).  
Taken together, the new PAK5 in-house antibody was sensitive to detect PAK5, and specific that 
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Figure 3-13 : Generation of recombinant PAK5-fusion proteins and validation for PAK5 in-house 
antibody A) Detection of GFP PAK5 and Myc-PAK5 at the estimated molecular weights. B) Detection of 
recombinant GFP-PAK5 protein overexpressed in T24 cells, but not GFP-PAK4 or GFP-PAK6 on Western 
blot using PAK5 in-house antibody. B) GFP antibody recognised all GFP-tagged recombinant Group-2 PAKs 
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 PAK5 protein expression is associated with epithelial differentiation of 
bladder cancer cell lines  
 
Having established the sensitivity and specificity of the in-house PAK5 antibody, I proceeded to 
screen the bladder cancer cell lines for endogenous expression of PAK5 by Western blotting. The 
antibody detected endogenous PAK5 protein at the estimated molecular weight of 81kDa (figure 
3.15).The endogenous PAK5 expression was strongest in RT4, followed by RT112 cells. Very 
low expression level of PAK5 was detected in T24, TCCSUP and 253J cells. The protein 
expression profile of PAK5 was reminiscent of the expression profile of E-cadherin, and inversely 
correlated to the N-cadherin expression, previously seen in for this panel of cell line (figures 3.5 
A & B).  
The differential expression of PAK5 in bladder cancer cell lines which correlated with Cadherin 
switching is a novel and interesting finding. This correlation (direct or inverse) had not been 
identified in the screen for PAK1, PAK4 or PAK6 in bladder cancer cell lines. Based on these 
results, I decided to focus my research on the role of PAK5 in the context of bladder cancer 
specifically, and loss of epithelial differentiation in general. The results of further experiments were 
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Figure 3-14 : Protein expression of PAK5 in bladder cancer cell lines A) Western blot of whole cell 
lysates of bladder cancer cell lines for PAK5, probed with PAK5 in-house antibody. B) Analyses of 
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 Endogenous PAK5 expression in also correlates with E-cadherin 
expression in breast and pancreatic cancer cell lines  
I previously observed that the protein expression of PAK5 positively correlated with the expression 
of E-Cadherin in bladder cancer cell lines. Therefore, in order to investigate whether the similar 
correlation occur in carcinoma cell lines from other organs, I screened for the expression of PAK5 
and E-Cadherin in selected breast and pancreatic cancer cell lines with distinct epithelial or 
mesenchymal morphology.  
Breast cancer cell line MDA-MB231 was selected to represent mesenchymal breast cancer cell 
line, with loss of E-Cadherin protein expression, whilst MCF7 cell line represented carcinoma cells 
with moderately differentiated epithelial morphology and protein expression of E-Cadherin 
(Lombaerts, van Wezel et al. 2006). Human mammary epithelial cell line, MCF10A was also 
included in this panel to represent cells with distinct epithelial phenotype (Maeda, Johnson et al. 
2005).  
Pancreatic cancer cell lines PaTu 8898T and PaTu 8898S were included in the panel due to their 
different morphological properties and EMT status, despite their common origin from the same 
metastatic tumour (liver metastasis) of pancreatic adenocarcinoma (Elsasser, Lehr et al. 1992). 
PaTu 8898T cells has mesenchymal growth characteristic while PaTu 8898S has distinct 
epithelial morphology and conserved cell-cell junctions at basal growth conditions (Belo, van der 
Sar et al. 2013).  
Similar to bladder cancer cell lines panel, the positive association between PAK5 and E-Cadherin 
was also observed within this selection of cell lines of breast and pancreatic origins (figure 5.1). 
Higher protein expression level of PAK5 was detected in cells with conserved epithelial 
morphology and protein expression of E-Cadherin (RT4, MCF7, MCF10A and PaTu 8898s). The 
protein expression of PAK5 was undetectable in cells with mesenchymal morphology with loss of 
E-cadherin expression (T24, MDA MB231 and PaTu 8898T).  
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Figure 3-15 : Expression of PAK5 and E-Cadherin in cancer cell lines with epithelial and mesenchymal 
morphology. Whole cell lysates of breast and pancreatic tumours were probed for protein levels of E-
Cadherin and PAK5 with GAPDH as loading control.  Lysates of bladder tumour cell lines T24 and RT112 
were included as positive and negative indicators. Western blots of relative protein expressions were 
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3.3 Discussion 
The initial aim of this project was to identify a member of the group 2 PAK family that exhibit 
differential protein expression in bladder tumours that may correlate with invasive potential. I have 
used bladder cancer cell lines in this study. The advantages of using cell lines include the (almost) 
unlimited supply of cells derived from each human tumour, and the stability of many phenotypes 
in standardised culture conditions.  The disadvantages include cross-contamination between the 
cell lines, spontaneous transformation, and that certain characteristics are not stable in long term 
culture conditions. 
Characterisation of the epithelial morphology of bladder cancer cell lines 
It is important that the bladder cancer cell lines used in this project be independently characterised 
to assure the validity and reproducibility of the experimental results presented in this theses. The 
bladder cancer cell lines in the screen were matched to represent different stages of urothelial 
tumour progression based on their epithelial or mesenchymal phenotypes.  The state of malignant 
transformation was characterised by looking at the arrangement of actin cytoskeleton, cell shape 
and formation (or disruption) of cadherin-based cell: cell adherens junctions.  
I have compared my findings on the descriptive cell morphology and the Cadherins expression 
with a study which specifically addressed the subject of EMT in the context of bladder cancer cell 
lines (Baumgart, Cohen et al. 2007). The study by Baumgart el al included RT4, RT112, TCCSUP 
and EJ (identical to T24 (O'Toole, Povey et al. 1983)) bladder cancer cell lines, and the descriptive 
classification of epithelial or mesenchymal morphology, and the expression of EMT markers (E-
cadherin and N-cadherin) were consistent to the phenotypes displayed by my panel of cell lines. 
Although the definition and occurrence of EMT in vivo remain controversial (Tarin, Thompson et 
al. 2005), the conceptual framework embracing the loss of epithelial markers and gain of 
mesenchymal markers have been associated with bladder cancer progression in a number of 
studies (Mialhe, Levacher et al. 2000, Baumgart, Cohen et al. 2007, Bryan, Atherfold et al. 2008).  
In section 3.2.3, I assessed the response of RT112 and RT4 cells to (paracrine) HGF-stimulation 
as a functional assay to induce cell-cell junction dissociation which may mimic the process of 
EMT. The dissociation of E-cadherin based cell-cell junctions in RT112 was more pronounced 
that the changes observed in RT4 cells colonies. RT112 cells, with less mature cell-cell junctions, 
may be considered to be in the intermediate state of EMT. Intermediate-stage cells harbour 
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greater plasticity to progress to a mesenchymal phenotype (Huang, Guilford et al. 2012), as 
observed in these 2 cell lines following HGF stimulation assay. Assessing the possible utility for 
HGF stimulation assay was very relevant to this study, as 2 members of the group 2 PAK family, 
PAK4 and PAK6, have been demonstrated to function downstream of HGF to induce cell-cell 
dissociation in prostate cancer cell line with epithelial morphology (Wells, Abo et al. 2002, Wells, 
Whale et al. 2010, Fram, King et al. 2013). 
My independent assessment of the actin characteristics, Cadherin isoforms expression profile, 
and the differential response to HGF stimulation suggest that in this panel of bladder cancer cell 
lines, RT4 cells represent well differentiated urothelial tumours and RT112 cells represent 
moderately differentiated tumours. The expression of N-cadherin (cadherin switch) and 
mesenchymal morphology in T24, 253J and TCCSUP would suggest invasive and metastatic 
potential of these cell lines. Taken together, despite more than 3 decades of culture, storage and 
propagation, these cell lines still represented the primary tumours from which they were originally 
cultured.  
Protein expression of PAK isoforms in bladder cancer cell lines 
Having characterised the bladder cancer cell lines to correspond with different stages of EMT and 
their invasive potential, I proceeded to screen for the protein expression of PAK1, and all 3 
isoforms of group 2 PAKs. The screen for PAK1 protein expression in bladder cancer cell lines 
was included as an arbitrary positive control, as PAK1 is the only member of the PAK-family that 
has been associated with urothelial tumorigenesis. 
 PAK1 has been studied in urothelial carcinoma of the bladder and the upper urinary tract, and its 
overexpression was associated with poor clinical prognosis. In a bladder cancer clinical study (Ito, 
Nishiyama et al. 2007), high expression of PAK1 at both gene transcription and protein expression 
levels were associated with high tumour grade, and increased risk of recurrence. Another clinical 
study which analysed surgical specimens of patients with urothelial tumour of the upper urinary 
tract, had also demonstrated that protein over-expression of PAK1, assayed by Western blotting 
and immunohistochemistry, was associated with increased risk of lymphovascular invasion and 
lymph node metastasis (Kamai, Shirataki et al. 2010).  
One of the studies (Ito, Nishiyama et al. 2007) had also included information for PAK1 in bladder 
cancer cell lines 253J and EJ. EJ cell line had  previously reported to be identical to T24 (O'Toole, 
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Povey et al. 1983). The endogenous expression level PAK1 (Western blot, antibody SCBT sc-
881) was reported to be relatively low in 253J compared to EJ (T24) cell line. I did not find 
significant difference in PAK1 protein expression assay on Western blotting (figure 3.10) between 
253J and T24 did not significantly differ as previously reported. This discrepancy may be due to 
the cell stock used, culture conditions, or the difference in the isoform specific PAK1 antibody 
used. 
Even though differential expression profile was noted within my panel of 5 cell lines, it did not 
correlate with the EMT characteristic of the cells. Despite the lowest expression level in the 
epithelial RT112 cells, the highest expression level of PAK1 was also detected in RT4, a cell line 
with well differentiated epithelial morphology. This finding was counterintuitive. Based on the 
previous publications on PAK1 in bladder cancer, I would have predicted that PAK1 expression 
would be the lowest in RT4 and RT112, and higher in the mesenchymal T24, 253J and TCCSUP.  
It could be speculated that the expression of total protein for PAK1 may not directly correlate with 
the activity of PAK1. PAK1 exists as inactive autoinhibited homodimers, where the two kinase 
domains from 2 different PAK1 molecules inhibit one another (Lei, Lu et al. 2000, Pirruccello, 
Sondermann et al. 2006). Upstream regulation of PAKs involves GTP-Cdc42 or Rac binding to 
the regulatory domain, and its displacement, which allows autophosphorylation of the kinase 
domain and maximal activation. Other members of group-1 PAKs, PAK2 and PAK3 are 
structurally very similar to PAK1, and regulated by GTP-dependent upstream molecular switches 
in a similar manner to PAK1 (Molli, Li et al. 2009).  In contrast to group 1 PAKs, the interaction of 
group 2 PAKs with Rho GTPases may not affect the kinase activity; instead, the interaction 
localises PAKs to specific intracellular structures, possibly bringing the PAKs into proximity with 
the substrates (Cotteret, Jaffer et al. 2003, Wu and Frost 2006). A number of studies had also 
demonstrated that overexpression of wild type group 2 PAKs could activate common pathways 
downstream of PAKs such as LIMK-Cofilin (Dan, Kelly et al. 2001) and JNK pathways (Dan, Nath 
et al. 2002), more efficiently than wild type group 1 PAKs, where overexpression of the 
constitutively active forms of group 1 PAKs, or co-expression of GTP-bound Rho GTPases were 
usually required. The observations indicate that group 2 PAKs may be constitutively active in 
basal condition, and regulated differently to group 1 PAKs. 
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Despite the poor correlation of PAK1 protein expression (intended arbitrary positive control) and 
the EMT stages of bladder cancer cell lines, I proceeded to screen for the expression profile of 
group 2 PAKs. Two members of group-2 PAK proteins, PAK4 and PAK6, were ubiquitously 
expressed in all 5 bladder cancer cell lines. The expression profile for PAK4 and PAK6 did not 
show any distinct differentiation or correlation between mesenchymal and epithelial cancer cell 
lines, which implied that the expression of these PAKs did not directly activate invasion and 
metastasis in bladder cancer. The role for PAK4 or PAK6 in the urothelial oncogenesis however 
could not be excluded as they may contribute to other cancer hallmark capabilities such as 
resisting cell death or sustaining proliferative signalling (Radu, Semenova et al. 2014). 
The protein expression profile of PAK5 however, differentiated the mesenchymal and epithelial 
phenotypes of bladder cancer cell lines in this panel. Indeed, the protein expression of PAK5 
positively correlated with the protein expression profile of E-cadherin, and negatively correlated 
with N-cadherin in this panel of cell lines. To my knowledge, this is the first time this correlation 
has ever been described. This finding elicits the notion that PAK5 may have a novel role in bladder 
cancer differentiation and progression, and may interact with cadherin in the maintenance of 
epithelial morphology in papillary urothelial tumour.  
My findings of high PAK5 expression in which correlated with epithelial morphology in bladder 
cancer cell lines may be contradictory to the previously described roles of PAK5 in invasion and 
metastasis, as suggested by studies done in the setting of colorectal (Gong, An et al. 2009, Wang, 
Gong et al. 2010), gastric (Gu, Li et al. 2013) and hepatocellular carcinoma (Fang, Jiang et al. 
2014).  On reviewing these publications, the sensitivity and specificity antibodies used to detect 
PAK5 could have contributed significantly to the conflicting result.  
Firstly, in a study which showed that PAK5 was overexpressed during colorectal cancer 
progression and regulated colorectal carcinoma cell adhesion and migration (Gong, An et al. 
2009), the isoform specificity of the polyclonal antibody used in this study for PAK5 had not been 
well described.  The epitope for antibody recognition was generated against 224-amino acids N-
terminal sequence of PAK5, and cross reaction with PAK4 had not been excluded in this paper. 
By Western blotting, the antibody was validated using Flag-PAK5, with myc-PAK1 and Flag PAK6, 
but not PAK4-fusion protein as negative controls. The molecular weight of the protein detected 
by the antibody in this study, hence referred to as PAK5, was smaller than 72kDa. The molecular 
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weight of ‘PAK5’ in the study was inconsistent with the molecular weight of PAK5 at 81kDa, as 
detected by my PAK5 specific antibody, and reported by other groups (Dan, Nath et al. 2002, 
Pandey, Dan et al. 2002, Cotteret and Chernoff 2006, Fang, Jiang et al. 2014).  As PAK4 is 
structurally closely related to PAK5, and has the lowest MW (64 kDa) amongst the group 2 PAKs, 
cross reaction of this antibody with PAK4 on Western blot, indirect immunofluorescence and 
immunohistochemistry must to be excluded. 
The validity of the antibody used in the study for the role of PAK5 in the development of gastric 
cancer (Gu, Li et al. 2013) was also unclear. The antibody, as published in the material section 
of this paper was a Mouse anti-PAK7 (PAK5) from Santa Cruz, Ca. In my work to screen for PAK5 
expression in bladder cancer, I have used 2 PAK5 isoform-specific antibodies from Santa Cruz, 
and the available antibodies for PAK5 were both produced in goat (H-20 and S-16).  The 
European representative for manufacturer, SCBT Europe was contacted, and confirmed that 
Santa Cruz did not have PAK7 antibody produced in mouse. In addition, this paper also showed 
distinct protein band for PAK5 in HEK293 cells on Western blotting, whereas previously published 
paper on PAK5 and SCBT product literature have reported that HEK293 cells did not express 
endogenous PAK5 ((Wu, Carr et al. 2008) and http://datasheets.scbt.com/sc-22155.pdf). 
There are also other known characteristics of PAK5 which could have contributed to the possible 
contradiction. Its role may vary in different types of epithelia, or at different stages of malignant 
transformation. In developmental studies, the expression of PAK5 has been shown to be tissue-
specific in mammalian physiology, being distributed predominantly in the brain, and at lower levels 
in several other tissues (Pandey, Dan et al. 2002, Li and Minden 2003). Whilst PAK5 was 
expressed in all regions of the brain, higher levels of expression ware detected in the cerebellum, 
cerebral cortex and olfactory bulb. However, when embryonic (E13) and adult brain were 
compared, it was noted that the expression of PAK5 in embryonic cerebellar primordium was 
negligible, in contrast to the high expression of PAK5 in the adult cerebellum, which suggests that 
PAK5 is preferentially expressed in mature neural systems (Pandey, Dan et al. 2002). This 
variation, observed in neuronal tissues in the context of developmental studies may also be a 
feature of PAK5 in oncogenesis. 
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In the following chapters, I continued to characterise the expression of PAK5 in bladder cancer 
cell lines, and investigated whether PAK5 has any direct role in the maintenance of epithelial 
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Chapter 4 : Characterisation of PAK5 expression in bladder 
cancer  
4.1 Introduction 
In chapter 3, I have identified a distinct protein expression profile of PAK5 in bladder cancer cell 
lines, where higher expression levels were observed in the cancer cell lines with differentiated 
epithelial morphology. To date, the role of PAK5 in bladder cancer has not been well 
characterised, and further research into PAK5 were required to assess its utility as a potential 
biomarker for non-invasive bladder cancer.  
In order to further understand the gene expression of PAK5 in bladder cancer, I screened the 
mRNA transcription profiles for PAK5 in patient-derived malignant and non-malignant bladder 
tissue specimen provided by Cardiff University collaborators. Publications and publicly available 
microarray data on Gene Expression Omnibus (GEO) were also searched for any information 
regarding the expression of PAK5 in bladder cancer. There has not been any peer-reviewed 
published data on PAK5 mRNA transcription in bladder cancer during the duration of my research. 
However, one high throughput genomic study (Dyrskjot, Kruhoffer et al. 2004) had included the 
gene expression of PAK5 in normal bladder tissue, and in urothelial tumours of different grades 
and stages (data could be accessed at http://www.ncbi.nlm.nih.gov/geoprofiles/14788769). The 
data on PAK5 had not been discussed in any publications by the authors from the group. I have 
therefore analysed the data, and the results were presented in sections of this chapter.  
In addition to screening of patient samples, I have also profiled the mRNA transcription of PAK5 
in bladder cancer cell lines in my panel. In this chapter, I presented my findings, where the profile 
mRNA transcription of PAK5 did not directly translate into protein expression in these cell lines. 
The postulations to explain this discrepancy were discussed at the end of this chapter. 
At protein level, studies to investigate the regulatory mechanism and function of PAK5 had 
identified different regulatory inputs controlling the subcellular localisation of PAK5, hence its 
functions (Wu and Frost 2006, Wu, Carr et al. 2008). Multiple Rho proteins interact with PAK5, 
including Cdc42, Rac, RhoD and RhoH, which targeted PAK5 to specific locations within the cells. 
Amongst the Rho GTPases, PAK5 binds with greatest affinity to constitutively active Cdc42 
(Cdc42V12). Co-expression of WT PAK5 with Cdc42V12 has been shown to substantially alter its 
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cellular localisation and directed WT PAK5 to filopodia within the plasma membrane, compared 
to overexpression of WT PAK5 alone which localised PAK5 to the mitochondria (Wu and Frost 
2006). In addition to localisation to the mitochondria and the cell membrane, studies have also 
identified the cellular localisation of PAK5 to the nucleus, cytoplasm and centrosome.  
Most of the studies that described the subcellular localisation of PAK5 were carried out in neuronal 
cells, or with PAK5 overexpression. In epithelial cell system, the subcellular localisation of 
endogenous PAK5 has not been well characterised. The distinct protein expression of PAK5 in 
bladder cancer cell lines RT4 and RT112, with differentiated epithelial morphology, had presented 
an opportunity to investigate the role of PAK5 in the urothelium specifically, which may be 
postulated to the epithelium in general. 
In this chapter, I presented my findings of PAK5 localisation at cell-cell adherens junctions at 
steady state, and its internalisation in distinct vesicular cytoplasmic structures following 
stimulation with exogenous growth factor ligand. The effects of PAK5 downregulation by siRNA 
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4.2 Results 
 Reduction in PAK5 mRNA transcription was associated with urothelial 
carcinoma in human patient bladder tissue specimen of Cardiff patient 
cohort  
The differential level of PAK5 protein expression in bladder cancer cell line strongly correlated 
with epithelial morphology. In order to investigate whether the expression level of PAK5 has the 
potential to be used as a biomarker, I have collaborated with Professor Wen Jiang and Dr Tracy 
Martin in at Cardiff University Hospital to access a small library of mRNA (reverse transcribed into 
cDNA for storage) from human bladder tissue samples. The screening for mRNA was identified 
as one of the suitable methods to screen for PAK5 expression in tissue samples at this point. 
Immunohistochemistry has not been done in this project as commercial antibodies for PAK5, 
previously tested in this lab failed to reliably detect PAK5. The in-house antibody I generated for 
PAK5 requires further assessment and validation for use in tissue immunostaining. 
The cDNA library used consisted of 34 samples of tumour tissues and 18 samples from bladder 
tissues without any malignancy. In this experiment, I decided to screen for the expression of 
PAK1, PAK5 and PAK6. Even though PAK1 protein expression did not correlate with invasive 
potential when screened in bladder cancer cell lines, the mRNA expression of PAK1 has been 
previously studied in bladder cancer and was shown to be associated with increased risk of 
tumour recurrence (Ito, Nishiyama et al. 2007). The mRNA expression for PAK6 was also included 
in the screen due to the structural similarity, and possible functional redundancy with PAK5, as 
suggested by mouse PAK5/PAK6 targeted knockout study(Nekrasova, Jobes et al. 2008).  
 For quantitative analysis of PAK1, PAK5 and PAK6 transcripts, I employed a quantitative real-
time polymerase chain reaction qRT PCR assay. The Ampliflor Uniprimer system was used as 
the probe system. The cDNA from the tissues were amplified simultaneously on an IcyclerIQ5 
system (Bio-Rad). The concentration of the respective transcript was calculated from the standard 
curve, which was simultaneously generated. The levels of the transcripts shown here are the 
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The values obtained from the assay indicated that in human patient samples, PAK1 and PAK6 
transcripts were expressed at higher levels in malignant urothelium, compared to non-malignant 
epithelium (figure 4.1A & C). The expression of PAK5 mRNA however, was lower in malignant 
epithelium compared to non-malignant bladder tissue (figure 4.1B). It was noted that the mRNA 
expression obtained in this assay varied greatly between each individual samples, even those 
within the subgroup (malignant/non-malignant), as indicated by the error bar on the chart. Due to 
this variation, the differential expression of PAK1, PAK5 and PAK6 detected in this assay did not 
achieve any statistical significance.  
The samples that I screened for PAK transcripts in this assay lacked the information for tumour 
grade, tumour stage or clinical follow-up outcomes. This has prevented me from doing any further 
subgroup analysis, especially in the subgroup with malignancy. I was therefore unable to 
interrogate whether differential expression could be detected between high grade and low grade 
tumours, as indicated by the differential expression of PAK5 protein seen in urothelial cancer cell 
lines. 
Despite the limitations, the results of the screening of PAK5 in the Cardiff cohort of patients were 
consistent with the cell line findings for PAK5 protein level in bladder cancer cell lines. I therefore 
continued to test my hypothesis that the reduction of PAK5 in bladder cancer could be associated 



















Figure 4-1 (A-C): The mRNA expression level for PAK1, PAK5 and PAK6 in normal and malignant 
urothelial tissue samples. The levels shown are the average (mean) values of PAK expression normalised 
to GAPDH. Standard error of the mean was calculated for all the samples included in the array. The results 
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 Reduction in PAK5 mRNA transcription was significantly linked to 
urothelial carcinoma in microarray data of human patient bladder tissue 
specimen on Gene Expression Omnibus 
 
As the mRNA expression profile for PAK5 obtained from bladder tissue samples described in 
section 4.2.1 was underpowered, I searched for publicly available microarray data which included 
PAK5 expression in bladder cancer tissue on Gene Expression Omnibus (GEO, 
http://www.ncbi.nlm.nih.gov/geo/) to expand my studies. One set of data was available which 
included the mRNA expression of PAK5 (referred to as PAK7 in the search) in 60 bladder tissue 
specimen with complete histopathological staging and grading of the tumour. The microarray data 
was linked to a publication on carcinoma in situ (CIS) of the bladder (Dyrskjot, Kruhoffer et al. 
2004), in which the association between PAK5 and CIS was not identified, or discussed.  
The data in the microarray (GEO: GPL96, 213990_s_at (ID_REF), GDS1479, 57144) had been 
normalised using the Robust Multi-array Analysis (RMA). First, the data were analysed by 
comparing the mRNA transcription of PAK5 in normal urothelial specimen in this population 
(including normal urothelium obtained from patients with past history of urothelial cancer), and 
specimen from malignant urothelium of all grades and stages. PAK5 expression was higher in 
normal bladder tissue, and was downregulated in tumour tissues (figure 4.2A), similar to the 
finding of PAK5 mRNA expression in Cardiff cohort (figure 4.1). In addition, the difference was 
statistically significant (Student’s t-test, ** = P < 0.05) 
To further analyse of PAK5 expression in this set of samples, I have subdivided the tumours into 
the following 4 groups to indicate the risk of bladder cancer progression, and progressively poorer 
prognosis: 
1. Normal bladder tissue 
2. Low risk non-muscle invasive bladder tumours (stage: pTa, grade: 2, no CIS) 
3. Moderate to high risk non-muscle invasive bladder tumours (stage pTa-1 grade 2 with CIS, 
CIS, all stage pTa-1 grade 3 tumours) 
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Analysis of PAK5 mRNA levels according to these subgroups also indicated that PAK5 mRNA 
transcription were lower in tumours of all subgroups, compared to normal bladder tissues (figure 
4.2B).  Statistical analysis comparing the expression levels between the 4 subgroups (one-way 
analysis of variance, ANOVA) detected significant difference in PAK5 mRNA expression in 
bladder cancer compared to normal tissue (figure 4.2B). However, no significant difference was 
detected in the expression of PAK5 between the low and high grade/stage bladder tumours. 
The data for mRNA expression of PAK1 and PAK6 were also analysed to compare the findings 
in this microarray population to the Cardiff mRNA library previously screened. The expression 
profile for PAK1 did not indicate any association with risks of tumour progression (figure 4.3A). 
For PAK6, the average (mean) expression levels suggested that PAK6 may be upregulated as 
tumours progress from normal to muscle-invasive disease (figure 4.3B). However, one-way 
analysis of variance (ANOVA) did not detect any statistically significant difference for PAK6 mRNA 
transcription between any of the tumour groups compared to normal bladder tissue specimens in 





















One-way analysis of variance   
  P value 0.0024 
  P value summary ** 
  Are means significantly different? (P < 0.05) Yes 
  Number of groups 4 
 
 
Figure 4-2 A): Analysis for expression of PAK5 mRNA transcript in a microarray of 60 urothelial tissue 
specimen A) mRNA expression of PAK5 in normal bladder tissue compared to bladder tumours. B) Micro 
array data for PAK5 mRNA were subdivided into groups for normal bladder tissue, low risk non-muscle 
invasive bladder cancer, (LR NMIBC), high risk non-muscle invasive bladder cancer, (LR NMIBC), and 
muscle invasive bladder cancer, (MIBC). B) Statistical analysis (ANOVA) for the difference in PAK5 mRNA 











One-way analysis of variance 
  PAK1 PAK6 
  P value 0.6309 0.2377 
  P value summary ns Ns 
  P < 0.05 No No 
  Number of groups 4 4 
 
 
Figure 4-3 A) Expression of PAK1 mRNA transcript in a microarray of 60 urothelial tissue specimen 
subdivided into groups of normal bladder tissue, low risk non-muscle invasive bladder cancer, (LR NMIBC), 
high risk non-muscle invasive bladder cancer, (LR NMIBC), and muscle invasive bladder cancer, (MIBC). 
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 PAK5 mRNA transcription did not show direct concordance with PAK5 
protein levels in bladder cancer cell lines  
 
To complement the profile for protein expression of PAK5 previously presented in chapter 3 
(section 3.2.9, figure 3.15), I have also assessed the mRNA transcription profile of PAK5 in the 
panel of cell lines. The results of the following assay will enable further postulations on whether 
the differential protein expression profile of PAK5 seen in bladder cancer cell lines was a direct 
gene translation. If the results were discordant, it is possible that epigenetic factors or post-
translational changes may also contribute to the distinct association between PAK5 and the 
epithelial differentiation of urothelial cancer cell lines. 
 The cells used in this assay were grown as monolayer in basal growth condition in 6-well plates 
for 24 hours before being harvested. Total RNA was extracted and purified from the cells, and 
then reverse transcribed into cDNA. Three sets of cDNA for each cell lines were prepared from 3 
separate experiments were used for statistical analysis. The mRNA expression levels presented 
here had been normalised to the GAPDH ratio.  
In this panel, RT112 showed the highest mRNA expression level for PAK5, whereas RT4, 
TCCSUP and 253J showed moderate level of mRNA expression. The lowest level of mRNA 
transcript for PAK5 was detected in T24, which also had the lowest protein expression of PAK5 
in this panel of cell lines (figure 4.4). The mRNA expression profile in the cell lines differed to 
protein expression profile presented in the previous section (figure 3.14). It could be speculated 
that the translation of PAK5 may be downregulated in RT112, TCCSUP, and 253J, resulting in 
reduced total protein expression. Conversely, it could also be speculated that the protein levels 
of PAK5 in RT4 cells are more stable, and less dependent on the mRNA transcripts compared to 
the other cell lines.  
Base on this result, great emphasis had to be placed on the quantification of PAK5 total protein 
as a conformational measure of PAK5 expression or downregulation in future experiments, as the 
mRNA transcription level for PAK5 may not reflect the protein expression affecting the 











Figure 4-4:  The mRNA expression profile for PAK5. Total mRNA for bladder cancer cell lines were 
extracted and reverse transcribed into cDNA for stability in storage. The values presented are the average 
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 Validation of PAK5 antibody for indirect immunofluorescence  
 
The role of PAK5 in urothelial tumour had not been previously characterised. Following my novel 
finding of high PAK5 protein expression in RT4 and RT112 cells, I sought to study the role of 
PAK5 in these cell lines. A validated PAK5 antibody that works on immunofluorescence would 
provide a valuable tool to characterise endogenous PAK5 expressed in these cells. I therefore 
proceeded to demonstrate the utility of the in-house antibody for the detection of PAK5 in 
immunofluorescent studies. 
The antibody was validated by showing that it detected GFP-fusion PAK5 protein over expressed 
in cell lines without endogenous protein expression for PAK5. T24 cells demonstrated the lowest 
mRNA expression level for PAK5, which corresponded with undetectable protein expression on 
Western blot, had provided a good model for the validation.  In this experiment, T24 cells were 
seeded on glass coverslips and transfected with GFP-PAK5 cDNA using Xtremegene HP 
according to manufacturer’s protocol. Cells on coverslips were fixed with 4% PFA, and stained 
with PAK5 in-house antibody (1:400 in 3% BSA: PBS solution) for indirect immunofluorescent as 
previously described. T24 cells transfected with GFP-empty vector was used as negative control. 
The in-house PAK5 antibody detected GFP-PAK5, but did not detect any proteins/subcellular 
structures in T24 cells over-expressing GFP-alone (figure 4.5). In T24 cells, I noted distinct GFP-
PAK5 overexpression in punctate subcellular structures, excluded from the nucleus. Over-
expressed GFP-PAK5 was also detected at lower level in the diffuse cytoplasmic background. 
These findings were consistent with previously reported observations ((Matenia, Griesshaber et 
al. 2005, Cotteret and Chernoff 2006, Wu and Frost 2006), over expression of PAK5 (WT). 
The findings of this validation experiment indicated that the in-house PAK5 antibody had the 
potential to sensitively and specifically detect endogenous PAK5 by immunofluorescence in RT4 












Figure 4-5 : Validation of in-house PAK5 antibody. A) GFP-PAK5 was overexpressed in T24 cells and 
immunolabelled with PAK5 in-house antibody conjugated to Alexafluor 568. Images were merged to 
emphasise sensitivity of the antibody. B) T24 cells overexpressing GFP-empty vector was used as negative 









T24 cells overexpressing GFP-PAK5 
T24 cells overexpressing GFP-empty vector 
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 Subcellular localisation of endogenous PAK5 in RT112 and RT4 cells 
under basal growth conditions 
 
There is substantial level of evidence to demonstrate that PAK5 is spatially regulated. Studies 
had presented the evidence that the regulatory N-terminal domain of PAK5 contained functional 
sequences that regulate the intracellular localisation, and this localisation was critical to the 
biological function of PAK5 (Cotteret, Jaffer et al. 2003, Cotteret and Chernoff 2006).  Interaction 
of PAK5 with different Rho GTPases, Cdc42 or RhoD via the CRIB domain had also been shown 
to direct PAK5 to specific subcellular localisations (Wu and Frost 2006). Interaction between 
PAK5 and constitutively active RhoD (V12) directed its localisation to the mitochondria. 
Mitochondrial localisation of PAK5 was necessary for the regulation of its anti-apoptotic property 
via phosphorylation of the downstream substrate BAD (Cotteret and Chernoff 2006). In contrast, 
co-expression of PAK5 with constitutively active Cdc42 (V12) directed its localisation substantially 
to the filopodia within the plasma membrane, and in punctate distribution excluding the 
mitochondria (Wu and Frost 2006).  The functional role or downstream target for PAK5 at the cell 
membrane, or the significance of the punctae containing PAK5 and Cdc42 had not been 
characterised. 
Using the in-house PAK5 antibody which I had validated in the previous section for indirect 
immunofluorescence, the expression of endogenous PAK5 in RT4 and RT112 cells were imaged. 
In RT4 cells (figure 4.6A), endogenous PAK5 protein was distributed in the cytoplasm in vesicular 
or punctate structures. In addition, distinct localisation of PAK5 in the membrane at the margins 
of cell-cell adhesion was noted. Co-staining of RT4 cells with E-Cadherin (HECD1) antibody 
detected co-localisation of PAK5 with E-cadherin at the cell-cell junctions, further analysed by line 
scanning of confocal images of the cells (figure 4.6B).  
As previously presented in chapter 3, the adherens junctions in RT112 were less mature (figures 
3.6), and the total expression of E-cadherin and PAK5 proteins were lower (figures 3.5 and 3.14) 
in RT112 compared to RT4 cells. Immunofluorescent staining for PAK5 in RT112 cells showed 
that endogenous PAK5 was also distributed in punctate structures in the cytoplasm (figure 4.7A).  
At the cell membrane, the expression of PAK5 colocalised with E-cadherin at margins of cell-cell 
adhesions (figure 4.7B).   
 
 





Figure 4-6 : Subcellular localisation of endogenous PAK5 in RT4 cells. Indirect immunofluorescent 
confocal microscopy images of RT4 cells at basal growth condition, co-probed with PAK5 and E-cadherin 









Figure 4-7 : Subcellular localisation of endogenous PAK5 in RT112 cells. Indirect immunofluorescent 
images of RT112 cells at basal growth condition, co-probed with PAK5 and E-cadherin antibodies. Nuclei 
were stained with DAPI. Bar = 10m. 
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 PAK5 also colocalised with internalised E-Cadherin following growth 
factor stimulation in RT4 cells 
I have previously shown that in RT4 cells, E-cadherin colocalised with PAK5 predominantly at the 
cell-cell junctions at steady state (section 4.2.5, figure 4.6). Signalling by tyrosine kinases such 
as Hepatocyte Growth Factor (HGF) has been demonstrated to regulate the intracellular 
trafficking of E-Cadherin, where exogenous HGF stimulation of epithelial cells resulted in 
increased translocation and redistribution of E-cadherin from the cell membrane into the 
cytoplasm ((Kamei, Matozaki et al. 1999, Miura, Nishimura et al. 2001, Fujita, Krause et al. 2002, 
Lu, Ghosh et al. 2003, Bryant, Kerr et al. 2007). I have also demonstrated that HGF stimulation 
could affect the stability of cell-cell adherens junctions in RT4 cells by redistributing E-cadherin 
away from the adhesion plaque at the cell membrane (section 3.2.3, figure 3.9).  
Growth factor signalling had also been demonstrated to regulate the subcellular localisation of 
some members of PAK-family kinases. HGF stimulation of MDCK cells resulted in the 
translocation of PAK1 to the membrane ruffles (Royal, Lamarche-Vane et al. 2000), but 
redistribution of PAK5 following HGF stimulation had not been reported. Stimulation of C17.2 
neuronal cells by EGF had been described, which triggered PAK5 shuttling from the cytoplasm 
to the nucleus (Cotteret and Chernoff 2006). However, the role of growth factors in the subcellular 
redistribution of PAK5 in epithelial cells had not been characterised.   
In this section I describe my findings on the subcellular localisation of E-Cadherin and PAK5 
following stimulation with HGF.  In control conditions, E-cadherin distribution was localised at the 
plaques of cell-cell adherens junctions, whilst PAK5 was distributed at the adherens junctions as 
well as in vesicular/punctate structures in the cytoplasm (figure 5.7A). Following HGF stimulation, 
E-Cadherin were redistributed away from the cell-cell adhesion plaques, and in a proportion of 
cells, accumulated in distinct, large vesicular structures (figure 4.6B & C). Accumulation of PAK5 
was also observed in these E-cadherin enriched vesicles.  A number of these vesicles were larger 
than 0.2M in diameter, and appeared lobulated or tubulated (figure 4.6C).Line scan analysis of 
confocal images of PAK5 and E-Cadherin staining in RT4 cells were performed to confirm the 
colocalisation of these proteins in the vesicular structures following HGF-stimulation (figure 5.8A). 
The accumulation of E-Cadherin and PAK5 in the vesicular structures at 30 minutes of HGF-
stimulation also coincided with maximal MAPK pathway activation in RT4 cells (figure 4.8B)   
 
 







Figure 4-8 : Subcellular localisation of PAK5 in RT4 cells following HGF stimulation A) RT4 cells in 
serum-starved conditions stained for nucleus, PAK5 and E-Cadherin. B) RT4 cells in following 30 minutes 
of HGF stimulation stained for nucleus, PAK5 and E-Cadherin. Boxed area in the merged image indicates 
the area magnified in figure (C), where the boxed area included the vesicular and membranous distribution 
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Figure 4-9 : HGF stimulation of RT4 cells. A) Co-localisation of PAK5 with E-cadherin in cytoplasmic 
vesicular structures in RT4 cells at 30-minutes of HGF-stimulation. Line-scans across the cytoplasmic 
vesicular structures of corresponding confocal images were performed, and the fluorescent intensities were 
quantified. The overlapping intensity peaks indicated co-localisation. B) Effects of HGF-stimulation on E-
Cadherin/PAK5 colocalisation in cytoplasmic punctate. For HGF-stimulation, cells were fixed after 30 
minutes following addition of HGF to serum-starved media. Values presented are the average (mean) 
representation of 50 cells from 3 independent experiments. Statistical significance compared to 


































Colocalisation plot of PAK5 and E-Cadherin 

























Figure 4-10 : Relative ERK phosphorylation of RT4 cells upon HGF stimulation. Whole cell lysates of 
RT4 cells at different time-points of   HGF-stimulation were assayed for ERK/MAPK activation. The levels of 
phosphorylated ERK was normalised relative to the total ERK levels. Relative expressions quantified 
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 Downregulation of PAK5 in RT4 cells by siRNA knockdown 
 
The high level of protein expression of PAK5, and its distinct colocalisation with E-cadherin at the 
cell-cell adhesions in RT4 cells presented it as a candidate as a model to study the role of PAK5 
in epithelial differentiation of bladder cancer. As previously presented and discussed in chapter 
3, very low or undetectable protein expression of PAK5 was detected in poorly differentiated 
bladder cancer cells such as T24, TCCSUP and 253J. I therefore hypothesised that PAK5 
contributes towards the maintenance of cell-cell adherens junctions, and investigated the effects 
of PAK5 down-regulation in RT4 cells. 
In order to downregulate PAK5 expression, I transiently transfected RT4 cells with PAK5 specific 
siRNA. Two different siRNA oligonucleotides were used for PAK5 gene silencing: Si63 and Si70. 
Oligonucleotide Si63 targeted PAK5 DNA in the coding region, whereas si70 targeted the 3’ 
untranslated region (UTR). In order to identify the dynamics of PAK5 expression following 
transient siRNA transfection, the total protein expressions of PAK5 at 24, 48 and 72 hours post 
transfection were assessed and quantified by Western blotting.  
At 24 hours (figure 4.6A), using PAK5 siRNA63 and siRNA70, the protein expression of PAK5 
was downregulated by 25% and 50% respectively, compared to the control experiment. The 
maximal downregulation of PAK5 protein expression was observed at 48 hours following transient 
transfection (figure 4.6B), where the average protein expression levels were reduced by 60% by 
both PAK5 siRNA63 and siRNA70.  At 72 hours, the protein expression levels for PAK5 recovered 
in RT4 cells transfected with siRNA63, with no significant difference detected for cells transfected 
with Si63 or control SiRNA at this time point (figure 4.6C).  
The optimisation of PAK5 siRNA transfection in RT4 was a challenge due to the combination of 
these 2 reasons; RT4 cells could not be transfected efficiently, and PAK5 protein expression was 
only transiently downregulated within a short window at approximately 48 hours post transfection. 
These limitations could restrict further functional studies on the effects of PAK5 downregulation 
beyond 48 hours. Based on these results, I concluded that the downregulation of PAK5 
expression in RT4 cells was most efficient at 48 hours when both PAK5 siRNA oligonucleotides 
were deployed to study the effects of PAK5 down regulation on the morphology of RT4 cells in 
the next section. 
 
 








Figure 4-11 : Optimisation of transient downregulation of PAK5 protein expression by siRNA 
knockdown. Western blots for total protein levels of PAK5 and quantification of relative expression 
normalised to GAPDH at; A) 24 hours, B) 48 hours, and C)72 hours of siRNA transfection. Data represent 
the mean of 3 independent experiments. Statistical significance compared with Scrambled SiRNA (ScRNA) 
was calculated using Student’s t-test; **, P, 0.05 
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 Morphological changes in RT4 cells following PAK5 SiRNA knockdown  
 
As demonstrated in the previous section, maximal downregulation of PAK5 protein level by siRNA 
knockdown was achieved at 48 hours of transient transfection. The morphological changes of the 
cells following PAK5 downregulation were therefore assessed in 2-D by immunofluorescence at 
this timepoint. The changes to the cell morphology and cell-cell adherens junctions following 
48hours of transient transfection with PAK5 siRNA63 and siRNA70 were compared to control 
RT4 cells (control siRNA transfection).   
RT4 cells transfected with control siRNA maintained the cobblestone-like appearance within the 
epithelial colonies, with minimal difference in cell morphology irrespective of the number of cells 
in-contact with one another within the cell-colony (figure 4.7A). RT4 cells transfected with PAK5 
siRNA63 and siRNA70 however appeared more rounded, with some cells showing varying stages 
of dissociation at the cell-cell adherens junctions (figure 4.7B, C).The changes to cell morphology 
and cell-cell adherens junctions were more pronounced when PAK5 was downregulated by si70, 
rather than si63, consistent with the efficiency of total PAK5 protein downregulation on Western 
blot presented in the previous section.  
The heterogeneity of the morphological changes was also affected by the size of the cell colony, 
and whether the cells were in completely surrounded by other cells (circumferential contact with 
adjacent cells).  
In order to quantify the state of cell-cell adhesion in RT4 following transient PAK5 siRNA 
knockdown, the model of cell-cell adhesion formation and maturation in 3 different stages (Adams, 
Chen et al. 1998, Vasioukhin, Bauer et al. 2000, Vasioukhin and Fuchs 2001) was used as a 
working concept. Briefly, cells with <50% of the membrane surface forming cell-cell contact with 
adjacent cells were considered to have less mature epithelial junctional formation and classified 
as ‘dissociating’ (diagram in figure 4.8A). The percentage, (%) of cells demonstrating ‘junctional 
dissociation’ as presented in figure 4.8B were calculated based on the following algorithm: 




- 130 - 
As the RT4 cells assessed in this assay for control and PAK5 siRNA were in small colonies 
instead of large epithelial sheets, a small proportion (15%) of RT4 cells in control experiment also 
demonstrated <50% membranous adherens cell-cell contact (indicated by arrow in figure 4.7A, 
quantified in figure 4.8B).  Following PAK5 siRNA knockdown, significant proportion of RT4 cells 
(45% for siRNA63 and 60% for siRNA70) demonstrated <50% membranous cell-cell contact, 





























Figure 4-12 : Representative images of RT4 cells at 48 hours of transfection with (A) control siRNA, (B) 
PAK5 siRNA63 and (C) siRNA70. Cells were stained for nucleus (DAPI) and E-cadherin.  Arrows indicated 
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Figure 4-13 : Quantification for cell-cell dissociation in RT4 cells following transient transfection with 
PAK5 siRNA.  A) Schematic representation of RT4 cells with established epithelial cell-cell adherens 
junctions (>50% cell-cell contact) and immature or dissociating junctions (<50% cell-cell contact). B) 
Quantification for the number of RT4 cells without established (mature) cell-cell junctions over the total 
number of cells. Quantification was performed on at least 50 cells per condition. The values presented are 
the average (mean) quantifications from 3 independent experiments; error bars indicate standard deviation 
of the means. Statistical significance for the difference compared to control siRNA was calculated using 
Student’s t-test, **, P < 0.05.  
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 Cell-shape analysis of RT4 cells following transient PAK5 knockdown 
 
Cell shape in 2-D as indicated by the F-actin staining of the cell membrane, was analysed using 
imageJ software using set measurements, which included of area (relative value) and shape 
descriptors (circularity and aspect ratio). The morphological chances as indicated by cell-shape 
in RT4 cells transiently transfected with PAK5 siRNA oligonucleotides (siRNA63 and siRNA70) 
was analysed, and compared to the cell-shape of RT4 cells transfected with control siRNA. 
The cell area measured indicated that RT4 cells with PAK5 knockdown were smaller compared 
to the control RT4 cells. The reduction in size following PAK5 downregulation was statistically 
significant following transfection using siRNA70, but not siRNA63 (figure 4.9A). The circularity, 
calculated using the formula; circularity = 4pi (area/perimeter2) was enhanced in RT4 cells 
following PAK5 siRNA knockdown, with statistically significant difference compared to control 
cells for both PAK5 siRNA oligonucleotides (figure 4.9B) . Consistent with the increase in cell 
circularity, the aspect ratio of RT4 cells was reduced by PAK5 downregulation, with statistically 






















Figure 4-14 : Cell shape analysis of RT4 following PAK5 siRNA knockdown. A) Area. B) Circularity. C) 
Aspect ratio. The values presented are the mean values and standard error of the mean calculated from 3 
independent experiments (50 cells analysed per condition/experiment). Statistical significance for the 
difference in morphological parameters of each PAK5 siRNA compared to control siRNA was calculated 
using Student’s t-test; ** = P < 0.05 
** 
** ** 
** ** ** 
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 Downregulation of total E-cadherin and P120-catenin associated with 
PAK5 siRNA knockdown 
 
The epithelial adherens junction is an E-cadherin-based complex that controls tissue integrity, 
and is stabilised at the plasma membrane by p120-catenin (Nelson and Nusse 2004, 
Schackmann, Tenhagen et al. 2013). In order to understand the mechanism for the dissociation 
of cell-cell junctions which occurred as a result of PAK5 siRNA knockdown, the fates of E-cadherin 
and p120-catenin were investigated. I thus assayed the total protein expression of both E-
cadherin and p120-catenin in RT4 cells at 48 hours of PAK5 siRNA knockdown by western 
blotting. 
The total protein expression for both E-Cadherin and P120-catenin were both downregulated 
following PAK5 silencing (figure 4.12). Consistent with the maximal PAK5 knockdown efficiency 
and maximal cell-cell dissociation index achieved by oligonucleotides siRNA70, the maximal 
downregulation of E-cadherin and P120-catenin protein levels were also attained by siRNA70. 
The down regulation was very prominent for P120-catenin (figure 4.12B). The antibody used in 
this assay has been reported to interact with all isoforms of p120-Catenin, with molecular weights 
ranging from 90-115kDa, which could have exaggerated the quantification accounting for the 
reduction of p120-Catenin levels at 48 hours of PAK5 knockdown compared to the E-Cadherin 
levels. 
Although PAK5 downregulation could potentially affect the phosphorylation states of 
serine/threonine residues of E-Cadherin or p120-Catenin, I had not investigated these further due 














Figure 4-15 : The effects of PAK5 siRNA knockdown at 48 hours on the total protein levels of A) E-
Cadherin, and B) P120-Catenin in RT4 cells. Western blots for total protein levels were quantified for relative 
expression normalised to GAPDH. Relative expressions quantified represent the mean of 3 independent 
experiments. Statistical significance compared with Scrambled SiRNA (ScRNA) was calculated using 
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4.3 Discussion 
The protein expression of PAK5 in bladder cancer cell lines indicated that PAK5 may be 
downregulated as the urothelial cancer cells progress from well differentiated epithelial 
morphology to become more mesenchymal. I had investigated whether the down-regulation of 
PAK5 can also be detected at mRNA transcription level in patient derived tissue samples, as well 
as the bladder cancer cell lines in the panel. The results for PAK5 mRNA expression from patient 
specimen cohort provided by my collaborators in Cardiff indicated that PAK5 levels were reduced 
in tumour tissues compared to normal bladder urothelium. However, the results for Cardiff cohort 
were not statistically significant, possibly due to the sample size and outliers. 
 The hypothesis for the downregulation of PAK5 in bladder tumours compared to normal bladder 
tissues was further supported by the profile for PAK5 mRNA expression available on Gene 
Expression Omnibus ((GEO: GPL96, 213990_s_at (ID_REF), GDS1479, 57144) associated 
publication (Dyrskjot, Kruhoffer et al. 2004)), where statistically significant downregulation of 
PAK5 mRNA was detected in bladder tumours, compared to normal bladder tissues. 
Despite the downregulation of PAK5 mRNA in bladder tumours compared to normal urothelium, 
differences or downregulation of PAK5 as the tumours progress to higher grades and stages were 
not detected. This indicated that PAK5 mRNA expression in bladder cancer may not 
comprehensively translate to its protein expression. The mRNA expression of PAK5 in bladder 
cancer cell lines was therefore assayed, which showed a different expression profile, compared 
to its distinct protein expression in these cell lines. The difference in the profile for mRNA and 
protein expression, albeit unexpected, may be accounted for by translational or post translational 
regulation of PAK5. The mechanism for this discrepancy between the transcription and translation 
of PAK5, or any other isoforms of PAKs has not been characterised in detail. However, one 
specific group of molecules which had recently gained attention that can affect the translation of 
PAK mRNAs to PAK proteins in bladder cancer are microRNAs.   
MicroRNAs (miRNAs) are endogenous small non-coding RNAs of 19 to 25 nucleotides in length 
that regulate gene expression, and it is estimated that these molecules regulate up to 30% of 
human genes by targeting mRNAs for cleavage or translational repression (Bartel 2004, Garzon, 
Calin et al. 2009, Spizzo, Nicoloso et al. 2009). A number of microRNAs had been identified to 
target PAKs. PAK1 mRNA has been reported to be a target of miR-7 and also Let-7 (Reddy, 
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Ohshiro et al. 2008, Hu, Guo et al. 2013). PAK4, a member of group 2 PAKs, has also been 
shown to be targeted by microRNAs such as miR-224 and miR-145 in cancer studies (Wang, 
Zhang et al. 2012, Zhang, Takahashi et al. 2013). In urothelial cancer studies, deregulation 
miRNA-145, a potential tumour suppressor, has been characterised, where low expression of 
miR-145 has been associated with cancer progression, and a marker of poor prognosis 
(Ostenfeld, Bramsen et al. 2010, Villadsen, Bramsen et al. 2012). Conversely, in addition to 
downregulation of tumour suppressor miRNAs,, upregulation of oncogenic miRNAs such as miR-
183, miR-96, miR-96, miR17-5p and miR-20a have also been described in urothelial cancer 
(Yoshino, Seki et al. 2013). To date, microRNAs targeting human PAK5 have not yet been 
identified or characterised, and the discrepancy in the mRNA and protein expression of PAK5 in 
these bladder cancer cell lines may provide useful resources for such study. 
As the protein expression of PAK5 in bladder cancer cell lines were closely related to epithelial 
differentiation and morphology, I focussed on characterisation of endogenous PAK5 expression 
in well differentiated urothelial cancer cell line RT4. Indirect immunofluorescence and confocal 
microscopy have identified distinct distribution of PAK5 at the cell membrane associated with cell-
cell adherens junction and colocalisation with E-cadherin. This is a novel finding, as endogenous 
PAK5 had only been localised to the cell membranes (and filopodia) in differentiated LAN 
neuroblastoma cells (Matenia, Griesshaber et al. 2005). A study by Wu et al on PAK5 localisation 
had demonstrated that PAK5 was spatially regulated by its interaction with Rho GTPases at its 
CRIB domain, where co-expression of PAK5 with Cdc42 directed PAK5 to the cell membrane, 
but not the expression of PAK5 alone or co-expression with another Rho GTPase RhoD (Wu and 
Frost 2006).  
The roles or functions for PAK5 subcellular localisation to the cell membrane have not been well 
characterised. PAK5 have been shown to interact, and directly phosphorylate p120-Catenin on 
serine 288 (Wong, Reynolds et al. 2010). P120-catenin is one of the constitutional proteins of the 
Cadherin-Catenin adherens junction complex, and the study co-localised PAK5 with P120-
Catenin (phosphor s288) in discrete punctate distribution within the cytoplasm of mouse fibroblast 
NIH-3T3 cells. The study however did not characterise the functional role of this interaction, nor 
linked PAK5 to cadherin-catenin complex, as the cells used did not express E-cadherin, or form 
characteristic epithelial cell-cell adhesion. 
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Downregulation of PAK5 in RT4 cells by siRNA technology was performed in my study to further 
understand the role of PAK5 in urothelial tumours. Two siRNA oligonucleotides were deployed to 
downregulate PAK5 protein expression. At 48 hours following siRNA transfection, maximal effects 
of the assay was detected for the PAK5 protein expression, associated with changes in RT4 cell 
morphology, stability of cell-cell adherens junctions, and downregulation of total protein levels of 
E-cadherin and P120-catenin.  
In order to present the findings on the morphological changes and the state of cell-cell adhesion 
in RT4 following transient PAK5 siRNA knockdown, I proposed an alternative quantitative 
approach, based on  the model of cell-cell adhesion formation and maturation in 3 different stages 
(Adams, Chen et al. 1998, Vasioukhin, Bauer et al. 2000, Vasioukhin and Fuchs 2001). This 
quantitative method was also a modification to junctional index quantification previously described 
(Cain, Vanhaesebroeck et al. 2010). Junctional index, which was calculated using the formula 
([junctional area/total area] × 100)/cell number, may not accurately represent the morphological 
changes due to a number of reasons. Firstly, following PAK5 siRNA knockdown, the total cell 
area of RT4 cells decreased with concurrent reduction in the area of cell-cell contact. The 
decrease in both parameters will directly increase the sum of the junctional index calculated, 
where the loss of cell-cell contact may be underestimated. Secondly, junctional index calculation 
was modelled on (endothelial) cells in a monolayer, whereas my assay, RT4 cells were seeded 
at low density to achieve small epithelial colonies of cells, in order to detect dissociation of cell-
cell adhesion. Thirdly, increase in junctional area parameter may also misrepresent the stability 
of the adherens junction, as the E-cadherin  in membranous adhesion plaques in mature epithelial 
junctions are redistributed into larger aggregates of punctae  in less mature (stages 1 and 2) 
epithelial junctions, and may increase in the area for cell-cell adhesion (Adams, Chen et al. 1998). 
The morphological changes and dissociation of cell-cell adherens junctions in RT4 are likely to 
be the direct effects of E-cadherin and P120-Catenin downregulation in this assay. The 
mechanism for which PAK5 siRNA knockdown affected the total protein levels of E-Cadherin and 
P120-catenin was unclear. What is already known, however, is that p120-catenin regulates 
cadherin turnover and is required for cadherin stability. It could be speculated that the reduction 
in the total E-cadherin protein levels to be the results of p120 downregulation, resulting in rapid 
degradation of E-cadherin by lysosomal destruction (Fujita, Krause et al. 2002, Palacios, Tushir 
et al. 2005). Serine threonine phosphorylation of P120-catenin by PAK5, and the loss of this 
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interaction following PAK5 downregulation may play a significant role in this process. In contrast 
to growth-factor stimulated tyrosine phosphorylation of P120-catenin, the role of its 
serine/threonine phosphorylation had not been well understood. Studies had demonstrated that 
serine/threonine residues of P120-Catenin were constitutively phosphorylated in many cell lines 
with epithelial differentiation such as MDCK, MCF-7, HCT-116 and A431; and p120 
serine/threonine phosphorylation positively correlated with the E-cadherin levels in the cells  (Xia, 
Mariner et al. 2003, Xia, Carnahan et al. 2006). In my siRNA knockdown assay, I was unable to 
clarify how the loss of PAK5 affected the serine/threonine phosphorylation of p120, as the total 
protein level was already reduced, possibly through degradation.  
A recently published research on the PAK5 in hepatocellular carcinoma had demonstrated that 
PAK5 silencing also downregulated the total pool of -catenin protein expression (Li, Yao et al. 
2013). In epithelial adherens junctions, -catenin is one of the core protein components; through 
its ability to bind to -catenin and link E-Cadherin to the actin cytoskeleton. However,-catenin 
leads a dual ‘life’ that it can also act as a transcriptional co-factor when stimulated by the Wnt 
signal transduction pathway, implicated in cancer progression and metastasis(MacDonald, Tamai 
et al. 2009). The pool of -catenin associated with Wnt-signalling pathway had thus far thought to 
be separate and functionally distinct from adherens-junctions related -catenin, and the functions 
have been intensely studied, sometimes in mutually exclusive settings. In a review, (Nelson and 
Nusse 2004) the authors had elegantly summarised this issue by asking a direct question: “Can 
the cadherin bound pool of -catenin be released and made available for signalling?”. The answer 
to this question is emerging, where it had been demonstrated that cadherin-bound -catenin feeds 
into the Wnt pathway and nuclear translocation upon adherens junctions dissociation, which 
provided the evidence for intersection between the two -catenin pools (Kam and Quaranta 2009). 
It is therefore unclear whether the downregulation of PAK5 which resulted in -catenin loss, as 
reported in hepatocellular carcinoma, could also affect adherens-junctions formation.   
Following PAK5 siRNA knockdown, RT4 cells also demonstrated morphological changes 
associated with ‘cell-rounding’, as demonstrated by cell-shape analysis which showed decreased 
cell area, and increased circularity and aspect ratio (figure 4.11). The circular morphology 
associated with loss of cell-cell adhesion due to E-cadherin inactivation in RT4 cells had 
previously been described in a study when RT4 cells were cultured in the presence of anti-E-
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Cadherin function-blocking antibody (Bryan, Atherfold et al. 2008). In addition to loss of E-
cadherin adhesive functions, loss of p120-catenin, as seen in PAK5 knockdown can also result 
in cell-rounding through deregulation of Rho-GTPases. P120-catenin is a potent regulator of the 
Rho family of small GTPases, which regulate the cytoskeletal dynamics (Yanagisawa, Huveldt et 
al. 2008) (Anastasiadis 2007). Specifically, p120-catenin inhibits RhoA; and decrease in p120 
levels in PAK5-siRNA RT4 cells could be speculated to increase RhoA activity. Increase in RhoA 
signalling promotes actin-contractility, cell rounding, and rounded-cell motility (Sahai and Marshall 
2003), and may be implicated in the morphological changes observed in PAK5-siRNA RT4 cells. 
In the next chapter, I aimed to further characterise the interaction of PAK5 with Cadherin-Catenin 
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Chapter 5 : Interactions between PAK5 and E-cadherin 
5.1 Introduction 
I have found that PAK5 protein expression levels were higher in bladder cancer cell lines with 
differentiated epithelial/colony-forming morphology compared to poorly differentiated cell lines. In 
RT4 and RT112 cells, PAK5 colocalised with E-cadherin at the cell-cell adherens junctions in 
basal growth conditions. SiRNA silencing of PAK5 in RT4 cells inhibited the maturation of cell-
cell adherens junctions, and loss of PAK5 expression was associated with downregulation of the 
core junctional proteins; E-Cadherin and p120-Catenin. 
The presence of adherens junctions (AJs) is a defining feature of all epithelial sheets (Fristrom 
1988, Baum and Georgiou 2011). The prototypical protein that forms the transmembrane core of 
adherens junctions is E-cadherin (figure 5.1). The understanding of E-Cadherin structure and 
domains is crucial to further characterise the interaction between PAK5 and E-Cadherin. E-
Cadherin has an ectodomain composed of five extracellular cadherin (EC) repeats, a single 
transmembrane region and a cytoplasmic domain (Shapiro and Weis 2009). Its extracellular 
domain is responsible for homotypic, calcium dependent interactions with E-Cadherins on the 
surface of adjacent cells.  
The cytoplasmic domain of E-Cadherin is 150 amino acids long, and is the most highly conserved 
domain in the Cadherin family of proteins (Nollet, Kools et al. 2000). It interacts with p120-Catenin 
and catenin through its juxtamembrane and catenin-binding domains respectively. catenin 
provides linkage between adherens junctions and the actin cytoskeleton through interactions 
involving catenin (Vasioukhin and Fuchs 2001, Nelson 2008).  
Newly synthesized E-Cadherin associates with catenin in the endoplasmic reticulum and these 
associated proteins are transported together to the cell membrane in the formation of cell-cell 
adherens junctions (Hinck, Nathke et al. 1994). The Catenin-binding region of Cadherins contains 
a sequence motif that is recognised by ubiquitin ligases, and disengagement of E-
Cadherin/catenin binding exposes this sequence which leads to proteosomal degradation of E-
Cadherin (Huber, Stewart et al. 2001, Huber and Weis 2001). 
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P120-catenin also stabilises E-cadherin at the cell-cell adherens junctions (Ireton, Davis et al. 
2002). P120 acts at the cell adherens junctions to control cadherin turnover, and p120 siRNA 
knockdown resulted in dose dependent elimination of E-cadherin and loss of cell-cell adhesion 
(Davis, Ireton et al. 2003). Downregulation of p120-catenin occurs frequently in cancer tissues, 
but paradoxically is uncommon in established cancer cell lines (Ireton, Davis et al. 2002, Stairs, 
Bayne et al. 2011). In the absence of E-Cadherin, p120 is stable in the cells, but had been 
described to be ‘stranded’ in the cytoplasm (Thoreson, Anastasiadis et al. 2000). PAK5 has 
previously been reported to interact with P120 in vivo using mouse brain extract, and in vitro pull-
down assays in N1E115 and HeLa cells, but this has not been tested in cells with a conserved 
epithelial morphology(Wong, Reynolds et al. 2010).  
 
 
Figure 5-1:  Model for E-Cadherin-Catenin protein complex at epithelial cell-cell adherens junctions 
 
In this chapter, I report the findings of further investigations on the interactions of PAK5 with the 
cadherin-catenin complex, utilising bladder cancer cell lines expressing endogenous PAK5, as 
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5.2 Results 
 PAK5 co-immunoprecipitated with E-cadherin, p120-catenin and -
catenin in RT4 cells 
I had discovered that in RT4 cells, PAK5 colocalised with E-Cadherin in adherens junctions, and 
siRNA knockdown of PAK5 resulted in reduced protein levels of E-Cadherin and p120-Catenin, 
associated with cell-cell dissociation from epithelial colonies. I therefore hypothesised that in RT4 
cells, endogenous PAK5 may interact with proteins in the Cadherin-Catenin adherens junction 
complex. 
A common and rigorous assay that can be performed to demonstrate the protein-protein 
interaction is co-immunoprecipitation (Berggard, Linse et al. 2007). High basal level of protein 
expression for PAK5 and E-Cadherin in RT4 cells had presented a potential cell-line model to 
investigate the interaction between PAK5 and the adherens-junctions proteins, where the proteins 
were in their native conformation. To test this hypothesis, I performed co-immunoprecipitation 
(Co-IP) assays and Western blots for endogenous PAK5 and adherens-junctions proteins using 
the whole cell lysates of RT4 cells cultured in basal growth conditions. Precipitates from RT4 
lysates incubated with control (anti-HA) antibody was used as negative control.  
I first investigated the interaction between PAK5 and E-cadherin. Using the in-house PAK5 
antibody. When PAK5 was used as the bait, E-Cadherin was co-immunoprecipitated (figure 5.2, 
lanes 2a and b). In parallel, this interaction was also validated by using E-Cadherin as the bait, 
PAK5 was co-immunoprecipitated with E-Cadherin (figure 5.2, lanes 3a and b).  
The co-immunoprecipitation of PAK5 with E-cadherin in RT4 cells had provided further evidence 
that PAK5 may be involved in the regulation of epithelial adherens-junctions. Thus, I proceeded 
to test whether PAK5 also interacted with other core proteins in the adherens-junctions complex; 
p120-Catenin, -Catenin and -Catenin. 
The interaction between PAK5 and p120-Catenin had previously been described in neuronal and 
HeLa cells (Wong, Reynolds et al. 2010), but not in epithelial cells with established cell-cell-
adhesions. Initially, I tested PAK5 immunoprecipitates for co-immunoprecipitation of p120-
Catenin. I was unable to detect the presence of P120-Catenin in the dissociated protein lysates   
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(figure 5.3, lanes 2a-b). However, in the immunoprecipitates of P120-Catenin, PAK5 was detected 
on the Western blots (figure 5.3, lanes 3a-b). 
Having confirmed that PAK5 co-immunoprecipitated with E-Cadherin and p120-Catenin under 
certain conditions, I proceeded to investigate whether PAK5 was also associated with - and -
Catenins; 2 other well characterised components of the adherens-junctions complex. In these 
experiments, E-Cadherin immunoprecipitates were nominated as positive controls. I was able to 
detect co-immunoprecipitation of PAK5 with-catenin (figure 5.4, lane 2a). However, co-
immunoprecipitation of PAK5 with -catenin was not detected in the precipitates of PAK5 antibody 
(figure 5.4, lane 2b).  Both - and -Catenins were detected in the E-Cadherin immunoprecipitates 
(figure 5.4, lanes 3a-b).  
These results of the co-immunoprecipitation assays indicate that there is an interaction between 
PAK5 and the adherens- junction complex. The most conclusive evidence for the interaction was 
seen in the co-immunoprecipitation assays for PAK5 and E-Cadherin (figure 5.2), which could be 


















Lanes 1a & b:  Immunoprecipitates of HA antibody (negative control) 
Lanes 2a & b:  Immunoprecipitates of PAK5 antibody 
Lanes 3a & b:   Immunoprecipitates of E-Cadherin (HECD) antibody 
Lanes 4a & b:  Whole cell lysates of RT4 
 
 
Figure 5-2 : Co-immunoprecipitation of endogenous PAK5 with E-Cadherin in RT4 cells. (A) RT4 whole 
cell lysates were incubated with PAK5 or E-Cadherin antibody, followed by Sepharose™ beads. Precipitated 
proteins were dissociated and analysed by western blots with antibody against PAK5 and E-Cadherin. 















Lanes 1a & b:  Immunoprecipitates of HA antibody (negative control) 
Lanes 2a & b:  Immunoprecipitates of PAK5 antibody 
Lanes 3a & b:   Immunoprecipitates of p120-Catenin antibody 
Lanes 4a & b:  Whole cell lysates of RT4 
 
Figure 5-3 : Co-immunoprecipitation assays for endogenous PAK5 with p120-Catenin in RT4 cells.  
RT4 whole cell lysates were incubated with PAK5 or p120-Catenin antibodies, followed by Sepharose beads. 
Precipitated proteins were dissociated and analysed by western blots with antibody against PAK5 and p120-









- 148 - 
 
 
Lanes 1a & b:  Immunoprecipitates of HA antibody (negative control) 
Lanes 2a & b:  Immunoprecipitates of PAK5 antibody 
Lanes 3a & b:   Immunoprecipitates of E-Cadherin (HECD) antibody 
Lanes 4a & b:  Whole cell lysates of RT4 
 
Figure 5-4 : Co-immunoprecipitation assays for endogenous PAK5 with - and -Catenin in RT4 cells. 
(A) RT4 whole cell lysates were incubated with PAK5 or E-Cadherin antibodies, followed by Sepharose™ 
beads. Precipitated proteins were dissociated and analysed by western blots with antibody against - and 











- 149 - 
 PAK5 co-immunoprecipitates with E-cadherin and -catenin in RT112 
cells 
 
I had demonstrated that the endogenous protein levels of E-cadherin and PAK5 detectable at 
lower intensity in RT112 compared to RT4 cells (figures 3.5 and 3.15). The cell-cell adherens 
junctions in RT112 were also less mature compared to RT4 (figure 3.6). As I had previously 
hypothesised that PAK5 may have a supportive role to stabilise the adherens junctions, I 
investigated whether PAK5 had a different interaction profile with the adherens-junction proteins 
in RT112 compared to RT4 cells.  
Similar to the experiments described in section 5.2.2, the whole cell lysates of RT112 cells were 
incubated the specified immunoprecipitation antibodies and the precipitated proteins were 
analysed by Western blotting.  Precipitates from RT112 lysates incubated with anti-HA antibody 
were used as negative control. 
The co-immunoprecipitation between PAK5 and E-cadherin in RT112 cells was first assayed by 
using the in-house PAK5 antibody. When PAK5 was used as the bait, I was able to co-
immunoprecipitate both PAK5 and E-Cadherin, and this was demonstrated when the precipitated 
protein complex were dissociated and assayed by Western blotting (figure 5.5, lanes 2a, and b). 
This interaction was further validated using E-Cadherin as the bait, in which the whole cell lysates 
of RT112 was incubated with E-Cadherin specific (HECD) antibody. The interaction between 
PAK5 and E-cadherin was also detected in the co-immunoprecipitation assay using E-Cadherin 
antibody (figure 5.5, lanes 3a, and b). I had also noted that the E-Cadherin antibody was able to 
co-immunoprecipitate PAK5 and E-Cadherin more efficiently than PAK5 antibody in these 
experiments.  
The interaction between PAK5 and P120 catenin was also investigated by co-
immunoprecipitation assays in RT112 cells by using PAK5 or E-Cadherin antibody. Using PAK5 
antibody, I was able to detect the immunoprecipitation of PAK5 (the bait), but not p120-Catenin 
(figure 5.6, lanes 2a, b). Co-immunoprecipitation of PAK5 with p120-Catenin was also not 
detected when the lysates of RT112 cells were incubated with p120-Catenin antibody (figure 5.6, 
lanes 3a, and b).   
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 The interactions demonstrated by the co-immunoprecipitation between PAK5 with - and -
catenins in RT112 cells were similar to the interactions previously observed in RT4 cells. In the 
Western blots for the precipitates of PAK5 antibody form RT112 cells, I was able to detect co-
immunoprecipitation of PAK5 with-catenin (figure 5.7, lane 2a). Co-immunoprecipitation of 
PAK5 with -catenin was not detected in the precipitates of PAK5 antibody (figure 5.7, lane 2b). 
In these experiments, precipitates of RT112 lysates incubated with E-Cadherin antibody were 
nominated as positive controls. Both - and -catenins were detected in the immunoprecipitates 























Lanes 1a & b:  Immunoprecipitates of HA antibody (negative control) 
Lanes 2a & b:  Immunoprecipitates of PAK5 antibody 
Lanes 3a & b:   Immunoprecipitates of E-Cadherin antibody 
Lanes 4a & b:  Whole cell lysates of RT112 
 
 
Figure 5-5 : Co-immunoprecipitation of endogenous PAK5 with E-Cadherin RT112 cells.  RT112 
whole cell lysates were incubated with PAK5 or E-Cadherin antibodies, followed by Protein A Sepharose 
beads. Precipitated proteins were analysed by western blots with antibody against PAK5 and E-Cadherin. 















Lanes 1a & b:  Immunoprecipitates of HA antibody (negative control) 
Lanes 2a & b:  Immunoprecipitates of PAK5 antibody 
Lanes 3a & b:   Immunoprecipitates of p120-Catenin antibody 
Lanes 4a & b:  Whole cell lysates of RT112 
 
Figure 5-6 : Co-immunoprecipitation assays for endogenous PAK5 with - and -Catenin in RT112 
cells. RT112 whole cell lysates were incubated with PAK5 or p120-Catenin antibodies, followed by 
Sepharose™ beads. Precipitated proteins were analysed by Western blots with antibody against - and -
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Lanes 1a & b:  Immunoprecipitates of HA antibody (negative control) 
Lanes 2a & b:  Immunoprecipitates of PAK5 antibody 
Lanes 3a & b:   Immunoprecipitates of E-Cadherin antibody 
Lanes 4a & b:  Whole cell lysates of RT112 
 
 
Figure 5-7 : Co-immunoprecipitation assays for endogenous PAK5 with - and -Catenin in RT112 
cells. (A) RT112 whole cell lysates were incubated with PAK5 or E-Cadherin antibodies, followed by 
Sepharose™ beads. Precipitated proteins were analysed by western blots with antibody against - and -
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 N-terminal (regulatory domain) PAK5 regulates the interaction between 
PAK5 and E-Cadherin 
 
The strong interaction between PAK5 and E-cadherin was a novel finding, and required further 
characterisation. PAK5, similar to other isoforms of PAKs contain an N-terminal regulatory domain 
and a highly conserved C-terminal catalytic kinase domain(Eswaran, Soundararajan et al. 2008). 
Located within the N-terminus of PAK5 are regulatory sequences which include the Cdc42/Rac 
interactive binding (CRIB) domain, the auto-inhibitory domain (AID), nuclear localisation/export 
sequences, mitochondria targeting sequences (Cotteret and Chernoff 2006).  The Cdc42/Rac 
interactive binding (CRIB) domain, positioned the N-terminal, has also been reported to play a 
critical role for proper spatial targeting of PAK5, and interactions with specific members of the 
Rho-family of GTPases targets PAK5 to distinct subcellular locations (Wu and Frost 2006).  
Although PAK5 has been shown to phosphorylate its downstream effectors such as RAF-1 and 
BAD (Cotteret, Jaffer et al. 2003, Cotteret and Chernoff 2006, Wu, Carr et al. 2008), increasing 
evidence indicates that some aspects of PAK5 regulation of cytoskeletal reorganisation does not 
require its kinase activity (Matenia, Griesshaber et al. 2005, Wong, Reynolds et al. 2010). A 
kinase-independent function, which could indicate a scaffolding role for PAK5, as has also been 
described for other isoforms of PAK (Frost, Khokhlatchev et al. 1998, Higuchi, Onishi et al. 2008). 
In order to investigate whether the interaction between PAK5 and E-Cadherin was mediated via 
its N-terminal regulatory domain or it C-terminal kinase domain, I generated PAK5 N-terminal (N-
PAK5) and C-terminal (C-PAK5) mutants (figure 5.5A) by polymerase chain reaction (PCR) and 
Gateway™ technology primers (forward and reverse primers listed in the chapter 2). The C-PAK 
mutant construct (aa 425-719) included the complete kinase domain of PAK5 (Eswaran, Lee et 
al. 2007). The cDNA for all the constructs were sequenced to confirm that no mutations had arisen 
in the DNA sequence during the cloning process.  
The PCR products for N-PAK5 and C-PAK5 mutants (figure 5.5B) were cloned into Gateway™ 
(modified) RFP destination vector, with the RFP-tag positioned at the amino- termini of the 
corresponding PAK5 protein domains. As the interaction between PAK5 and E-cadherin was 
detected most robustly in RT4 cells, and in these cells the proteins colocalised at the cell-cell 
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junctions, I investigated where thePAK5 domain mutants were localised compared to full-length 
PAK5. 
When I overexpressed the RFP-tagged PAK5 constructs in RT4 cells, I observed distinct changes 
to the distribution of C-PAK5 compared to FL-PAK5 or N-PAK5 (figure 5.5C). FL-PAK5 and N-
PAK5 were both expressed in the cytoplasm in vesicular/punctate distributions, and excluded 
from the nucleus. C-terminal domain of PAK5 however accumulated in the nucleus, with diffuse 
(non-vesicular) cytoplasmic distribution. The strong nuclear accumulation and diffuse cytoplasmic 
distribution of endogenous PAK5 had not been observed in RT4 cells in steady state. 
 
 




























Figure 5-8 : Generation of PAK5 N-terminal and C-terminal mutants. A) Schematic representation of full 
length PAK5 and N- and C-termini PAK5 protein fractions. B) PCR products of full length PAK5, and N- and 
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Figure 5-9 : Fluorescent images of RT4 cells transiently transfected with RFP-tagged full length PAK5, 
and N- and C-termini mutant. Nuclei were stained with DAPI, A) RFP-FL-PAK5 was distributed in 
punctate distribution in RT4 cells. B) N-terminal PAK5 protein was also distributed in distinct punctate. C) C-
terminal PAK5 was distributed in RT4 cells in diffuse cytoplasmic distribution and nuclear accumulation. Cell 





- 158 - 
I was unable to transfect RT4 cells efficiently with PAK5 (C- and N-termini) DNA constructs to test 
my hypothesis and study the protein-protein interaction by pull-down assay. Therefore, as an 
alternative, HEK293 cell line was used for over expression of PAK5 (C- and N-termini) and E-
cadherin due to its high transfection efficiency. HEK293 cells overexpressing E-Cadherin-GFP 
were co-transfected with FL-PAK5, N-PAK5 or C-PAK5 mutant cDNA constructs. HEK293 cells 
over-expressing E-Cadherin GFP alone were used as negative control. PAK5 specific antibody 
previously used in the endogenous PAK5 pull-down assays could only be utilised to 
immunoprecipitate FL-PAK5 and N-PAK5, but not C-PAK5 as the antibody was designed to 
interact with the epitope (aa 146-160) within the N-terminal of PAK5. 
The first set of pulldown assays were performed by using RFP-tagged FL-, N-, and C-PAK5 
constructs, and RFP-antibody was used for the immunoprecipitation assay. The RFP-PAK5 
precipitated products were probed for co-immunoprecipitation of E-Cadherin-GFP (figure 5.6A). 
To test the validity of the interactions observed in the co-immunoprecipitation assay using RFP 
antibody, I included PAK5 antibody to IP the negative (E-cadherin –GFP only) and positive (co-
transfection with E-Cadherin GFP and RFP-FL-PAK5) control lysates. Immunoprecipitation using 
PAK5 antibody co-precipitated E-cadherin-GFP in the lysates of HEK293 cell overexpressing E-
Cadherin GFP and RFP-FL-PAK5, but not E-Cadherin GFP alone (figure 5.5B). 
Immunoprecipitation using RFP antibody however, also detected direct binding to E-Cadherin 
GFP, independent of RFP-PAK5 expression in HEK293 cells.  
I therefore proceeded to generate PAK5-mutants and FL-PAK5 cloned in Gateway™ HA-
expression vector to reduce the non-specific cross-reactivity in the co-immunoprecipitation assay. 
Using HA-tagged PAK5 constructs, I was able to demonstrate that E-Cadherin overexpressed in 
HEK293 cells interacted most avidly with FL-PAK5 (figure 5.5B). Interaction between the E-
Cadherin and N-PAK5 protein was detected in the pulldown assay, but not between E-cadherin 
and C-PAK5.  
Based on these results, I concluded that the N-terminal regulatory domain of PAK5 had a 
significant role in the regulation of PAK5 interaction with E-Cadherin. The co-immunoprecipitation 
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A 
  
Lane 1:  Negative control: Over-expression of E-Cadherin-GFP only 
Lane 2:  Negative control: Over-expression of E-Cadherin-GFP only 
Lane 3:  Positive control: Over-expression of E-Cadherin-GFP and RFP-FL-PAK5 
Lane 4:  Positive control: Over-expression of E-Cadherin-GFP and RFP-FL-PAK5 
Lane 5:  Over-expression of E-Cadherin-GFP and RFP-N-PAK5 





Figure 5-10 : Interactions between E-Cadherin-GFP and RFP-tagged Full-length PAK5, and N- and C-
termini PAK5 fractions overexpressed in HEK293 cells. A) Whole cell lysates of HEK293 cells 
transfected with E-Cadherin-GFP with or without RFP-(FL/N/C)-PAK5 were incubated with RFP or PAK5 
antibodies as indicated. Precipitated proteins were analysed by Western blots and probed for co-
immunoprecipitation of E-Cadherin-GFP. Co-immunoprecipitation of E-Cadherin-GFP and RFP-tagged 
PAK5 N- or C-termini constructs could not be verified using RFP antibody as direct interaction between RFP 
antibody with E-Cadherin-GFP protein was  observed in the immunoprecipitation of negative control lysates 
(RFP-PAK5 null cells). PAK5 antibody was used to confirm both positive and negative controls. B) Input 
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A 
 
Lane 1:  Negative control: Over-expression of E-Cadherin-GFP only 
Lane 2:  Negative control: Over-expression of E-Cadherin-GFP and HA-FL-PAK5 
  (without IP antibody) 
Lane 3:  Positive control: Over-expression of E-Cadherin-GFP and HA-FL-PAK5 
Lane 4:  Over-expression of E-Cadherin-GFP and HA-N-PAK5 





Figure 5-11 : Interactions between E-Cadherin-GFP and HA-tagged Full-length PAK5, and N- and C-
termini PAK5 fractions overexpressed in HEK293 cells. A) Whole cell lysates of HEK293 cells 
transfected with E-Cadherin-GFP with or without HA- (FL/N/C)-PAK5 were incubated with HA antibody as 
indicated. Precipitated proteins were analysed by Western blots and probed for co-immunoprecipitation of 
E-Cadherin-GFP. B) Input lysates for cells over-expressing E-Cadherin-GFP and HA-(FL/N/C)-PAK5 which 
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5.3 Discussion  
 
E-Cadherin is a ‘classical’ member of the Cadherin family of cell surface proteins that plays a 
fundamental role in the formation of adherens junctions in epithelial tissues (Shibamoto, 
Hayakawa et al. 1995, Yap, Brieher et al. 1997, Shapiro and Weis 2009). Downregulation or loss 
of E-Cadherin correlates with increased metastatic potential, associated with the loss of the 
cellular adhesive properties (Hajra and Fearon 2002, Gumbiner 2005), and E-cadherin 
loss/switch has also been reported in the tumour progression in bladder cancer (Garcia del Muro, 
Torregrosa et al. 2000, Popov, Gil-Diez de Medina et al. 2000, Clairotte, Lascombe et al. 2006, 
Bryan, Atherfold et al. 2008).  
The interaction between PAK5 and E-Cadherin in bladder cancer cell lines is a novel discovery 
of my project, and this chapter attempted to further characterise this interaction. I have applied 
the in-house PAK5 antibody to co-immunoprecipitate endogenous PAK5 with its interacting 
partners in 2 bladder cancer cell lines; RT4 and RT112, as these cell lines both have detectable 
protein expression of PAK5 and E-Cadherin. 
The interaction between PAK5 and E-Cadherin was most distinct in RT4 cells. RT4 cells are well 
differentiated bladder cancer cell lines with conserved epithelial morphology and mature cell-cell 
junctions in basal growth conditions. In addition, I have also previously demonstrated that siRNA 
knockdown of PAK5 decreased the area of cell-cell contact (section 4.2.8) and the total protein 
level of E-Cadherin (section 4.2.10) in RT4 cells. Taken together, I speculated that the protein-
protein interaction of PAK5 and E-Cadherin affected the intracellular trafficking and intracellular 
functions of E-cadherin, by maintaining a steady state of E-Cadherin at the cell-cell adherens 
junctions. 
A well characterised adherens junction protein that has been previously demonstrated to be an 
interacting partner to PAK5 is p120-Catenin (Wong, Reynolds et al. 2010). In a series of 
publications, p120-Catenin have been shown to regulate E-Cadherin exocytosis, endocytosis and 
overall intracellular protein turnover (Chen, Kojima et al. 2003, Davis, Ireton et al. 2003, Xiao, 
Allison et al. 2003, Xiao, Garner et al. 2005).  When p120 is localised to the plasma membrane, 
the p120 ARM domain associates with the E-Cadherin juxtamembrane region, which results in 
stabilisation and maturation of adherens junctions (Yanagisawa and Anastasiadis 2006). In RT4 
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cells, I found that PAK5 also co-immunoprecipitated with p120 catenin (figure 5.3), and it is likely 
that the interaction between PAK5 and E-Cadherin at the cell adherens junctions involves p120-
Catenin. Although p120 has been shown to be a substrate of PAK5 by phosphorylation on serine 
288, the role for this interaction remains unclear (Wong, Reynolds et al. 2010). Unlike tyrosine 
phosphorylation, the role for serine/threonine phosphorylation of p120 has not been extensively 
characterised. In contrast to the transient tyrosine phosphorylation in response to growth factor 
stimulation (Mariner, Davis et al. 2004), serine/threonine phosphorylation of p120 appears to be 
constitutive, with exception to S873 (Xia, Mariner et al. 2003). 
In the absence of E-cadherin, p120 is stranded in the cytoplasm where it is mostly 
(serine/threonine) unphosphorylated, and E-cadherin expression restores both membrane 
localisation and serine/threonine phosphorylation of p120 (Thoreson, Anastasiadis et al. 2000, 
Fukumoto, Shintani et al. 2008). Using site- and phosphor-specific antibodies, Xia et al identified 
that signalling of p120 via serine/threonine phosphorylation requires membrane localisation of 
p120, and the serine/threonine phosphorylation at individual sites of S268, S288, T310 and T910  
was in dependent of E-Cadherin expression (Xia, Carnahan et al. 2006). Wild-type and 
constitutively active PAK5 have been demonstrated to phosphorylate p120-Catenin on S288, 
without prominent effect on S268, T310 and T916 (Wong, Reynolds et al. 2010), whereas 
constitutively active (but not wild-type) PAK4 phosphorylates S288 as well as T310.  
Although PAK5 and PAK4 can both phosphorylate p120 on S288, the work by Wong et al had 
highlighted a number of fundamental differences between these group-2 PAKs in their interaction 
with p120 (Wong, Reynolds et al. 2010). Firstly, there were no significant difference in the level 
of phosphorylated S288 in the presence of wild-type or constitutively active PAK5. Secondly, the 
subcellular co-localisation of PAK5-p120 and PAK4-p120 differed; PAK5 co-localised with p120 
(total or pS288) in distinct vesicular/punctate distribution, whereas (constitutively active) PAK4 
colocalised with p120 in diffuse cytoplasmic distribution when co-expressed in NIH-3T3 mouse 
embryonic fibroblast cells. It must also be noted that over-expression of constitutively active PAK4 
caused translocation of p120 to the nucleus, whereas the pool of p120 remained in the cytoplasm 
of NIH-3T3 cells upon PAK5 over-expression. Nuclear p120 may control transcription through 
direct interaction with Kaiso, which relieves the transcriptional repression of Kaiso target genes 
(Daniel and Reynolds 1999, Daniel, Spring et al. 2002). Studies have examined the localisation 
of Kaiso in relation to p120, and have indicated that nuclear Kaiso localisation is decreased when 
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p120 translocates to the nucleus(Soubry, van Hengel et al. 2005), with relief of repression for 
Kaiso targets such as WNT11, MMP7 and CyclinD1 with strong links to cancer (Park, Ji et al. 
2006, Hong, Park et al. 2010, Musgrove, Caldon et al. 2011). 
So how does expression of PAK5 in RT4 cells support the steady state of E-Cadherin at adherens 
junction? As the work to characterise the interaction is still at its infancy, it can only be speculated 
that the phosphorylation of S288 on p120 by PAK5 may target p120 to the membrane, therefore 
stabilising the adherens junction complex, and protecting the protein components of AJ from 
endocytic pathways. However, one may also speculate that PAK5 may interact directly with E-
Cadherin as an adaptor protein to stabilise E-Cadherin at the cell membrane, which in turn 
maintains the membrane localisation and serine/threonine phosphorylation of p120. 
-catenin also immunoprecipitates with PAK5 in both RT4 and RT112 cells is. As part of adherens 
junctions, -catenin binds to the cytoplasmic domain of E-Cadherin and to -catenin (Shapiro 
and Weis 2009). In a parallel assay, I was unable to detect protein-protein interaction between 
PAK5 and -catenin. In the experiments conducted thus far in my project or any external 
published studies, it has not yet clear whether the interaction between PAK5 and -catenin is 
direct or mediated by E-Cadherin. A number of speculations however can be proposed towards 
the role of this interaction, as there are evidence that the interaction of E-Cadherin and -catenin 
is modulated/strengthened by serine/threonine phosphorylation (Lickert, Bauer et al. 2000, 
Serres, Filhol et al. 2000, Choi, Huber et al. 2006), and it is possible that in RT4 and RT112 cells, 
PAK5 may also modulate the stability of cell-cell adherens junctions by serine/threonine 
phosphorylation. However, a role for PAK5 as a scaffolding protein, which stabilises the adherens 
junction complex independent of its kinase activity must also be considered, as PAK1, the 
founding PAK-family member have been shown to serve as a scaffold to facilitate PAK1-Akt 
pathway at the cell membrane (Higuchi, Onishi et al. 2008). In addition, PAK5 has previously 
been shown to be involved in the regulation of microtubules and F-actin network, where the 
binding between PAK5 and MARK2 inhibits the activity of MARK2 towards its target, tau protein 
independent of phosphorylation/kinase activity (Matenia, Griesshaber et al. 2005). 
In order to further interrogate the how PAK5/E-cadherin interact, a number of strategies were 
considered to determine whether PAK5 interacts with E-Cadherin as a scaffolding (adaptor) 
protein or by its kinase activity. This includes direct comparison between the affinity of E-Cadherin 
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binding to wild-type PAK5 (PAK5-WT) or kinase-dead PAK5 (PAK5-NE). However, in the study 
on group-2 PAKs interaction with p120-catenin, a protein closely associated with E-cadherin at 
the adherens junctions, no significant differences were demonstrated in the affinity binding or 
serine/threonine (S288) phosphorylation of p120-catenin between PAK5-WT and PAK5-NE. 
Therefore, in this project, I have generated PAK5 N-terminal (N-PAK5) and C-terminal (C-PAK5) 
mutants to investigate whether the interaction between PAK5 and E-Cadherin was mediated via 
its N-terminal regulatory domain or it C-terminal kinase domain. 
When RFP-tagged PAK5 constructs were overexpressed in RT4 cells, I observed distinct 
changes to the distribution of C-PAK5 compared to FL-PAK5 or N-PAK5 (figure 5.5C). FL-PAK5 
and N-PAK5 were both expressed in the cytoplasm in vesicular/punctate distributions, and 
excluded from the nucleus. C-terminal domain of PAK5 however accumulated in the nucleus, with 
diffuse (non-vesicular) cytoplasmic distribution. The strong nuclear accumulation and diffuse 
cytoplasmic distribution of endogenous PAK5 had not been observed in RT4 cells in steady state.  
The effect of regulatory domain deletion on the subcellular localisation of C-PAK5 is in agreement 
with previous reports on the role of PAK5 N-terminal regulatory domain of the subcellular targeting 
of PAK5 , where a number of N-terminal regions have been identified that regulate the localisation 
of PAK5; a mitochondrial targeting sequence, a nuclear export sequence, and a nuclear 
localisation sequence.  (Cotteret, Jaffer et al. 2003, Cotteret and Chernoff 2006, Wu and Frost 
2006).  Deletion of mitochondrial and nuclear targeting sequences causes PAK5 to be retained 
in the nucleus and suppresses PAK5 cellular activity (Cotteret and Chernoff 2006).  
An important sequence located in the N-terminal regulatory domain of PAK5 is the conserved 
PBD: AID. PAK5 preferentially binds to Cdc42 in the presence of GTP, and the AID motif is 
essential for this interaction (Pandey, Dan et al. 2002). The interaction between PAK5 and Cdc42 
directed substantial fraction of PAK5 to the filopodia within the cell membrane.  In addition to 
Cdc42, PAK5 was also observed to interact with RhoD and RhoH.  The interaction with RhoD 
targets PAK5 to subcellular locations different from those stimulated by Cdc42 (Cotteret, Jaffer et 
al. 2003, Wu and Frost 2006). Therefore, deletion of the regulatory domain (including PBD: AID) 
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In order to assay the protein-protein interaction between PAK5 and E-Cadherin, HEK-293 cells 
were used as a cargo for PAK5 over expression to ensure maximal transfection efficiency and 
protein levels. Although PAK5 constructs were tagged to RFP have previously been used for 
localisation studies, these constructs were unsuitable for co-expression with E-cadherin –GFP in 
my set-up for co-immunoprecipitation assays. Experiments to co-immunoprecipitate RFP-PAK5 
(FL/N/C) using RFP antibody also detected direct binding of the antibody to E-Cadherin GFP, 
independent of RFP-PAK5, as seen in the negative control as seen in the lysates HEK293 cells 
expressing E-Cadherin-GFP alone. I therefore proceeded to generate PAK5-mutants and FL-
PAK5 cloned in Gateway™ HA-expression vector to reduce the non-specific cross-reactivity in 
the co-immunoprecipitation assay. Using HA-tagged PAK5 constructs, I was able to demonstrate 
that E-Cadherin overexpressed in HEK293 cells interacted most avidly with FL-PAK5 (figure 
5.5B). Interaction between the E-Cadherin and N-PAK5 protein was detected in the pull-down 
assay, but not between E-cadherin and C-PAK5. 
The finding of my study which showed that E-cadherin interacts with N-terminal PAK5 highlighted 
the importance of PAK5 regulatory domain, and suggested a scaffolding role for PAK5 in the 
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Chapter 6 : Concluding remarks 
Taken together, I speculated that the N-terminal of PAK5 binds onto the cytoplasmic domain of 
E-cadherin, and this binding was closely associated with p120-Catenin and -Catenin (figure 6.1). 
 
Figure 6-1 Schematic representation of PAK5 interaction with E-cadherin, p120-catenin and -catenin at 
cell-cell adherens junction. 
 
Downregulation of PAK5, as previously demonstrated (section 4.2.10), resulted in protein loss of 
E-Cadherin and p120-catenin. In addition, although presented in a different context, PAK5 
downregulation by siRNA in HepG2 (well differentiated, polarised hepatocellular carcinoma) cells 
has been demonstrated to reduce the protein expression of -catenin (Fang, Jiang et al. 2014).  
Binding of p120-catenin and b-Catenin to E-Cadherin cytoplasmic domain  stabilises the cadherin 
complex by preventing cadherin internalisation and degradation (Huber, Stewart et al. 2001, 
Huber and Weis 2001, Davis, Ireton et al. 2003, Xiao, Allison et al. 2003). The findings of my 
study, using PAK5 siRNA and co-immunoprecipitation assays in RT4 and RT112 cells, and an 
independent study by Fang et al (Fang, Jiang et al. 2014) suggest that PAK5 contributes to 
support the stability of the adherens junction by maintaining a steady state and availability of 
adherens junction proteins at the cell membrane to maintain stable cell-cell adhesion and 
epithelial morphology. In contrast to previously reported reports where PAK5 expression was 
associated with tumour progression and cancer metastasis, I propose a role for PAK5 as a 
suppressor of EMT-related invasion and metastasis in bladder cancer. 
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Potential application of PAK5 research findings in bladder cancer 
The clinical outcomes related to cancer diagnosis and treatment for many cancers have improved 
over the last decades but not so for bladder cancer, for which mortality has changed very little in 
the last few decades in England and Wales (Shah, Rachet et al. 2008). Most patients with muscle 
invasive bladder cancer (MIBC) will still succumb to the disease associated with metastasis 
despite radical treatment regimens (Gakis, Efstathiou et al. 2013, Sternberg, Bellmunt et al. 2013), 
while patients with non-muscle invasive bladder cancer (NMIBC) are faced with lifelong 
surveillance due to the characteristic high recurrence rate of urothelial cancer (Burger, Oosterlinck 
et al. 2013). Although the molecular events that characterise urothelial carcinoma are increasingly 
defined and our understanding of the relevant pathways and networks has evolved, it remains 
surprising that no significant markers either for diagnosis of MIBC or NMIBC, let alone a marker 
able to risk stratify recurrence or relative prognosis, have gained widespread acceptance and 
consistent validity.  
One of the proteins that can potentially differentiate urothelial tumours into low or high risk of 
disease progression is E-Cadherin. E-Cadherin is the major mediator of cell-cell adhesion in 
epithelial tissues, and is expressed by most epithelial cells (Saito, Tucker et al. 2012). Decreased 
E-cadherin immune-reactivity was first described in bladder cancer in 1993 (Bringuier, Umbas et 
al. 1993). A number of studies then followed, which demonstrated cadherin switching in the setting 
of bladder cancer, associated with late stage, high grade disease (Rieger-Christ, Cain et al. 2001, 
Clairotte, Lascombe et al. 2006, Lascombe, Clairotte et al. 2006, Bryan, Atherfold et al. 2008, 
Mandeville, Silva Neto et al. 2008). A detailed study on cadherin switching using pT1 and T2-T3 
bladder tumours (Lascombe, Clairotte et al. 2006) demonstrated that N-Cadherin expressing 
bladder cancer progressed more rapidly, and the majority of T2-T3 tumours demonstrated no 
expression of E-cadherin.  
In my research to investigate the role of PAKs and bladder cancer, I have discovered the positive 
correlation between PAK5 and E-Cadherin protein expression in well and moderately 
differentiated urothelial cancer cell lines (RT4 and RT112) which form cell-cell adherens junctions. 
Conversely, low or undetectable protein expression of PAK5 was associated bladder cancer cell 
lines with mesenchymal phenotype, lacking in cell-cell adherens junctions (T24, TCCSUP and 
253J). Indirect immunofluorescence studies of endogenous proteins by confocal microscopy 
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showed that PAK5 colocalised with E-Cadherin and p120-catenin at cell-cell adherens junctions. 
Upon growth factor stimulation, which resulted in E-cadherin disengagement from the cell 
membrane, E-Cadherin colocalised with PAK5 in punctate distribution, which suggests that these 
proteins may share a common pathway of transport in endocytosis.  
Further investigations to characterise the function of PAK5 in bladder cancer cells with well 
differentiated epithelial phenotype revealed a novel role for PAK5 to support a steady state of E-
Cadherin protein levels in the cells, and maintenance of stable cell-cell epithelial junction (figure 
6), as siRNA knockdown of PAK5 in RT4 cells resulted in decreased protein levels of E-Cadherin 
and p120-Catenin. In addition, PAK5 was demonstrated to interact with p120-Catenin and -
Catenin, well-characterised proteins which binds to the cytoplasmic domain of E-Cadherin in 
stable adherens junction complex.  
 
 
Figure 6-2: Proposed mechanism for Cadherin/Catenin engagement at the cell membrane in association 
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There are still a number of questions that remain unanswered for the mechanism on how PAK5 
is involved in the regulation of E-Cadherin and cell-cell adherens junctions. Although I have 
elucidated that the N-terminal (regulatory domain) PAK5 binds more avidly to E-cadherin 
compared to C-terminal (kinase domain) PAK5, it is still unclear whether the scaffolding function 
of PAK5 upon engagement with E-Cadherin is associated with serine/threonine phosphorylation 
of E-Cadherin or the Catenins within the protein complex in the endogenous system. The 
uncertainty arises as the N-terminal of PAK5 contains several subcellular localisation sequences, 
as well as the PBD: AID domain, and its deletion as seen in C-PAK5 ablates the spatial regulation 
of PAK5, where it may not engage and consequently phosphorylate its downstream target.  
In contrast to well characterised tyrosine phosphorylation of E-Cadherin and Catenins which 
results in decreased cell-cell adhesions, the evidence for PAK modulation of adherens junctions 
by direct serine/threonine phosphorylation of E-Cadherin or p120-/- Catenins is limited. Although 
p120-Catenin has been shown to be a substrate of PAK4 (phosphorylation of T310 and S288) 
and PAK5 (phosphorylation of S288), the role for these interactions remain to be characterised 
(Wong, Reynolds et al. 2010). The study by Wong et al also highlighted the difference in 
subcellular localisation of PAK4 and PAK5 in their interactions with a common substrate. In 
addition, PAK4 interaction with p120-catenin was only observed when PAK4 was in constitutively 
active state (PAK4NE), whereas wild-type PAK5 and constitutively active PAK5 both have similar 
binding affinity and phosphorylation intensity to p120-Catenin. Although a common substrate and 
phosphorylation site on p120 may indicate functional redundancy of PAK4 and PAK5, it can also 
be speculated that these proteins may compete for the same phosphorylation site, and 
competitively inhibit one another to exert different cellular functions and morphology. 
Further work is required to characterise the interaction between PAK5 and adherens junction 
proteins. In carcinomas, morphological transition known as epithelial to mesenchymal transition 
(EMT) has been proposed to play a significant role in tumour invasion and metastasis (Hanahan 
and Weinberg 2011). Key targets of the pathways that induce EMT include E-cadherin and the 
catenins that form the core of the adherens junctions. The mechanisms by which these proteins 
may be affected are diverse. E-cadherin may be downregulated by transcriptional or epigenetic 
silencing (Matsumura, Makino et al. 2001), as well as post-translational modifications to target 
the protein for lysosomal degradation (Reinhold, Reimers et al. 2010). catenin may be targeted 
by proteosomal degradation, which destabilises adherens junctions, but in certain conditions 
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where it is no longer coupled to E-cadherin, translocates to the nucleus and acts as a 
transcriptional co-factor implicated in cancer progression and metastasis (Nelson and Nusse 
2004). 
The findings of my research on PAK5, in parallel with emerging publications, some with 
contradictory conclusions, are reminiscent of research findings on p120-Catenin, which was 
initially identified as a substrate of the oncogenic non-receptor tyrosine kinase Src (Reynolds, 
Roesel et al. 1989). Ironically, although much is known about p120, its roles in cancer remain 
mysterious, with several lines of evidence suggesting that p120 is both a tumour suppressor and 
metastatic promoter (Shimazui, Schalken et al. 1996, Syrigos, Karayiannakis et al. 1998, 
Nakopoulou, Zervas et al. 2000, Reynolds and Roczniak-Ferguson 2004, Silva Neto, Smith et al. 
2008, Soto, Yanagisawa et al. 2008, Yanagisawa, Huveldt et al. 2008, Schackmann, Tenhagen 
et al. 2013).  
In contrast to previous reports where PAK5 expression was associated with tumour progression 
and cancer metastasis, I propose a role for PAK5 as a suppressor of EMT-related invasion and 
metastasis in bladder cancer. 
 
Future work 
The novel findings of my research on PAK5 in bladder cancer could provide the basis for further 
work on the role of PAK5 in the regulation of cell-cell adherens junction Cadherin-Catenin protein 
complex. With further resources in time and funding, I would like to take the work further by 
generating and inducible PAK5 knockdown system to investigate the role of PAK5   in epithelial 
cells in greater detail. Further research on the interaction between PAK5 and E-Cadherin/p120-
Catenin using biosensor technology may also be beneficial to quantitatively examine in real-time, 
the role of phosphorylation on protein-protein interactions in signalling pathways. Further 
characterisation of PAK5 protein expression on validated bladder cancer tissue samples, in 
conjunction with expression and localisation of E-Cadherin or p120-Catenin will also move the 
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Appendices 
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Appendix 4: Vector maps 
 
Clontech pRK5 Myc vector (modified for Gateway™ Cloning system) 
 
 




- 176 - 
SiRNA oligonucleotide sequences 
 
Target Supplier Sequence Location  
Control/   
non 
silencing 
Qiagen AAT TCT CCG AAC GTG 
TCA CGT 
  
Pak5 Dharmacon  3’ UTR Si1 
Dharmacon  3’ UTR Si2 
Dharmacon  3’ UTR Si3 
Dharmacon  3’ UTR Si4 
Qiagen ATG ATC TGG ATC CGT 
ATT ATA 
Coding region Si63 
Qiagen ATG GTG TGC ACG TTT 
CAT TAA 
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